The Function of Mismatch Repair Proteins in Response to DNA Damage caused by Chemotherapeutic Agents by Fischer, F
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2007
The Function of Mismatch Repair Proteins in Response to DNA Damage
caused by Chemotherapeutic Agents
Fischer, F
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-34422
Dissertation
Published Version
Originally published at:
Fischer, F. The Function of Mismatch Repair Proteins in Response to DNA Damage caused by Chemother-
apeutic Agents. 2007, University of Zurich, Faculty of Science.
 
 
 
 
 
The Function of Mismatch Repair Proteins in Response 
to DNA Damage caused by Chemotherapeutic Agents 
 
 
 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der  
 
Universität Zürich 
 
von 
 
Franziska Fischer 
 
von 
 
Oberengstringen ZH 
 
 
Promotionskomitee 
 
Prof. Dr. Josef Jiricny (Leitung der Dissertation) 
Prof. Dr. Michael Hengartner 
Dr. Anne Müller 
Dr. Massimo Lopes 
 
 
 
 
Zürich, 2007 
 
 
Index 
 
 
INDEX 
 
Zusammenfassung.................................................................................................................................... 1 
Summary ............................................................................................................................................................. 4 
 
1. Introduction................................................................................................................................................ 7 
 
2. DNA repair mechanisms................................................................................................................ 8 
 
2.1 Direct repair ............................................................................................................................................ 8 
2.1.1 Photolyase............................................................................................................................................. 8 
2.1.2 O6-methylguanine-DNA methyltransferase (MGMT) .......................................... 9 
2.1.3 AlkB............................................................................................................................................................. 10 
 
2.2 Base excision repair (BER) ...................................................................................................... 10 
2.2.1 Overview................................................................................................................................................. 10 
2.2.2 Glycosylases........................................................................................................................................ 11 
2.2.2.1 Uracil-DNA glycosylase (UNG)........................................................................................ 13 
2.2.2.2 Thymine-DNA glycosylase (TDG).................................................................................. 14 
2.2.2.3 Methyl-CpG binding domain protein 4 (MBD4)................................................... 18 
2.2.2.4 Single strand-selective monofunctional uracil-DNA glycosylase 1 
(SMUG1)............................................................................................................................................................... 19 
 
2.3 Mismatch repair (MMR)................................................................................................................ 20 
2.3.1 Where it all started ..........................................................................................................................20 
2.3.2 Biological significance of MMR ............................................................................................. 21 
2.3.3 MMR in E. coli .................................................................................................................................... 21 
2.3.3.1 E. coli MutS protein.................................................................................................................... 24 
2.3.3.2 E. coli MutL protein.................................................................................................................... 25 
2.3.3.3 E. coli MutH protein ................................................................................................................... 26 
2.3.3.4 E. coli UvrD helicase ................................................................................................................ 27 
2.3.4 MMR in yeast ...................................................................................................................................... 27 
2.3.5 MMR in higher eukaryotes ....................................................................................................... 29 
2.3.5.1 The leading actors...................................................................................................................... 29 
2.3.5.2 Human MutS................................................................................................................................ 31 
2.3.5.3 Human MutS ................................................................................................................................ 32 
2.3.5.4 Human MutL ................................................................................................................................ 32 
2.3.5.5 Human MutL................................................................................................................................. 33 
2.3.5.6 Human MutL.................................................................................................................................. 34 
2.3.5.7 Reconstituted MMR systems............................................................................................. 34 
2.3.5.8 Other functions of MMR......................................................................................................... 38 
 
 
3. The role of MMR in cancer and cancer therapy ...................................................... 40 
 
3.1 MMR and HNPCC (hereditary non-polyposis colorectal cancer) ........ 40 
3.2 MMR, DNA-damage tolerance and clinical implications.............................. 41 
3.2.1 Methylating agents..........................................................................................................................41 
3.2.1.1 Temozolomide (TMZ) and dacarbazine.................................................................... 43 
3.2.2 6-thioguanine (6-TG)..................................................................................................................... 44 
Index 
 
 
3.2.3 Cisplatin ................................................................................................................................................... 45 
3.2.4 Topoisomerase inhibitors .......................................................................................................... 46 
3.2.4.1 Camptothecin and its derivatives ................................................................................... 46 
3.2.5 5-fluorouracil (5-FU)....................................................................................................................... 48 
3.2.5.1 TS inhibition and incorporation of fluoropyrimidines into DNA............... 49 
3.2.5.2 Incorporation of fluoropyrimidines into RNA.......................................................... 50 
3.2.5.3 Clinical applications................................................................................................................... 50 
 
4. Aim of my studies ................................................................................................................................ 51 
 
5. References .................................................................................................................................................. 52 
 
6. Results ............................................................................................................................................................ 74 
6.1 5-fluorouracil is efficiently removed from DNA by the base  
excision and mismatch repair systems 
(Gastroenterology, manuscript submitted)................................................................................ 75 
6.2 O6-methylguanine in the template strand: a futile challenge for  
human mismatch repair ?  
(manuscript in preparation).................................................................................................................... 101 
6.3 Characterization of the "mismatch repairosome" and its role in  
the processing of modified nucleosides in vitro  
(Methods in Enzymology, 2006)........................................................................................................ 126 
6.4 Expression of the MutL homologue hMLH3 in human cells and its 
role in DNA mismatch repair  
(Cancer Research, 2005)........................................................................................................................ 146 
 
7. Conclusions............................................................................................................................................... 155 
 
8. Acknowledgments ...............................................................................................................................159 
 
Curriculum Vitae Franziska Fischer 
 
 
 Zusammenfassung 
 
Zusammenfassung 
 
Um die Effizienz der Fehlpaarungs-Reparatur (mismatch repair, MMR) zu 
studieren und gleichzeitig die reparierten DNA-Abschnitte sichtbar zu 
machen, nutzten wir ein spezielles in vitro-System: verschiedene 
Heteroduplex-Substrate mit je einem einzigen fehlgepaarten Basenpaar in der 
Erkennungssequenz eines Restriktionsenzymes wurden mit Kernextrakt von 
MMR-profizienten oder –defizienten Zell-Linien und in der Anwesenheit von 
radioaktiv markierten Nukleotiden inkubiert. Das resultierende 
Restriktionsmuster gibt Aufschluss über das Reparatur-Ausmass, während 
die eingebaute Radioaktivität die reparierten Abschnitte in den verschiedenen 
Fragmenten zeigt. 
Ich befasste mich während meiner Doktorarbeit mit der MMR-abhängigen 
Prozessierung von zwei bestimmten DNA-Läsionen, welche beide durch 
chemotherapeutische Substanzen verursacht werden: O6-Methylguanin (mG) 
und 5-Fluorouracil (5-FU). 
mG entsteht als geringfügige Untermenge bei der Behandlung von Zellen mit 
SN1-methylierenden Mitteln, wie zum Beispiel N-methyl-N’-nitro-N-
nitrosoguanidin (MNNG) oder das in Kliniken verwendete Temozolomid 
(TMZ). mG ist nicht nur mutagen, sondern auch zytotoxisch und es konnte 
gezeigt werden, dass ein funktionales MMR-System für die mG-induzierte 
Zytotoxizität verantwortlich ist: im Gegensatz zu MMR-profizienten Zellen 
tolerieren MMR-defiziente Zellen nämlich den Methylierungs-Schaden. Der 
genaue Mechanismus des durch mG verursachten Zelltods ist nicht bekannt, 
doch es existieren dazu mehrere Modelle. Die sogenannte “futile repair”-
Hypothese (“vergebliche Reparatur”) geht davon aus, dass die MMR-
Maschinerie mG  erkennt und versucht, den Schaden zu beheben. Da die 
Läsion aber im Matrizenstrang liegt und das MMR-System nur den neu-
synthetisierten Strang reparieren kann, laufen vergebliche 
Exzision/Resynthese-Zyklen gegenüber des Schadens ab. Als Konsequenz 
dieser nicht erfolgreichen Reparaturversuche entstehen möglicherweise 
Doppelstrangbrüche, welche schlussendlich zum Zelltod führen könnten. Eine 
Alternative zu dieser Hypothese ist ein Modell, welches besagt, dass MMR-
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Faktoren die nicht reparierbare Modifikation erkennen und direkt Apoptose 
einleiten. 
5-FU dagegen ist die klassische chemotherapeutische Substanz zur 
Behandlung von kolorektalem Krebs (CRC). Dieser Anti-Metabolit kann 
sowohl in RNA als auch in DNA eingebaut werden und hemmt zudem die 
Thymidylat-Synthase (TS), was eine Verlangsamung der DNA-Replikation zur 
Folge hat. Das MMR-System ist auch in die 5-FU-Prozessierung involviert: 
verschiedene Studien haben bewiesen, dass Patienten mit MMR-defizientem 
CRC keinerlei Wirkung auf Chemotherapien mit 5-FU zeigen und die 
Beobachtungen konnten in vitro bestätigt werden. Diese Resultate lassen den 
Schluss zu, dass das MMR-System eine wichtige Rolle in der 5-FU-basierten 
Krebstherapie spielt. Auf der anderen Seite ist 5-FU aber auch ein Substrat 
für alle bekannten menschlichen Uracil-DNA-Glykosylasen: uracil-DNA 
glycosylase (UNG), thymine-DNA glycosylase (TDG), single-strand selective 
monofunctional uracil-DNA glycosylase 1 (SMUG1) und methyl-CpG binding 
domain protein 4 (MBD4). 
Das erste Projekt meiner Doktorarbeit widmete sich der Frage, ob diese 
vergeblichen Reparatur-Zyklen gegenüber mG tatsächlich stattfinden. 
Gleichzeitig richteten wir unser Augenmerk auf die Entstehung von 
abweichenden DNA-Zwischenprodukten, wie zum Beispiel einzelsträngige 
Regionen, und untersuchten das Verhältnis der gegenüber mG eingebauten T- 
und C-Basen. Unsere Resultate zeigen, dass das MMR-System mG-
enthaltende DNA-Substrate in vitro erkennt und prozessiert. In 
Übereinstimmung mit früheren Ergebnissen konnten wir bestätigen, dass das 
hMLH1/hPMS2-Heterodimer für die 5’-gerichtete Fehlpaarungs-Reparatur in 
unserem in vitro-System entbehrlich ist. Die Affinität von hMutS für ein G/T-
Fehlpaar in Bandshift-Experimenten ist erheblich grösser als für mG/T oder 
mG/C, was die tiefere Reparatur-Effizienz in unserem MMR-System in vitro 
erklärt. mG/T- und mG/C-Fehlpaare, bei welchen sich mG im eingeschnittenen 
Strang befindet, stellen schwache Substrate dar und werden mit der gleichen 
Ineffizienz prozessiert und repariert. Pulse-Chase-Experimente zeigten keine 
wesentliche Exzision von radioaktiv markiertem dAMP und so konnte weder in 
5’- noch in 3’-Substraten eine MMR-abhängige Abnahme der Radioaktivität 
aufgrund vergeblicher Reparatur-Zyklen beobachtet werden. Als Alternative 
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versuchten wir das bei diesen mutmasslichen Reparatur-Zyklen exzisierte 
radioaktiv markierte dAMP mittels Dünnschicht-Chromatographie 
aufzutrennen. Da der von uns verwendete Kernextrakt aber die intrinsische 
Fähigkeit besass, dATP zu hydrolysieren, wurden die Resultate von dieser 
Hintergrund-Aktivität überdeckt. Aufgrund der schwachen Erkennung von mG-
enthaltenden Substraten durch unser in vitro-MMR-System konnten weder 
Einzelstrang-Lücken detektiert noch klare Aussagen über den Einbau von C 
oder T gegenüber mG gemacht werden. Nichtsdestotrotz bestätigte eine 
Forschungs-Gruppe im Sommer 2006 die Existenz der vergeblichen 
Reparatur-Zyklen gegenüber mG in vitro und lieferte so einen ersten 
biochemischen Beweis für die “futile repair”-Hypothese. 
Das zweite Projekt konzentrierte sich auf verschiedene Fragen im 
Zusammenhang mit der 5-FU-Prozessierung in vitro. Als erstes überprüften 
wir die Fähigkeit unseres in vitro-MMR-Systems, 5-FU-Substrate zu 
reparieren. In einem zweiten Schritt immuno-dezimierten wir eine Glykosylase 
nach der anderen aus dem Kernextrakt, um schliesslich die 
Verantwortliche(n) der 5-FU-Reparatur zu finden. In einem letzten Schritt 
untersuchten wir die Kompetition zwischen MMR und Glykosylasen auf dem 
5-FU-Substrat. Wir konnten zeigen, dass sowohl G/5-FU- als auch A/5-FU-
Fehlpaare in zirkulären DNA-Substraten von der MMR in menschlichen 
Zellextrakten  angegangen werden. Im Übrigen wird G/5-FU durch die Basen-
Exzisions-Reparatur sehr effizient zu G/C repariert. In diesem Prozess spielt 
TDG eine übergeordnete Rolle. Kompetition zwischen den beiden 
Reparatursystemen konnte beobachtet werden.  
Methylierende Substanzen und 5-FU sind feste Bestandteile etablierter 
Chemotherapien im Kampf gegen eine Vielzahl von Krebsarten. Es ist 
deshalb von grosser Wichtigkeit, den genauen molekularen Mechanismus des 
jeweiligen Zellgiftes zu kennen, um endogene und erworbene Resistenzen 
gegenüber chemotherapeutischen Mitteln möglichst zu vermeiden. Unsere in 
vitro-Resultate rücken die Glykosylasen als mögliche Zielproteine in der 5-FU-
basierten Krebstherapie in ein neues Licht und weisen vielleicht den Weg für 
eine erfolgreichere Behandlungsstrategie.  
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Summary 
 
Mismatch repair (MMR) efficiency and repair tract visualization can be studied 
in an in vitro MMR assay as follows: different heteroduplex substrates 
containing a single mismatch within a restriction endonuclease site are 
incubated with nuclear extract from either MMR-proficient or –deficient cell 
lines, in the presence of radiolabeled nucleotides. The resulting restriction 
pattern gives information about the repair extent and the incorporated 
radioactivity in the different fragments reveals the repair tracts.  
I’ve studied the MMR-dependent processing of two particular DNA lesions 
induced by chemotherapeutic substances: O6-methylguanine (mG) and 5-
fluorouracil (5-FU). 
mG arises as a minor subset in cells treated with SN1-type methylating agents, 
such as N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) or its clinical 
counterpart temozolomide (TMZ). This lesion, besides being mutagenic, 
causes cell death and since MMR-deficient cells exhibit a methylation-tolerant 
phenotype, MMR has been shown to be instrumental in mediating the 
observed mG-induced cytotoxicity. But the exact mechanism by which mG kills 
the cells remains elusive, although a number of models have been proposed. 
One model, the futile repair hypothesis, suggests that the MMR system will 
attempt to process the mG lesions, but as the modified base is in the template 
strand, and as MMR is exclusively targeted to the newly synthesized strand, 
several rounds of futile excision/resynthesis cycles are the consequence. 
These unsuccessful repair events may end up in double-strand breaks and 
thus lead to cell death. An alternative to this model suggests that MMR factors 
recognizing the unrepairable lesion directly signal apoptosis. 
5-FU, on the other hand, is the agent of choice in the treatment of colorectal 
cancer (CRC) and this antimetabolite can be incorporated into both RNA and 
DNA. Furthermore, it inhibits thymidylate synthase (TS), thereby slowing 
down DNA replication. MMR is involved in 5-FU-processing as well: patients 
with MMR-deficient CRCs were reported not to benefit from 5-FU-based 
chemotherapy, and these findings appear to be confirmed by in vitro studies. 
This implies a role for the MMR system in the response to 5-FU treatment. But 
5-FU is also a substrate for all four known human uracil DNA glycosylases: 
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uracil-DNA glycosylase (UNG), thymine-DNA glycosylase (TDG), single-
strand selective monofunctional uracil-DNA glycosylase 1 (SMUG1) and 
methyl-CpG binding domain protein 4 (MBD4). 
The first project of my PhD study mainly addressed the question whether or 
not futile repair cycles are taking place opposite mG. Concomitantly, we 
looked in more detail at the formation of possible aberrant DNA intermediates 
such as single-stranded regions and examined the T:C ratio of incorporation 
opposite mG. Our results show that the mismatch repair machinery recognizes 
and processes DNA substrates containing mG in vitro. In agreement with 
earlier findings, hMLH1/hPMS2 heterodimer is not essential for 5’-directed 
MMR in our in vitro assays. The affinity of hMutSα for the G/T mispair in 
bandshift experiments is substantially greater than for mG/T or mG/C, 
consistent with lower repair efficiency in our in vitro mismatch repair assays. 
mG/T and mG/C mismatches (lesion in the nicked strand) are processed and 
repaired with equally low efficiency. Pulse chase experiments did not show a 
significant excision of the radiolabeled dAMP, and therefore no visible MMR-
dependent decrease of radioactivity due to futile repair cycles were detected, 
neither in the 5’- nor in the 3’-substrates. Thin layer chromatography assays to 
separate the radiolabeled dAMP, which was expected to be excised during 
the putative iterative repair cycles, could not overcome the problem due to the 
hydrolytic activity of the used nuclear extracts masking the result. Because of 
the weak recognition of our mG-containing substrates by MMR, neither gaps 
nor non-ambiguous C- or T-incorporation opposite the lesion could be clearly 
confirmed with our system. However, in summer 2006, another group 
reported the existence of iterative excision opposite mG in vitro, thus 
confirming the futile repair model. 
In the second project, we focused on different questions concerning the 5-FU 
processing in the above-described in vitro assay. First, we checked repair 
capability of the MMR machinery on 5-FU substrates. Second, we 
immunodepleted one glycosylase after the other from the nuclear extracts to 
find the one(s) responsible for 5-FU repair. In the last step, we looked at the 
competition between MMR and glycosylases on the 5-FU substrate. We could 
show that both G/5-FU and A/5-FU base pairs incorporated into circular DNA 
substrates are addressed by the MMR system in extracts of human cells. In 
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addition, the former substrate is very efficiently repaired to G/C by base 
excision repair (BER). In this processing, TDG plays the predominant role. 
Competition between the two repair pathways could be observed.  
Since methylating agents and 5-FU are inherent parts in approved 
chemotherapies against a variety of cancers, it is of maximum importance to 
understand the exact molecular mechanism of the appropriate drug to avoid 
endogenous and acquired resistance. Our in vitro results may point to the 
glycosylases as an additional class of target proteins, which deserve closer 
consideration in order to improve 5-FU-based regimens. 
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1. Introduction 
 
DNA is constantly subjected to alterations by exogenous and endogenous sources. 
Ionizing and UV radiation, or carcinogens contained in food, cigarette smoke and 
particular environments rank among the former, cellular metabolites causing 
hydrolysis or methylation and active oxygen species constitute the latter [1]. To deal 
with this permanent threat and to avoid consequent genomic instability, nature 
armed living cells with a series of sophisticated defense mechanisms: damage 
repair, damage tolerance and the possibility of checkpoint activation (Fig. 1).  
 
Figure 1 Responses to 
DNA damage. DNA 
damage (illustrated as a 
black triangle) results in 
either repair or tolerance. 
a During damage 
tolerance, damaged sites 
are recognized by the 
replication machinery 
before they can be 
repaired, resulting in an 
arrest that can be relieved 
by replicative bypass 
(translesion DNA 
synthesis).  
b DNA repair involves the 
excision of bases and 
DNA synthesis (red wavy 
lines), which requires 
double-stranded DNA. 
Mispaired bases, usually 
generated by mistakes 
during DNA replication, 
are excised as single 
nucleotides during 
mismatch repair. A 
damaged base is excised 
as a single free base 
(base excision repair) or 
as an oligonucleotide 
fragment (nucleotide 
excision repair). Such fragments are generated by incisions flanking either side of the damaged base. 
Nucleotide excision repair can also transpire in some organisms by a distinct biochemical mechanism 
involving only a single incision next to a site of damage (unimodal incision).  
c The cell has a network of complex signalling pathways that arrest the cell cycle and may ultimately 
lead to programmed cell death (from [2]). 
   
DNA repair encompasses a multitude of metabolic processes, which come into play 
in dependence of the respective kind of damage.  
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Four broad repair categories can be distinguished, including direct reversal of 
damage, excision of the damaged region, followed by precise replacement (base 
excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), 
repair of interstrand cross-links), double-strand break repair and damage tolerance 
(damage bypass). 
The following section will be confined to the particular subset of DNA repair 
mechanisms used in my studies, namely direct repair, BER and MMR. 
 
2. DNA repair mechanisms 
 
2.1 Direct repair 
In the simplest type of DNA repair, the damaged base is repaired directly, e.g. 
dealkylated, by a one-step mechanism, rather than being excised and replaced by 
the correct one. 
 
2.1.1 Photolyase 
Figure 2 Photoreactivation reverses DNA damage. DNA 
exposed to ultraviolet (UV) radiation results in covalent 
dimerization of adjacent pyrimidines, typically thymine residues 
(thymine dimers), illustrated here as a purple triangle. These 
lesions are recognized by a photoreactivating enzyme, which 
absorbs light at wavelengths >300nm (such as fluorescent light 
or sunlight) and facilitates a series of photochemical reactions 
that monomerize the dimerized pyrimidines, restoring them to 
their native conformation (taken from [2]). 
 
UV radiation promotes the formation of a cyclobutyl 
ring between adjacent thymine residues on the 
same DNA strand to form an intrastrand thymine 
dimer. Similar cytosine and thymine-cytosine dimers 
are likewise formed, but at lesser rates. Such 
pyrimidine dimers locally distort DNA’s base paired 
structure so that it can form neither a proper 
transcription nor replication template. By using blue-
light photons as an energy source, photolyases, 
monomeric proteins of 55-65 kDa with two chromophore cofactors, split these 
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aberrant structures. There are two types of photolyases, one that repairs 
cyclobutane pyrimidine dimers (photolyase) and the other that repairs (6-4) 
photoproducts (6-4 photolyase) [3-6]. In 1949, this so-called photoreactivation was 
the first DNA repair process to be discovered (Fig. 2). 
 
 
2.1.2 O6-methylguanine-DNA methyltransferase (MGMT) 
Many carcinogens in the environment [7], tobacco smoke [8] and food [9], in addition 
to endogenous metabolic products [10], methylate DNA. One of the consequences is 
the formation of the highly mutagenic and cytotoxic lesion O6-methylguanine. It is 
repaired by MGMT (also referred to as O6-alkylguanine-DNA alkyltransferase, AGT), 
which removes the methyl group from guanine in a single step, transferring it to an 
internal cysteine residue. This methyl-group transfer inactivates MGMT and restores 
guanine in the DNA ([11], Fig. 3). In contrast to the above-described photolyases, 
which are not found in E. coli, yeast and mammals, O6-methylguanine-DNA 
methyltransferases are nearly universally distributed in nature. For example, E. coli 
expresses two genes encoding proteins of this type, one is inducible (ada) and one 
is constitutively expressed (ogt). The Ada protein not only repairs methylated bases 
but also regulates the so-called adaptive response, involving the induction of the 
ada, alkA, alkB and aidB genes upon exposure to methylating agents [12].  
 
 
Figure 3 A line drawing 
of the overall methyl-
transferase suicide 
repair reaction. This 
shows the methyl group 
being transferred from 
the O6-position on a 
guanine in DNA to the 
sulfur side-chain of the 
active site thiol (from 
[13]). 
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2.1.3 AlkB 
AlkB, like Ada, is also a damage-reversal protein and was recently shown to be an 
-ketoglutarate-Fe(II)-dependent dioxygenase, which repairs 1-methyladenine and 
3-methylcytosine in DNA by oxidative demethylation ([14], Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 AlkB-mediated demethylation of N1-methyladenine and N3-methylcytosine. The methyl 
groups are converted to hydroxymethyl moieties, which are spontaneously lost in the form of 
formaldehyde to regenerate the unmodified bases (the aberrant methyl groups and their oxidation 
products are shown in red). Note that the cofactors (blue) are consumed during the reaction in 
stoichiometric amounts (from [15]). 
 
2.2 Base excision repair (BER) 
 
2.2.1 Overview 
As the name implies, the initial step in BER is the removal of an aberrant or 
damaged base, and this job is carried out by specialized enzymes, DNA 
glycosylases. While several of them have very narrow substrate specificity, most 
glycosylases remove more than one structurally different damaged or mispaired 
base, thereby addressing modifications like oxidation, deamination or alkylation. It 
has been possible to reconstitute the BER process using purified proteins from 
bacteria to mammals, and it is fundamentally conserved throughout evolution [16-
21]. After recognition of the suspect base, glycosylases remove it by cleaving the N-
glycosidic bond between the base and the sugar-phosphate backbone of the DNA. 
The resulting abasic site is subsequently processed by one of two BER pathways: in 
short-patch BER, removal of the aberrant base is followed by strand cleavage 5’ to 
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the formed abasic site by an AP endonuclease (APE1 in humans). In the next step, 
the baseless sugar-phosphate is replaced by polymerase , attaching a single 
nucleotide to the newly generated 3’-OH end and removing the sugar-phosphate 
moiety by its lyase activity [21]. DNA ligase III, which interacts with polymerase  
through the XRCC1 protein (X-ray cross-complementation protein 1), seals the nick 
to restore the original DNA sequence [17]. In an alternative mechanism, long-patch 
BER, APE1 makes the 5’ incision to the AP site, and then the combination of DNA 
polymerase /, RFC, PCNA, and FEN1 displaces the strand 3’ to the nick to 
produce a flap of 2-10 nucleotides, which is excised at the junction of the single- to 
double-strand transition by the flap-endonuclease FEN1. Concomitantly, repair 
synthesis of the eliminated patch is carried out by polymerase /, RFC, PCNA or 
polymerase  [20-22]. Finally, the nick is ligated by DNA ligase I. The short-patch 
repair pathway presumably predominates and, in certain cases, appears to be used 
exclusively, for example when base excision is mediated by DNA glycosylases/AP 
lyases (Fig. 5) [23]. Long-patch BER may serve as a back-up pathway and could be 
important for the removal of modified abasic sites that are resistant to the AP lyase 
activity of polymerase  [18].  
 
2.2.2 Glycosylases 
Mechanistically, glycosylases can be divided into two classes: (1) monofunctional 
DNA glycosylases, and (2) bifunctional DNA glycosylases/AP lyases. The former 
cleave the glycosidic bond using water as a nucleophile and generate apurinic or 
apyrimidinic (AP) sites (Fig. 6). The latter utilize an amino group of the enzyme as a 
nucleophile to form a Schiff’s base intermediate, which undergoes enzyme-catalyzed 
-elimination cleaving the phosphodiester bond 3’ from the abasic site [24].  
The four known monofunctional uracil-DNA glycosylases in humans, namely UNG 
(uracil-DNA glycosylase), TDG (thymine-DNA glycosylase), MBD4 (methyl-CpG 
binding domain protein 4) and SMUG1 (single-strand selective monofunctional 
uracil-DNA glycosylase 1) accompanied me during the studies of my thesis and 
therefore I will turn my attention in particular to this quadripartite team of UDGs.  
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Figure 5 Overview of base excision repair pathways: The short-patch BER pathway shown in the 
center is predominant. Excision of a damaged base by a DNA glycosylase or spontaneous base loss 
generates an abasic site, which is processed to a single-strand break by an AP endonuclease. The 
repair synthesis of one nucleotide and the excision of the abasic site is brought about by polymerase 
, and DNA ligase III seals the remaining nick to restore the original DNA sequence. The short-patch 
pathway involving a bifunctional DNA glycoylase/AP lyase is outlined on the right. This pathway also 
requires APE1, Pol  and DNA ligase III, with the difference that Pol  is not involved in the removal of 
the baseless sugar-phosphate. In the long-patch repair pathway, Pol / supported by the replication 
factors RFC/PCNA, makes a repair tract of 2±6 bases and FEN-1, supported by PCNA, excises the 
overhanging oligonucleotide. DNA ligase I then seals the nick (from [25]). 
 
All of them display affinity for bases that arise through deamination of cytosine 
and/or 5-methylcytosine residues. While three of them (UNG, SMUG1 and TDG) 
belong to the UDG family of DNA glycosylases, possess the same fold, and have 
probably evolved from a common ancestor [26], MBD4 is a member of the helix-
hairpin-helix (HhH) family of DNA glycosylases [25]. All DNA glycosylases flip the 
target nucleotide out of the double helix and into an active site pocket of the enzyme 
where catalysis takes place. This pocket consists of aromatic residues that stack 
against the base, polar side chains that make specific hydrogen bonds, and 
12
  DNA repair mechanisms
   
 
hydrophobic residues that control shape and size of the pocket. The mechanism of 
glycosidic bond cleavage is very similar for most enzymes and involves the attack of 
an activated nucleophile at the anomeric position to displace the damaged base [25]. 
 
Figure 6 The general mechanism of monofunctional DNA glycosylases. The structure indicated in 
brackets represents the transition state, in which substantial partial positive charge accumulates on 
the 2-deoxyribose ring, especially at the positions denoted by +. 
 
2.2.2.1 Uracil-DNA glycosylase (UNG)  
Uracil in DNA can be introduced via two mechanisms, deamination of cytosine and 
misincorporation of dUMP during replication. Whereas U/G mispairs resulting from 
deamination of cytosines are mutagenic, misincorporation of dUMP during replication 
leads to U/A mispairs, which, although not miscoding, may produce cytotoxic and 
mutagenic AP site intermediates due to repair events. To prevent cytotoxic and 
mutagenic effects of the above lesions, all living organisms express uracil-DNA 
glycosylases. 
Uracil-DNA glycosylase activity was first detected in 1974 by Tomas Lindahl in 
extracts of E. coli [27], and has since been isolated from various other sources 
including yeast [28], mammals [29-31] and large eukaryotic DNA viruses [32]. 
Eukaryotic cells have both a nuclear and a mitochondrial form of uracil-DNA 
glycosylase [33-35] and it is assumed that the mitochondrial splice variants of many 
eukaryotic DNA glycosylase mRNAs protect the mitochondrial DNA against damage 
resulting from its proximity to the electron transport system [36]. The evolutionarily 
highly conserved human uracil-DNA glycosylase was cloned in 1989 and it could be 
shown that the in vitro expressed protein not only exhibited uracil-DNA glycosylase 
activity, but could also restore wild-type phenotype when expressed in E. coli ung 
mutants [37, 38]. Since then, UNG has been extensively studied, and its structure 
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and molecular mechanism of catalysis and specificity established [39-42]. The 
enzyme removes uracil in vitro in the order of preference ssU > U/G > U/A [43], and, 
in addition, excises 5-hydroxyuracil, isodialuric acid and alloxan, although at very low 
rate compared with uracil [44]. Several lines of evidence ascribe a major role in 
postreplicative removal of misincorporated uracil in mammalian cells to UNG2 by 
showing its interaction with RPA and PCNA and colocalization with these two 
proteins to replication foci [45]. Studies with Ung-/- mice underline these results by 
showing significant accumulation of dUMP in the DNA of the knockout cells [46]. 
Since neither overt phenotype abnormalities, nor predisposition to cancer could be 
observed [46], the finding that the increase in uracil content of genomic DNA in the 
knockout cells had only a marginal effect on the spontaneous mutation frequency 
suggested that murine UNG is involved primarily in the removal of uracil incorporated 
during replication. Therefore it was speculated that in higher eukaryotes, a redundant 
activity such as SMUG1 could instead be the responsible glycosylase for excision of 
deaminated cytosines [47]. However, bacterial and yeast ung mutants display a 
mutator phenotype as they are unable to repair deaminated cytosines [48, 49] and 
Kavli et al. could show that recombinant nuclear UNG2 likely is the major nuclear 
enzyme for removal of deaminated cytosines in both double- and single-stranded 
DNA in vitro [50]. The contribution of UNG2 to repair of deaminated cytosines 
therefore remains controversial and demands further investigation. 
 
2.2.2.2 Thymine-DNA glycosylase (TDG)  
Cytosine and 5-methylcytosine are subject to spontaneous deamination. While 
deamination of cytosine produces uracil, which can be readily removed by uracil-
DNA glycosylase [51], deamination of 5-methylcytosine yields thymine, thus 
generating a G/T mispair. In an attempt to prove that such mismatches are corrected 
in favor of guanine, Brown and Jiricny introduced specific G/T mispairs into the 
genome of SV40 and determined the fate of the mismatched bases in African Green 
Monkey (CV1) cells [52]. Indeed, a G/T directed repair activity that efficiently 
replaced the T with a C could be observed. The subsequent purification of a G/T 
binding and processing enzyme from nuclear extract of HeLa cells and the molecular 
cloning of the respective cDNA led to the discovery of the human thymine-DNA 
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glycosylase [53-56]. Orthologs in bacteria [57], yeasts, insects [58] and frogs are 
known, all of them belonging to the MUG branch superfamily of monofunctional 
uracil-DNA glycosylases that share a common /-fold structure [26]. Although the 
human TDG is best known for its ability to remove T from a T/G mismatch, MUG 
proteins of different origin were shown to have rather broad substrate spectra with U 
mispaired to G being the common, most efficiently processed physiological DNA 
lesion [57-60]. Derivatives of U with modifications or substituents at the 5-carbon 
position (e.g. 5-bromouracil, 5-fluorouracil) turned out to be very efficiently and 
universally processed substrates as well [58]. Moreover, the MUG protein family act 
also on DNA lesions as divergent as ethenoadducts [58, 61, 62], deaminated purines 
[58] and thymine glycol [63]. Studies of the three-dimensional structure of the E. coli 
Mug protein revealed some unique features: while UNG and SMUG enzymes 
establish highly specific hydrogen bonds with the uracil residue [64-66], Mug forms a 
large hydrophobic pocket with space for a variety of substrates as described above, 
without contacting the base to be hydrolyzed [66], but, instead, interacts with the 
complementary DNA strand opposite the target base. Thus, Mug, and probably the 
entire MUG family, uses the complementary base for substrate discrimination, while 
other UDGs establish specific contacts with the substrate base. Apparently, MUG 
proteins have evolved with little selective pressure, so that, in accordance with the 
specific needs of individual species, enzymes or enzyme complexes with rather 
distinct functionalities could develop. 
It is also noteworthy that human TDG was shown to bind to an AP-site opposite G 
with an affinity that is higher than that to any of its preferred substrates (e.g. G/U or 
G/T mismatches [67, 68]). Thus, the available experimental evidence suggests that a 
conformational change, involving the N-terminal domain of TDG, provides unspecific 
DNA interactions that facilitate processing of a wider spectrum of substrates at the 
expense of enzymatic turnover. SUMOylation then reverses this structural change in 
the product bound TDG (Fig. 7) [69]. 
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Figure 7 A model for 
dynamic DNA 
interactions associated 
with base excision by 
TDG. Experimental 
evidence predicts four 
different conformational 
states of TDG.   
A DNA-free TDG has an 
open conformation. 
B Upon encountering a 
DNA molecule, the N-
terminus forms a closed 
structure with the 
catalytic CORE, 
mediating nonspecific 
DNA binding. This mode 
of interaction may allow 
TDG to slide along the 
DNA, to dissociate and 
reassociate with DNA, 
in search of a potential 
substrate. 
C and D G•U- or 
G•APsite bound TDG reflects a third conformational state, where an amino acid wedge penetrates the 
DNA duplex and forms specific contacts with the guanine opposite. The nonspecific and the specific 
DNA contacts now cooperate to prevent the dissociation of TDG from the substrate. 
E SUMO modification of TDG then induces a fourth conformational state, neutralizing the nonspecific 
DNA interactions of the N-terminus and facilitating the dissociation of the enzyme from the AP site. 
F APE1 gains access to the AP site and continues the BER process. Demodification by SENP 
proteins allows recycling of TDG and SUMO (from [69]). 
 
Concerning the biological functions of TDG, interesting considerations can be taken 
into account. As discussed above, UNG-deficient cells accumulate significant 
amounts of dUMP in their DNA despite the presence of TDG, MBD4 and SMUG1 
[46]. These A/U mispairs arising during replication are reported to be poor substrates 
for TDG [60], arguing strongly against a major contribution of the enzyme to the 
elimination of U that gets misincorporated opposite A. A direct replication-associated 
function of TDG is further excluded by the fact that the protein is actively degraded 
by the proteasome pathway at the G1/S boundary of the cell cycle and then remains 
undetectable during the entire S-phase (Ulrike Hardeland et al., manuscript 
submitted). To keep the diverged features of MUG proteins in mind: in fission yeast 
S. pombe, unlike in mammalian cells, the replicative uracil-DNA glycosylase Ung1 
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acts synergistically with the TDG ortholog Thp1 to eliminate U that gets 
misincorporated during DNA replication.  
As mentioned above, the fact that inactivation of UNG in mouse did not significantly 
alter the mutation frequency argues for G/U correction being achieved by redundant 
activities. But since the C  T transition frequency at hprt locus of Ung-deficient 
mouse cells increases synergistically when Smug1 is silenced by siRNA, both UNG2 
and SMUG1 are good candidates [70]. However, TDG is likely to act on deaminated 
cytosine as well, since it is highly active on a G/U substrate and is expressed in most 
mammalian cell types.  
With four enzymes competing for uracil excision in mammalian cells, the situation is 
complex and implies functional separation. Hence, whereas UNG and SMUG1 may 
act more globally on genome repair, the G/U processing by TDG (and MBD4) may 
be confined to certain areas of the genome and/or to specific physiological states of 
the cells. 
Already in 1992, a physical interaction of mouse TDG with the transcription factor c-
Jun has been reported [71]. Since then, a multitude of physical and functional 
associations between TDG and transcription factors could be observed [72-78] and 
the question arises whether and how the DNA glycosylase activity of TDG can be 
reconciled with a role in gene regulation in a plausible functional concept. Possibly, 
the specific recruitment to gene regulatory elements through the interaction with 
transcription factors would allow TDG to interrogate the integrity of methylated and 
unmethylated CpG sequences [79]. 
In embryonic development, TDG probably has a non-redundant essential function, 
as homozygous Tdg null-embryos lose viability at midgestation (Primo Schär et al.; 
Tetsuya Ono et al., manuscripts in preparation). 
As an apparent jack-of-all-trades, TDG presumably also plays a critical role in cancer 
therapy. 5-fluorouracil (5-FU), an antimetabolite used in chemotherapy against a 
wide range of human cancers, is an excellent substrate for the MUGs [58]. 
Surprisingly, inactivation of TDG in mouse embryonic fibroblasts causes 
hyperresistance to moderate doses of 5-FU (Christophe Kunz and Primo Schär, 
manuscript in preparation). Thus, TDG contributes significantly to the DNA-directed 
cytotoxicity of 5-FU. We can strongly confirm this finding with our in vitro results, 
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where we observe a predominant role of TDG in the removal of 5-FU from 5-FU/G 
mismatches on circular heteroduplex substrates (see Results, Fischer et al., 
manuscript submitted). It remains to show the correlation between TDG activity in 
human tumors and the response to 5-FU-based chemotherapy. 
Finally, the G/T processing function of TDG may also exhibit chemotherapeutic 
relevance. Since T is a substrate for TDG when mispaired with O6-methylguanine 
[80, 81] (a cytotoxic lesion arising by using SN1-type methylating chemotherapeutic 
agents) and O6-methylguanine is a substrate for mismatch repair machinery when 
mispaired with either T or C, BER competes with MMR on the same substrate, thus 
maybe affecting the cytotoxicity of O6-methylguanine-inducing drugs. 
 
2.2.2.3 Methyl-CpG binding domain protein 4 (MBD4) 
MBD4, also known as MED1, was identified by using two different screening 
methods. In 1998, Hendrich and Bird isolated the human and mouse MBD4 genes 
due to DNA sequence homology to the methyl-binding domain of MeCP2, a human 
5-methylcytosine binding protein and transcriptional repressor [82]. The second 
identification of MBD4 was based on an interaction with the mismatch repair protein 
MLH1 that was found by using a yeast two-hybrid system [83]. The MBD4 protein is 
unusual in that it contains a methyl-CpG binding domain at the N-terminus [83] as 
well as a DNA glycosylase domain at the C-terminus [84-86]. Although structurally 
unrelated, MBD4 has enzymatic properties very similar to those of TDG and the 
optimal substrates are G/T and G/U mispairs in the context of CpG or 5-meCpG sites 
[85], suggesting a main role in counteracting the mutagenic potential of 5-meC 
deamination in CpG sequences. But other, albeit weaker, substrates for MBD4 have 
also been described: 5-meC from 5-meC/G [86], 5-FU from 5-FU/G [85] and T from 
T/O6-meG [87] can all be removed by the action of this glycosylase.  
Loss of MBD4 function in mouse embryonic fibroblasts causes several mismatch 
repair (MMR) proteins to be down-regulated, an effect manifested at the protein level 
but not the mRNA level [87]. This could be interesting, because it may show a 
functional link between the BER and MMR pathways.  
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The interaction discovered between MBD4 and FADD (Fas-associated death domain 
protein) may provide an explanation for the fact that MBD4-deficient cells fail to 
undergo apoptosis upon treatment with DNA damaging agents [87, 88]. 
MBD4-null mice are viable and fertile and are without apparent increase in tumor 
susceptibility, although they show a small increase in C  T mutations at CpG sites, 
which would be consistent with a defect in the repair of deaminated 5-meC that 
cannot be fully compensated for by the presence of TDG [89, 90]. On the other 
hand, the group of Primo Schär found that inactivation of TDG in mouse embryonic 
stem cells and fibroblasts reduces the G/T processing in cell extracts to undetectable 
levels, indicating that TDG provides the predominant activity against the products of 
5-meC deamination in these cells (Christophe Kunz, Yusuke Saito, Primo Schär, 
manuscript in preparation). 
The only conclusion that can be drawn at this point is that G/T repair in vertebrate 
cells is conducted by at least two distinct DNA glycosylases that may act in a 
partially redundant manner. 
 
2.2.2.4 Single strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1) 
In an attempt to sort rapidly through libraries of expressed proteins to detect DNA 
repair activity, Haushalter and colleagues devised an in vitro expression cloning  
(IVEC) approach and identified the SMUG1 protein from Xenopus laevis. Hence, the 
human counterpart was found due to extensive homology of the frog protein to 
several human expressed sequence tags (ESTs). Nicking assays revealed that both 
xSMUG1 and hSMUG1 acted upon U/A and U/G with no preference for either, but 
processed uracil residues in single-stranded DNA much more efficiently than in 
double-stranded DNA. Neither the Xenopus nor the human protein showed any 
enzymatic activity on G/T mismatches. hSMUG1 is furthermore localized to the 
nucleus [91], but is not cell cycle-regulated and, in contrast to UNG2, does not 
accumulate in replication foci [50]. This would agree with the suggested function of 
hSMUG1 being the main enzyme to eliminate U from U/G mismatches resulting from 
cytosine deamination [47]. Other studies, however, claim that UNG2 may be the key 
player in the repair of deaminated cytosines [50].  
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SMUG1 is not found in bacteria and yeast, but is present in higher eukaryotes. 
Boorstein et al. proposed hSMUG1 as the major enzyme for removal of 5-
hydroxymethyluracil (5-hmeU) [92]. 5-hmeU is a result of oxidation of the 5-methyl 
group of thymine in DNA due to ionizing radiation and other forms of oxidative stress 
[93]. It is also the product of the deamination of 5-hydroxymethylcytosine, which may 
be formed via oxidation of 5-methylcytosine [94]. The latter forms a 5-hmeU/G base 
pair, which would be mutagenic if left unrepaired. 
A recent study from Tomas Lindahl’s lab attributes SMUG1 a possible role in cancer 
chemotherapy. Their data show that accumulation of 5-fluorouracil (5-FU) in the DNA 
of 5-FU-treated Smug1-deficient mouse embryonic fibroblast cells is cytotoxic and 
overexpression of Smug1 in wild-type cells protects cells against 5-FU-mediated 
killing [95]. From our in vitro studies we cannot confirm a significant contribution of 
hSMUG1 to the repair of 5-FU-containing mismatches (see Results, Fischer et al., 
manuscript submitted). 
 
2.3 Mismatch repair (MMR) 
 
2.3.1 Where it all started… 
DNA damage has different faces, including strand breaks, a variety of chemical 
alterations of the standard bases, incorporation of cytotoxic base analogs, but also 
classical mispairs and insertion-deletion-loops (IDLs) that have escaped the 
proofreading exonuclease activity during DNA replication. The latter lesions become 
substrates for the mismatch repair system (MMR), whose task is to restore the 
information contained in the template strand. But to accomplish this challenging 
mission, the responsible repair system must be able a) to recognize base-base 
mismatches and IDLs, and b) to distinguish between the parent and the daughter 
strands [96]. Whereas other repair systems (e.g. BER) recognize modified or 
damaged DNA components, MMR addresses mismatches composed of unmodified 
standard nucleotides and therefore depends on a solid strand discrimination 
mechanism in order to avoid correction of the wrong moiety.  
Due to his enormous experience with restriction enzymes and based on the finding 
that the transient undermethylation of the newly synthesized strand in E. coli might 
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provide the bias for strand discrimination [97, 98], Modrich and colleagues described 
in 1983 a substrate that permitted in vitro analysis of mismatch repair, thereby 
creating a breakthrough in this field. They could show that the in vitro repair activity 
in E. coli extracts is dependent on ATP, the state of dam methylation of mismatch 
heteroduplexes, and products of mutH, mutL, mutS and uvrE loci [99]. 
This provided the signal for a series of elucidating experiments and since the 
discovery of a link between the MMR system and hereditary non-polyposis colon 
cancer (HNPCC) in 1993 [100, 101], the study of this complex repair pathway 
proceeded in quantum leaps. 
 
2.3.2 Biological significance of MMR 
MMR corrects not only replication errors, but also mismatches that arise as a natural 
consequence of genetic recombination when the heteroduplex intermediate spans 
genetic differences between recombining helices [102, 103]. The absence of MMR 
permits illegitimate recombination between quasi-homologous sequences [104, 105]. 
In addition, a variety of base pair anomalies are also subject to processing by 
mismatch repair. These include base pairs containing O6-methylguanine [106-110], 
8-oxoguanine [111, 112], carcinogen adducts [113], UV photoproducts [114-116], 
and cisplatin adducts [107, 117, 118].  
Genetic inactivation of the mismatch repair system elevates spontaneous mutability 
50-1000-fold [119-124] and defects in this repair complex result in highly elevated 
rates of base substitutions and frameshift mutations, and render mammalian cells 
resistant to the cytotoxic effects of several classes of DNA damaging agents [123, 
125-127]. The remarkable discovery of a causal relationship between deficiencies in 
MMR and a familiar form of human colorectal cancer (hereditary non-polyposis colon 
cancer, HNPCC) [128-131] and the inactivation of mismatch repair in a subset of 
sporadic tumors occurring in a variety of tissues [129, 131-134] make this repair 
pathway an important clinical target in the fight against cancer. 
 
2.3.3 MMR in E. coli 
The mechanistic steps of MMR are well defined in E. coli and the entire repair 
reaction has been reconstituted in vitro [135]. Biochemical and genetic studies 
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implicated eleven activities in methyl-directed mismatch repair, namely MutS, MutL 
and MutH proteins, DNA helicase II (also called UvrD), exonuclease I (ExoI), 
exonuclease VII (ExoVII), Rec J exonuclease, exonuclease X (ExoX), single-
stranded DNA binding protein (SSB), DNA polymerase III holoenzyme and DNA 
ligase [135-138]. The repair reaction can be divided into three steps: initiation, 
excision, and resynthesis. In the initial phase, the homodimeric MutS [139, 140] 
protein detects a mismatch in a process that requires ATP and, upon interaction with 
a homodimer of MutL [139, 140] in the presence of ATP, activates the single-strand 
endonuclease MutH, which incises the unmethylated strand of a hemimethylated 
GATC site 5’ to the G [141, 142]. MutH incision can occur either 3’ or 5’ to the 
mispair on the unmodified strand, providing MMR with a bidirectional capability. How 
the communication between MutS-MutL and MutH occurs is still a matter of debate. 
There exist three different models for ATPase function in MutS and MutS 
homologues at the moment, each with experimental support. In one model (“ATP-
dependent translocation model”), on the basis of electron microscopic visualization, 
the MutS-MutL complex is proposed to loop out the DNA in an ATP hydrolysis-
dependent manner, actively searching for the nearest d(GATC) methylation site 
either 5’ or 3’ to the mismatch [143-145]. A second model (“sliding clamp model”) 
suggests that MutS-MutL or MutS-MutL bind the mismatch in an ADP-bound 
state, which provokes an ADP-ATP exchange. The ATP-bound complex undergoes 
a conformational change into a clamp with reduced affinity for the mismatch and 
diffuses freely along the DNA in an ATP hydrolysis-independent fashion. Thus, 
MutS-MutL or MutS-MutL complexes may interact with and activate the MutH 
endonuclease in the bacterial scenario [146] and may induce downstream events in 
eukaryotes [147, 148], respectively. The third model (“induced fit model”) proposes 
that MutS (or MutS) remains bound at or near the mismatch during the course of 
repair, thus challenging the idea that MutS (or MutS) leaves the mismatch [149]. In 
this model, interaction of the mismatch and the strand signal is mediated by DNA 
bending. While details about this communication remain to be further elucidated, it is 
clear that once a nick at the nearest hemi-methylated d(GATC) site is generated, the 
MutS-MutL heteroduplex complex is also sufficient to activate the methyl-directed 
excision step, which includes DNA helicase II (UvrD) and several single-strand 
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specific exonucleases with appropriate polarity [136, 150]. By the action of these 
additional set of proteins, the DNA tract between the incised, hemi-methylated GATC 
site and the mismatch is removed [151, 152] and resection of the damaged DNA 
stops about 100 bp past the mismatch [143]. The single-stranded template is 
stabilized by single-stranded DNA binding protein (SSB) until DNA polymerase III 
holoenzyme is recruited to resynthesize the gap. In the last step of resynthesis, DNA 
ligase seals the nick, thereby completing the repair process and restoring the 
integrity of DNA [135, 140] (Fig. 8). 
 
 
 
 
 
 
 
 
Figure 8 Mechanism of E. coli methyl-directed mismatch repair. Details of the reaction are described 
in the text. Although not shown, DNA ligase restores covalent continuity to the repaired strand after 
DNA polymerase III holoenzyme fills in the gap. Green arrows indicate MutS- and MutL-dependent 
signaling between the two DNA sites involved in the reaction [266]. 
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2.3.3.1 E. coli MutS protein 
MutS, a 95 kDa polypeptide, exists as an equilibrium mixture of dimers and 
tetramers [140, 153] and recognizes seven of eight possible mismatched base pairs 
(C/C is refractory to the bacterial protein) and binds to IDLs 1-4 nucleotides in length 
[140, 154-156]. The crystal structure of E. coli MutS bound to a G/T mismatch [157] 
revealed that the MutS homodimer encircles the mismatch-containing DNA as a pair 
of “praying hands” (reviewed in [158]), with the thumbs folded inwards, and the DNA 
passing between the fingertips and the thumbs (Fig. 9).  
 
 
 
 
Figure 9 The MutS sliding clamp and its activation. 
a The ADP-bound MutS homodimer binds to a G–T mismatch in duplex DNA. In the absence of DNA, 
the finger domains are unstructured and open, and the ATP-binding sites are dimerized. 
b In the presence of the mismatched DNA, the ADP-bound form of MutS is wrapped around the DNA 
like a pair of praying hands, and is anchored at the mismatch site by a Phe-X-Glu wedge (the thumb 
of one of the hands) that is inserted into the minor groove of the duplex. 
c ADP/ATP exchange brings about a conformational change that releases the Phe-X-Glu thumb from 
the mismatch site, but leaves the fingers closed around the duplex. The clamp is now free to 
translocate along the DNA in either direction (only one direction shown here). Although no eukaryotic 
MutS structure is available, biochemical experiments indicate that these heterodimers function 
analogously to the bacterial proteins. The idea of the ‘praying hands’ was taken from [158]. 
 
Each subunit consists of five distinct domains:  
Domain I (“mismatch binding domain”) at the N-terminus forms the top segment of 
the thumb and harbours the highly conserved GXFY(E) motif for mismatch 
recognition. The phenylalanine residue (F) was shown to be essential for mismatch 
recognition in the E. coli MutS protein [159], in the Msh6p of S. cerevisiae [160], and 
in hMSH6 [161].  
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Domain II (“connector”) and Domain III (“core”) constitute the backbone of each 
subunit, or in visual words the second and third segment of the thumb, and are 
involved in transmitting allosteric information of bound DNA cofactors to the ATPase 
domain. 
Domain IV (“DNA clamp”) is, like Domain I, involved in DNA binding and forms the 
fingers. 
Domain V (“ATPase”) contains the highly conserved Walker A and B motifs found in 
many DNA repair proteins [162]. The ATPase domains of the two subunits of the 
MutS homodimer are intertwined, an arrangement that is likely to coordinate 
conformational changes of both monomers [149, 157, 163], changing the affinity for 
mismatch-containing substrates [164, 165]. 
Remarkably, only one subunit contacts the DNA at the mismatch site, rendering 
MutS a functional heterodimer, in analogy with the asymmetric yeast and human 
counterpart MSH2/MSH6 [160, 161].  
 
2.3.3.2 E. coli MutL protein 
The homodimeric MutL is a 68 kDa polypeptide and serves to interface mismatch 
recognition by MutS to activation of downstream activities. It is recruited to the 
heteroduplex in a MutS- and ATP-dependent manner [139]. On the basis of 
sequence and structural analyses, MutL belongs to the ATPases of the GHKL 
(gyrase/Hsp90/histidine-kinase/MutL) family [166], with a conserved nucleotide 
binding site at the N-terminus (aa1-335), a flexible and poorly conserved linker, and 
a much less well conserved dimerisation domain in the C-terminal region (aa439-
615). The crystal structure of the N-terminal 349 amino acid residues revealed that 
binding of ATP or the non-hydrolysable ATP analogue AMP-PNP brings about a 
dramatic structural change and dimerisation [167, 168]. The idea that ATP is used to 
modulate conformational changes in the protein, thereby facilitating interactions with 
other protein and/or DNA partners [167, 169], is supported by mutational studies 
showing that impairment of either ATP binding or ATP hydrolysis by MutS or MutL 
abolishes the mismatch repair process [170]. A physical interaction between the N-
terminal ATPase domain of MutL and MutH has been detected by protein cross-
linking [168, 171] and several groups suggest direct interactions of MutL with UvrD 
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[169, 172, 173]. One recent study describes the structure of the C-terminal 
dimerisation domain of bacterial MutL and the authors propose a working hypothesis 
for MutL-mediated mismatch repair in E. coli, in which a large central cavity might 
form around DNA upon ATP binding-dependent association of the N-terminal 
ATPase domains of the two MutL subunits dimerised at the C-termini [173]. Whereas 
no DNA binding but binding and hydrolysis of ATP by MutL is required for mismatch-
dependent activation of MutH [170], they postulate that during activation of UvrD 
helicase, MutL contacts DNA adjacent to the mismatch site as well as where UvrD 
unwinds the duplex, thereby looping out the intervening sequence in its large central 
cavity. However, the role of ATP hydrolysis in UvrD activation in vivo remains 
speculative. Moreover, the above study conflicts with a revised model derived from a 
series of bioinformatic analyses of the quaternary structure of the C-terminal domain 
of MutL, suggesting a conserved hydrophobic surface patch as the responsible 
region for dimer formation [174]. 
Another enigmatic aspect of the MutL protein is the biological significance of its DNA 
binding activity in MMR. Several groups have shown that MutL binds both double- 
and single-stranded DNA with no sequence specificity [167, 170, 173, 175, 176], 
while others report that MutL does not bind DNA [177], or suggest that binding to 
DNA may be irrelevant to its function [146]. In addition, purified MutL catalyzes a 
very slow ATP hydrolysis reaction that is stimulated by the presence of ssDNA and is 
essential for MMR [167-169]. Recently, presented data from genetic and biochemical 
assays using a MutL protein containing a single point mutation at the conserved 
position 266 (MutL-R266E) and therefore exhibiting a DNA binding defect [167, 178] 
strongly suggest DNA binding as an indispensable part of the MMR process [179].  
Given the multiple roles in MMR, MutL is likely to be the master coordinator in the 
mismatch repair reaction, with still a lot of secrets to disclose.  
 
2.3.3.3 E. coli MutH protein 
MutH is a monomeric endonuclease that cleaves DNA at hemi-methylated d(GATC) 
sites 5’ to the G [141, 142] and its activity is greatly stimulated in a mismatch-
dependent manner by MutS, MutL and ATP. The crystal structure of E. coli MutH 
revealed a clamp-like structure with two “arms” separated by a large cleft that can 
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accommodate a DNA duplex [180]. When MutH incision occurs 5’ to the mismatch, 
excision depends on ExoVII or RecJ exonuclease [137, 143], both hydrolyzing 
single-stranded DNA with 5’ to 3’ polarity [181, 182]. On the other hand, cleavage 3’ 
to the mispair requires ExoI, ExoVII or ExoX [135-138, 143], all of which support 3’ to 
5’ hydrolysis of single-stranded DNA [181, 183, 184] (Fig. 8). 
Although the MMR system is highly conserved through evolution, the MutH function 
is not present outside of gram-negative bacteria. Organisms lacking MutH might 
initiate exonucleolytic degradation of the heteroduplex at pre-existing strand 
interruptions [185-187]. 
 
2.3.3.4 E.coli UvrD helicase 
UvrD is a superfamily I DNA helicase that exhibits modest processivity (40-45bp) 
[188-190]. Since MMR can require unwinding of up to 1-2kb of DNA, MutL is 
proposed to load multiple molecules of UvrD in an iterative process onto the 
substrate to increase the rate of progressive unwinding and to facilitate the 
unwinding of long duplex regions (reviewed in [191]). 
 
2.3.4 MMR in yeast 
The genetically best-characterized eukaryotic MMR system is that of the yeast 
Saccharomyces cerevisiae. Six MutS (MSH1-MSH6) and four MutL (MLH1-MLH3 
and PMS1) homologs exert diverse functions (Table 1): MSH1 is required for the 
repair and maintenance of mitochondrial DNA [103] and has not been identified in 
mammalian cells; MSH2, MSH3 and MSH6 are required for the stability of nuclear 
DNA [192, 193]; and MSH4 and MSH5 are involved in meiotic recombination 
processes [194, 195]. The mitochondrial-specific function of MSH1 suggests that a 
primitive version of this protein may be the founding MutS family member in 
eukaryotic organisms, and recent phylogenetic analysis supports this hypothesis 
[196]. 
The current model of yeast MMR is that mismatch recognition is effected by two 
distinct MutS-like heterodimers composed of MSH2 together with either MSH3 or 
MSH6. In vitro binding studies have demonstrated that MSH2-MSH6 binds to base-
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base mismatches or insertion/deletion loops, whereas MSH2-MSH3 binds only to 
duplexes containing insertion/deletion loops [197-200].  
Like the MutS protein in E. coli, the yeast MSH proteins possess ATP binding and 
hydrolysis activity that is located in the highly conserved C-terminal region. In the 
presence of ATP, MSH2-MSH6 mismatch binding is abolished in vitro and results in 
proteolysis-sensitive conformational changes in the complex [201-203], presumably 
reflecting the sliding clamp feature of MutS proteins (Fig. 9).  
The first evidence of a close conservation of the MMR pathway was the identification 
of the yeast MutL homolog PMS1 (yeast PMS1 = human PMS2), whose name 
reflects the fact that pms1 mutants exhibit increased levels of postmeiotic 
segregation [204, 205]. The remaining three MutL homologs (MLH1-MLH3) were 
identified on the basis of amino acid conservation with MutL [206, 207]. MLH1 forms 
heterodimers with the remaining three MutL homologs [208]. The MLH1-PMS1 
heterodimer is the major player in MMR [207], whereas MLH1-MLH2 and MLH1-
MLH3 complexes are specialized to repair distinct classes of mutational 
intermediates [206, 209].  
 
Table 1 E. coli and S. cerevisiae proteins required for DNA mismatch repair (from [124]). 
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MSH4 and MSH5 were identified because of their effects on meiotic recombination, 
and show no detectable involvement in mismatch correction [194, 195], consistent 
with the absence of a conserved N-terminal MutS/MSH domain responsible for 
mismatch binding [196].  
The availability of yeast MMR mutants were of inestimable value for the 
understanding of MMR-deficient human cell phenotypes and the identification of 
human MMR genes [210-214], thanks to the conservation of the amino acid 
sequences from bacteria to yeast to man. 
 
2.3.5 MMR in higher eukaryotes 
 
2.3.5.1 The leading actors 
Although eukaryotic cells possess a MMR pathway that is homologous to the E. coli 
methyl-directed, MutHLS-dependent repair [186, 187], there is a major difference 
between the two systems: While the bacterial MutS and MutL proteins are 
homodimers, the eukaryotic counterparts function as heterodimeric complexes. 
Among the several eukaryotic homologues of MutS (designated MutS homologues 
MSH2 to MSH6), three are involved in mitotic genetic stability where they participate 
in repair of base-base mismatches and IDLs: MSH2 interacts with MSH6 or MSH3 to 
form MutS [215] or MutS [216, 217], respectively. MutS supports repair of all 
eight base-base mismatches including C-C, as well as ID mispairs containing up to 
about ten unpaired nucleotides, whereas MutS corrects IDLs containing two to 
about ten nucleotides but is only weakly active on single nucleotide mismatches 
[216, 217]. MSH4 and MSH5 – as shown for their yeast counterparts - are restricted 
to meiosis where they play important roles in crossing over [218, 219]. 
Albeit not as well studied as the MutS homologues, four MutL counterparts, MLH1, 
MLH3, PMS1 and PMS2, have been identified [213, 214, 220, 221]. MutL, a MLH1-
PMS2 heterodimer [222, 223], is capable of supporting repair initiated by MutS or 
MutS [215], therefore playing the first fiddle in MMR. MutL, which is composed of 
MLH1 and PMS1, could not be shown to participate in MMR in vitro [224]. 
Nevertheless, it cannot be completely ruled out that this heterodimer might be 
involved to some extent in some mismatch repair events, since Pms1-knockout mice 
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exhibit low microsatellite instability (MSI) in mononucleotide runs [225]. Interestingly, 
latest findings from the lab of Paul Modrich identified an endonuclease activity in the 
subunit PMS2 of MutL, with the consensus endonuclease sequence being 
conserved in MLH3, but not in PMS1. This explains the observation that MutL 
shows no or only marginal MMR activity [226]. Similarly, MutL, consisting of MLH1 
and MLH3, which appears to be involved in meiosis [227], participates, albeit 
inefficiently, in the repair of base-base mismatches and single-nucleotide IDLs 
([228], see Results, Cannavo et al. (2005), Cancer Research). 
In addition to MutS and MutL homologues, human mismatch repair requires several 
other factors, one of which is the homotrimeric proliferating cell nuclear antigen 
(PCNA). By interacting with MSH3 and MSH6 [229-231], PCNA has been shown to 
be of importance not only during DNA resynthesis as a processivity factor for 
polymerase  [232], but already during MMR initiation prior to the excision steps 
[233]. Thus, PCNA may exert multiple functions in the process of MMR, with 
proposed roles in facilitating mismatched DNA binding and mobilizing the 
MutS/MutL complex away from the mismatch [234], and suggested functions as a 
strand discrimination signal [233, 235] or as a key protein in the differential activation 
of the appropriate hydrolytic system [236]. 
Another group of important players are the exonucleases. Since the human MMR 
system acts bidirectionally, degradation in 3’5’ and 5’3’ must be accomplished. 
Yeast genetic studies implicated the 3’5’ proofreading activities of DNA 
polymerase  and/or polymerase  in MMR [237, 238], but no significant involvement 
of the polymerase  editing exonuclease was evident in human mismatch-provoked 
excision in vitro [239]. Other findings indicated that the 3’5’ exonuclease activity of 
MRE11 might also be required in vivo [240]. Among the 5’3’ exonucleases, only 
exonuclease-1 (EXO1) has been shown to act in vivo and in vitro [241], in agreement 
with recent in vitro results, showing that EXO1 is sufficient for both 3’5’ and 5’3’ 
mismatch correction [236]. Nevertheless, it can be concluded from knock-out mice 
models that there must be some redundant activities besides EXO1 in vivo [242].  
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2.3.5.2 Human MutS 
In 1988, a first description of a factor binding G/T mispairs in HeLa extracts was 
published [243]. Analogous to its function, it was named GTBP (G/T-binding protein) 
and the purest fraction of this activity contained two bands of apparent molecular 
mass of 100 and 160 kDa [244], the smaller of them thought to be formed by 
proteolysis of the larger one. This hypothesis, however, turned out to be wrong: the 
observed bands represent two proteins encoded by distinct genes [245]. The 100 
kDa protein was shown to be the product of the hMSH2 gene [246] and the 160 kDa 
protein, originally called GTBP [244], was renamed hMSH6 due to its close 
relatedness to the S. cerevisiae MSH6 protein [193]. These results mirror the 
asymmetric nature of the hMutS heterodimer and implied that the two subunits play 
distinct roles during mismatch recognition. Indeed, cross-link experiments with 
mismatch-containing DNA only succeeded with hMSH6 [164]. And correspondingly 
to the finding of Malkov et al. with MutS protein of T. aquaticus [159], a PheAla 
substitution in the highly conserved N-terminal motif of hMSH6, but not hMSH2, 
severely attenuated binding and mismatch repair functions of hMutS [161]. A 
similar effect could be shown by mutating the equivalent amino acid in the Msh6p of 
S. cerevisiae [160].  
MutS homologues are members of the ABC (ATP binding cassette) transporter 
family of ATPases [247] with their C-terminal domains being highly conserved. 
Since the Phe-X-Glu motif described above resides in the N-terminus and is 
therefore far away from the C-terminal ATP-binding sites, nucleotides are 
dispensable for the initial binding of MutS and MutS to their respective substrates 
[215, 217, 245, 248]. This was confirmed by the findings that mutations in the ATP-
binding sites of different MutS homologues had little effect on mismatch binding, but 
resulted in a significant decrease in the ATP-driven dissociation of the proteins from 
DNA [164, 201, 203, 249]. On the other hand, mutations in ATP-binding sites of 
either subunit of hMutS, but particularly in hMSH6, resulted in MMR deficiency in 
an in vitro assay [164], as well as in vivo [165].  
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One major difference between hMutS and MutS is the simultaneous occupancy of 
the nucleotide binding sites: whereas MutS sliding clamp contains two bound ATP 
molecules, hMutS has two nucleotide binding sites with differential specificities for 
ADP and ATP [250].  
However, the roles of nucleotides in MMR need to be further elucidated. 
 
2.3.5.3 Human MutS 
Repair assays with extracts from cells deficient either in MSH6 or MSH2 proteins 
revealed that although MSH2-deficient extracts lacked the ability to repair G/T 
mismatches and IDLs, MSH6-deficient extracts were partially proficient in the repair 
of two-nucleotide loops [215], implying the existence of a MSH6-independent loop 
repair.  
Subsequently, Palombo et al. showed that MSH2 forms by heterodimerization with 
MSH3, MutS [217]. MutS is responsible for the repair of IDLs in the range of two to 
ten nucleotides, weakly recognizes single-nucleotide IDLs and is essentially inert on 
base-base mismatches [216, 245]. In vivo, the ratio of MutS/MutS is around ten to 
one [216, 251, 252]. Overexpression of MSH3 leads to a dramatic change in the 
relative levels of MutS and MutS, with the consequence of base-base mismatch 
repair deficiency due to depletion of MutS [253]. 
 
 
2.3.5.4 Human MutL 
The human counterpart of the bacterial MutL is a heterodimeric factor, MutL, 
consisting of MLH1 and PMS2 [222], and although it is essential for MMR, its precise 
function is unclear. MutL accounts for about 90% of the MLH1 in human cells [224, 
228], the remaining MLH1 is involved in the formation of two low abundance 
complexes, MutL (MLH1/PMS1; [224]) and MutL (MLH1/MLH3; [221]).  
In the presence of ATP, human MutS and human MutL form relatively stable ATP-
dependent ternary complexes on oligonucleotide substrates [223, 254, 255]. Since 
substitutions in the ATP binding sites of MutL do not affect the formation of the 
ternary complex with MutS on DNA, but induce deleterious effects, the latter could 
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be linked to a step downstream [223], confirming the reputation of MutL proteins as 
so-called “molecular matchmakers”.  
 
 
Figure 10 Diagrams of 
the initial incision step of 
MMR in E. coli and 
humans. 
A In E. coli, MutS 
recognizes a mismatch, 
binds it and bends the 
DNA by 60° towards the 
major groove. The newly 
synthesized and 
unmethylated daughter 
strand is shown in grey. 
In the presence of ATP, 
MutL is recruited to the 
MutS-mismatch com-
plex, and together they 
activate MutH to nick the 
daughter strand on either 
the 5’ or 3’ side of the 
mismatch. Since the 
DNA-binding activity of MutL is not necessary for this step and slightly inhibits MutH activation [170], 
we propose that the DNA in between the mismatch and incision site is looped out. 
B In humans, MutS is made of MSH2 (green) and MSH6 (blue) and interacts with PCNA (purple). The 
daughter strand is marked by a pre-existing strand break. A break 3’ to the mismatch is shown here 
as an example. MutS may have a strand preference when loaded by PCNA. The ensuing MutS–MutL-
mismatch complex could also be biased due to the asymmetric (heterodimeric) nature. Incisions by 
the PMS2 subunit of MutL on the 3’ side of the mismatch may be guided by PCNA and MutS, and 
incisions on the 5’ side may be limited by how far the C-terminal domain of MutL (the endonuclease 
active site) can extend from the MutS–MutL complex located on the mismatch site (taken from [256]). 
 
Recently, Paul Modrich and his colleagues could celebrate another triumph in the 
MMR field by the discovery of an intrinsic endonuclease activity in the PMS2 subunit 
of MutL [226]. After having speculated for a long time about an unknown cryptic 
3’5’ exonucleolytic activity, the authors observed cleavage of the daughter 
(discontinuous) strand on either side of the mismatched base, guiding them finally 
towards the answer to this problem (Fig. 10). 
 
2.3.5.5 Human MutL 
PMS1 is expressed in human cells and interacts with MLH1 with high affinity to form 
the heterodimer MutL [224]. Since tumor cell lines lacking either MLH1 or PMS2 
exhibit apparently similar phenotypes [257], a significant functional redundancy 
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between PMS2 and other MutL homologues was excluded. In addition, mice carrying 
a disruption of the Pms1 gene display neither MSI nor cancer predisposition [225]. 
However, identification of one patient with an HNPCC family background who 
harbored a mutation in the PMS1 gene [213] and the findings that the PMS1 
homologue in yeast, Mlh3p, interacts with Mlh1p in a yeast two-hybrid assay and 
contributes to the repair of a subset of IDLs [122, 206, 258], challenged this 
statement. Nevertheless and although biochemically characterized, participation of 
MutL in mismatch repair could not be shown so far and thus remains to be 
demonstrated.  
 
2.3.5.6 Human MutL 
Human MutL, a heterodimer consisting of MLH1 and MLH3, was identified by Far 
Western Blots [221], but its role in MMR was not characterized. Studies in S. 
cerevisiae, where MLH3 was first identified, showed an interaction between scMlh3p 
and scMlh1p [206, 208]. Furthermore, involvement of MLH3 in yeast [259, 260], 
human [261, 262] and murine [262] meiotic recombination has been reported. 
Recently, we could confirm the existence of hMutL in vivo and suggest a back-up 
role in MMR for this heterodimer in correcting base-base mispairs and one 
nucleotide IDLs with low efficiency [228].  
 
2.3.5.7 Reconstituted  MMR systems 
Based on data deriving from reconstituted in vitro systems [239, 263], the current 
scheme of human MMR suggests that the mismatch-bound MutS undergoes an 
ATP-dependent conformational change, converting the heterodimer into a sliding 
clamp which is capable of translocating along the DNA backbone in vitro [145, 148, 
165]. 
In a second ATP-dependent step, the MutS-ATP-DNA complex recruits MutL 
[222], forming a mobile complex with the ability to translocate bidirectionally along 
the DNA contour in search of a strand discontinuity. Although endowed with 
bidirectionality, different protein sets are required, depending on the polarity of the 
encountered nick. 
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Figure 11 5’ to 3’ default hydrolytic system. EXO1, which is activated in a mismatch- and MutS 
dependent manner, initiates 5’ to 3’ hydrolysis at the strand break [263-265]. Excision on a 5’- 
heteroduplex terminates upon mismatch removal in a manner that depends on RPA and MutL. 
MutS also activates EXO1 on a 3’-heteroduplex, but in this case hydrolysis proceeds with the wrong 
directionality for mismatch removal. Green arrows indicate a requirement for signaling between the 
mismatch, which activates excision, and the strand break where hydrolysis initiates (from [266]). 
 
A four protein system, consisting of purified MutS, MutL, RPA and exonuclease-1 
(EXO1), was shown to be sufficient to mediate excision of a 5’-heteroduplex (nick 
located 5’ to the mismatch, Fig. 11), terminating in the region of 60 to 230 
nucleotides beyond the mispair [265]. In this scenario, RPA enhanced MutS-
dependent EXO1 activation in the presence of MutL. Even though MutL is not 
essential for 5’3’ degradation, it improved the selectivity of the reaction in favor of 
the heteroduplex substrates. 
Interestingly, exactly the same happened in the presence of a 3’-heteroduplex (nick 
located 3’ to the mismatch, Fig. 11), resulting in an excision reaction proceeding 
away from the mismatch with incorrect 5’3’ polarity ([236], Fig. 11).   
Supplementation of both PCNA and RFC (clamp loader of PCNA [267]) yields a 
system that supports mismatch removal from 5’- and 3’-heteroduplexes [236]. More 
precisely, MutS, RFC, and PCNA activate a latent MutL endonuclease in an ATP- 
and mismatch-dependent manner [226], which incises both 3’- and 5’-
heteroduplexes with a strong bias for the nicked strand (Fig. 12). 
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Like this, a 5’ initiation start point on a 3’-heteroduplex is generated, subsequently 
leading to the removal of the mismatch by the 5’3’ action of MutS-activated 
EXO1 (Fig. 12).  
 
Figure 12 MutL endonuclease in mismatch-provoked excision. MutL endonuclease, which is 
activated in a mismatch-, MutS-, PCNA-, RFC-, and ATP-dependent manner, incises (red arrows) 
the discontinuous strand of 5’- or 3’-heteroduplex DNAs in an ATP-dependent manner [226]. Incision 
of a 3’-heteroduplex on the distal side of the mispair relative to the strand break yields a 5’ terminus 
that serves as an entry site for MutS-activated EXO1, which removes the mismatch by the 5’ to 3’ 
hydrolytic reaction shown in Fig. 11. Excision tracts shown in this model span the mismatch and the 
original heteroduplex strand break, as observed in human cell extracts [185, 187, 268]. Because 
MutL activation depends on a heteroduplex strand break and because endonuclease action is 
restricted to the nicked heteroduplex strand, signaling must occur between mismatch and 
heteroduplex strand break (green arrows). Adapted from Kadyrov et al. [226]. 
 
By supplementing this six-component excision team with DNA polymerase  and 
DNA ligase I, the MMR process could be fully reconstituted in vitro ([239, 263], Fig. 
13).  
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Figure 13 The reconstituted 
human mismatch-repair 
system. The mismatch repair 
(MMR) process was recently 
reconstituted [239, 263] from 
either MutS or MutS, 
MutL, replication protein A 
(RPA), exonuclease-1 
(EXO1), proliferating cell 
nuclear antigen (PCNA), 
replication factor C (RFC), 
DNA polymerase  (Pol ) 
and DNA ligase I. The 
following is proposed to take 
place. The mismatch (red 
triangle)-bound MutS (or 
MutS) recruits MutL. The 
ternary complex undergoes 
an ATP-driven 
conformational switch, which 
releases the sliding clamp 
from the mismatch site. 
a Clamps that diffuse 
upstream encounter RFC 
that is bound at the 5’ 
terminus of the strand break, 
and will displace it and load 
EXO1. The activated 
exonuclease commences 
the degradation of the strand 
in a 5’-3’ direction. The 
single-stranded gap is 
stabilized by RPA. When the 
mismatch is removed, EXO1 
activity is no longer 
stimulated by MutS, and is 
actively inhibited by MutL. 
Pol  loads at the 3’ terminus 
of the original discontinuity, 
which carries a bound PCNA molecule. This complex fills the gap and DNA ligase I seals the 
remaining nick to complete the repair process. 
b Clamps that migrate downstream encounter a PCNA molecule that is bound at the 3’ terminus of 
the strand break. The recruitment and the activation of EXO1 results in the degradation of the region 
between the original discontinuity and the mismatch, possibly through several iterative EXO1-loading 
events. RFC that is bound at the 5’ terminus of the discontinuity prevents degradation in the 5’-3’ 
direction (away from the mismatch). Once the mismatch is removed and the EXO1 activity is inhibited 
by bound RPA and MutL, the gap is filled by Pol . DNA ligase I seals the remaining nick to 
complete the repair process (from [269]). 
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2.3.5.8 Other functions of MMR 
Mammalian MMR is not only involved in correcting biosynthetic errors, but performs 
a wide choice of tasks in the field of DNA transactions. Here are some relevant and 
experimentally substantiated examples: 
 
I) MMR and its role in homologous recombination 
Mismatches arising as the result of heteroduplex formation during homologous 
recombination are processed by the same MMR machinery that removes DNA 
replication errors. Whenever MMR proteins encounter mismatch-containing 
recombination intermediates, two different processes can take place: simple 
mismatch correction or complete abortion of the recombinational event, thereby 
preventing strand exchange between similar but non-identical (homologous) 
sequences [104, 270]. Studies in E. coli demonstrated that inactivation of MutS 
and MutL dramatically increases the frequency of homologous exchanges 
between quasi-homologous sequences [271-274]. Subsequent studies with yeast 
and mammalian cells suggested similar functions for the MutS and MutL 
homologues [104, 105]. 
II) MMR and its role in meiosis 
Initial studies of the involvement of MMR proteins in meiotic recombination were 
conducted in yeast. Mutants defective in MLH1 or MLH3 [275, 276] and in MSH4 
and MSH5 [194, 195] show a two- to threefold reduction in crossing-over, thus 
indicating that the heterodimers MSH4-MSH5 and MLH1-MLH3 function during 
meiosis [208]. It has been hypothesized that MSH4-MSH5 and MLH1-MLH3 
complexes promote the formation and stabilization of Holliday junctions and their 
preferential resolution into cross-overs rather than noncross-overs [277]. 
Interestingly, abnormal meiosis activates a checkpoint leading to cell death via 
Msh4-Msh5 and Mlh1-Mlh3 complexes [277], underscoring the ability of MMR 
proteins to signal DNA damage and promoting apoptosis (reviewed in [269, 278, 
279]). 
III) MMR and its role in triplet repeat instability 
The cause of several neurogenerative diseases such as myotonic dystrophy, 
Huntington’s disease, fragile-X syndrome, and Friedreich’s ataxia is aberrant 
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expansion and hence instability of triplet-repeat sequences. MutS seems to play 
a major role in triplet-repeat destabilization, since repeat tracts are more stable in 
MSH3-null mice compared to MSH6-null animals [280]. Triple-repeat sequences 
readily form hairpins and mismatches in the context of these secondary 
structures cause aberrant recognition by Msh2-Msh3. In addition, altered 
nucleotide affinity and suppressed ATPase activity led to the assumption that the 
compromised function of MutS may lead to stabilization of the loops and 
consequently to expansion instead of repair [281]. But, despite all the existing 
models, the detailed molecular events remain to be established. 
IV) MMR and somatic hypermutation of immunoglobulin genes 
Antibody diversity is achieved by three different processes that take place in 
immunoglobulin genes during clonal expansion of B-lymphocytes: V(D)J 
recombination, class-switch recombination (CSR) and somatic hypermutation 
(SHM) [282]. The finding that MSH2-deficient mice showed diminished proportion 
of dA:dT mutations led to the model that somatic hypermutation acts in two 
phases:  
The first stage requires activation-induced cytidine deaminase (AID), which 
converts C residues to U [283]. The consequently formed dU:dG mismatches 
then become substrate for a number of different DNA repair pathways. First, they 
may be fixed as transition mutations by replication. Second, UNG excises the 
uracil residue, thereby creating an abasic site. Should the latter become a 
template for replication, almost any other base can be incorporated opposite the 
empty position, resulting in transversion and transition mutations [284]. Last but 
not least, the dU:dG or the abasic site:dG are recognized by MutS [116, 285], 
and by the possible involvement of DNA polymerases with low fidelity, mutations 
in the vicinity of the original dC deamination target can be introduced. 
Indeed, the interaction between MutS and polymerase  stimulates synthesis of 
second stage mutations at bases located downstream of the initial dU lesion, 
including A:T pairs ([285], see below). 
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In a second stage, mutations are predominantly generated in dA:dT pairs. Deficiency 
in either MSH2, MSH6, EXO1 or polymerase  reduces mutations at dA:dT, but does 
not abolish them [286-295], thus indicating that MMR is only part of the process and 
not the sole path in phase two mutations. 
It has also been suggested that MMR is an important part of the mechanism for 
conversion of single-strand breaks to double-strand breaks in class-switch 
recombination (CSR) [296]. 
 
3. The role of MMR in cancer and cancer therapy 
 
3.1 MMR and HNPCC (hereditary non-polyposis colorectal cancer) 
In attempts to unravel the mystery of the observed instability of microsatellites in 
12% of the studied colorectal cancer (CRC) tissues [297, 298] and in an effort to 
locate the HNPCC gene(s) in families with early-onset CRC [100, 101], several 
groups of scientists, in 1993, drew nearer a nameless culprit. The markers used in 
the search for the HNPCC locus mapped to the short arm of chromosome 2 [100] 
and since they hybridized with microsatellite sequences [101], the suspicion arose 
that the candidate gene may encode a factor involved in DNA replication or repair. 
And, once again, mutator mutants of S. cerevisiae offered good services and 
provided the “missing link” by demonstrating convincingly that stability of simple 
repeats in mutator mutants lacking MMR was up to three orders of magnitude lower 
than in wild-type strains [299]. This was the starting signal for the identification of 
human MMR genes and their genetic loci.  
Now we know that the cause of the familial syndrome HNPCC (also known as Lynch 
syndrome) is the inheritance of a mutated allele of a MMR gene and a concomitant 
predisposition to cancers of the colon and endometrium and, with much lower 
frequency, to cancers of the stomach, bladder, brain, ovaries and other organs. The 
reason underlying this predominance for cancer development in the colon is not 
known, but since the formation of adenomatous polyps in HNPCC patients arises 
about two decades earlier than in healthy individuals, the presence of a germline 
MMR mutation seems to increase the transformation rate in the colonic epithelium 
[300-302]. HNPCC is inherited in an autosomal dominant way, but MMR deficiency 
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only arises when the wild-type MMR allele is mutated or lost. Thus, the disease is 
recessive at the somatic level. 
Colorectal cancers can be divided into two main groups according to their type of 
genetic instability [303-305]. Microsatellite instability, the hallmark of MMR 
deficiency, occurs in approximately 15% of all colorectal cancers and can arise 
through either inheritance of germline mutations in MMR gene(s) (5%) or epigenetic 
biallelic methylation of the MLH1 promoter (10%). In HNPCC, MLH1 and MSH2 
alterations account for almost 90% of all identified mutations, MSH6 is mutated in 
about 10% of all cases and the share of PMS2 is less than 5% [134]. Detection of 
sequence variants in MLH3 in the germline of families predisposed to colorectal 
cancer [306, 307] suggests a possible role in human cancer, maybe in combination 
with other factors [228].  
 
3.2 MMR, DNA-damage tolerance and clinical implications  
DNA mismatch repair defects are common in a variety of cancers and can be 
detected by MSI analysis and/or immunohistochemical staining for MMR protein 
expression [308]. The major obstacle for the successful treatment of cancer is the 
resistance to chemotherapeutic agents. Interestingly, MMR-deficient cell lines are 
more resistant to killing by several different cytotoxic drugs than matched proficient 
ones (reviewed in [127]), making the MMR system an important indicator for cancer 
therapy and manifesting its involvement in DNA damage response [269, 279].  
 
3.2.1 Methylating agents 
Methylating agents are capable of reacting with a number of nucleophilic sites on 
DNA (Fig. 14), and can be subdivided into two families: SN1 and SN2 [309].  
Methyl methane sulfonate (MMS) and dimethyl sulfate (DMS) are examples for SN2-
type (bimolecular nucleophilic substitution) agents, whereas N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), N-methyl-N-nitrosourea (MNU) and the 
chemotherapeutics temozolomide (TMZ) and dacarbazine [310] belong to the SN1-
type reagents. The predominant DNA adducts resulting from SN1-type methylating 
agents are N7-methylguanine, N3-methyladenine, O4-methylthymine, O6-
methylguanine and methyl-phosphotriesters. 
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Figure 14 Potential 
sites of chemical 
methylation in double-
strand DNA. The 
arrows point to each 
methyl adduct and 
whether the adduct is 
known to be 
predominantly toxic or 
mutagenic. The open 
arrows represent sites 
that are methylated by 
MMS, MNNG, and 
MNU. The filled arrows 
point to sites that are 
methylated by MNNG 
and MNU but not 
detectably by MMS. 
Note that the 
methylation of different 
sites on the same base 
at the same time is 
extremely rare. The 
size of the arrows roughly represents the relative proportion of adducts. In single-stranded DNA, the 
N1-adenine and N3-cytosine positions display a greater reactivity (from [309]). 
 
 
N7-methylguanine and N3-methyladenine comprise 90% of the damage [311] and 
can be efficiently removed by BER [25]. Interestingly, the cytotoxicity of SN1-type 
reagents has been ascribed to O6-methylguanine that accounts for only 7% of the 
adduct burden in DNA [311]. O6-methylguanine can be repaired directly by O6-
methylguanine-DNA methyltransferase (MGMT, see Direct Repair) [12] and high 
levels of this enzyme protected cells against killing by SN1-type methylating agents 
[125], which implicated O6-methylguanine in this process. In addition, cell lines 
defective in both MMR and MGMT are generally 100-fold more resistant to killing 
induced by SN1-type methylating agents than matched proficient ones [125], 
providing evidence that the MMR system potentiates the toxicity of DNA damaging 
drugs such as MNU and MNNG. But the mechanism of MMR-potentiated cell killing 
due to O6-methylguanine lesions remains enigmatic, although a number of models, 
which will be discussed, have been proposed.  
The “futile repair” hypothesis has been discussed already in 1982 by Karran and 
Marinus [108] and suggests that the MMR system, which is exclusively directed to 
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the newly synthesized strand, encounters O6-methylguanine in the template. 
Unsuccessful attempts to process the lesion lead to iterative degradation and re-
synthesis cycles, ultimately resulting in secondary DNA intermediates, such as gaps. 
The persistence of these aberrant DNA structures into the second cell cycle may 
trigger cell killing due to harmful recombination intermediates [312]. The idea of such 
a scenario is not new: in 1971, Plant and Roberts suggested that replication past O6-
methylguanine may produce single-stranded gaps that are converted to double-
strand breaks in the second cell cycle [313]. Interestingly, MMR-proficient cell 
extracts perform aberrant O6-methylguanine-dependent DNA synthesis and inhibit 
DNA replication on in vitro methylated substrates, a phenomenon which cannot be 
observed in MMR-deficient extracts, thus representing a first biochemical proof for a 
direct link between MMR and O6-methylguanine-derived cytotoxicity [314-316]. 
Recent findings from our lab perfectly confirm this model by showing that MNNG 
treatment induced a MMR-dependent cell cycle arrest only in the second G2 phase 
after treatment [312]. MMR-dependent formation of single-stranded regions behind 
yeast and mammalian replication forks upon MNNG treatment could be visualized by 
electron microscopy and may further substantiate the above-described hypothesis 
(preliminary unpublished data from Massimo Lopes). In summer 2006, York and 
Modrich supplied first evidence for the “futile repair” model in vitro by studying MMR-
dependent iterative excision on heteroduplex substrates containing a single O6-
methylguanine lesion incubated with nuclear extracts [317]. Although testing different 
approaches we could not confirm the futile cycling scenario on our heteroduplex 
substrates (see Results, Fischer et al., manuscript in preparation).  
An alternative to the “futile repair” model, the “sliding-clamp signaling” model, 
suggests that O6-methylguanine is recognized by MutS homologues and the ATP-
activated sliding clamps translocate along the DNA, thereby directly signaling  
apoptosis ([318], Fig. 15), without the need for DNA processing.  
 
3.2.1.1 Temozolomide (TMZ) and dacarbazine 
Dacarbazine is considered to be the most active drug for the treatment of metastatic 
melanoma, with a response rate of 15-20% [319]. As in the case of 5-FU, a number 
of combination regimens which include dacarbazine increase this response rate. 
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Temozolomide spontaneously decomposes into the active metabolite of dacarbazine 
[320] and recently has been approved for the treatment of recurrent gliomas. 
Furthermore, it is in phase II/III clinical trials for the treatment of melanoma. Since 
temozolomide penetrates the blood-brain barrier, it could be beneficial in preventing 
or treating melanoma metastases in the central nervous system [319]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Models for MMR-dependent apoptosis in response to DNA damage. 
A The “futile cycle” model 
B The “sliding-clamp signaling” model (adapted from [321]). 
 
A recent study demonstrates that up-regulation of MGMT activity and impaired MMR 
account at least in part for TMZ resistance in melanoma cells [322]. This is a little 
step forward to a better understanding of the mechanisms underlying primary and 
acquired drug resistance. 
 
3.2.2 6-thioguanine (6-TG) 
6-TG is an important drug used for the treatment of acute leukemia [323] and acts as 
an immunosuppressant in organ transplant patients [127]. After incorporation into 
DNA as 2’-deoxy-6-thioguanosine triphosphate [324], 6-TG residues are methylated 
in vivo by SAM to form S6-methylthioguanine. During DNA replication, thymine or 
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cytosine can be incorporated opposite this modified base with roughly equal 
probability, resulting in 6-TG/T mismatches which are recognized by MutS [325]. 
The substantial similarity of the miscoding properties and the cytotoxic action 
between O6-methylguanine and 6-TG was confirmed by the findings that MMR-
deficient, O6-methylguanine-resistant cells generally exhibit 10-fold cross-tolerance 
to the antimetabolite 6-TG [326-329]. 
 
3.2.3 Cisplatin 
Figure 16 In the cells, cisplatin is converted into a charged electrophilic drug that reacts with DNA to 
form intrastrand and interstrand crosslinks, monoadducts and DNA-protein crosslinks (from [330]). 
 
Cisplatin or CDDP (cis-diamminedichloroplatinum(II)) is an important drug used in 
the treatment of many tumors ([331]), especially of testicular and ovarian cancers 
[332]. It forms DNA-protein cross-links, DNA monoadducts, and both interstrand and 
intrastrand crosslinks (Fig. 16). 1,2-d(GpG) and 1,2-d(ApG) intrastrand crosslinks 
formed between neighbouring purine bases and representing 90% of the adducts 
are thought to be the key lesions in cisplatin-mediated cytotoxicity [333-335]. 
Although, in human cells these bulky structures are mainly addressed by nucleotide 
excision repair (NER), there is some evidence that MMR might contribute to the 
repair of cisplatin-induced DNA damage as well.  
First, the 1,2-d(GpG) intrastrand crosslink in oligonucleotides is recognized and 
bound by MutS [107]. Second, restoration of MMR capacity in human and mouse 
cells results in a concomitant two- to three-fold sensitivity to cisplatin [336-339]. 
One possible scenario could be that MMR factors recognize cisplatin adducts after 
DNA translesion polymerases bypassed the lesion and incorporated an incorrect 
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nucleotide [340-343]. NER would be competitively impeded to repair the damage by 
the bound MMR complex. This could trigger futile repair processes in a way similar 
to that described for O6-methylguanine mispairs, eventually resulting in cell death 
(reviewed in [330]). 
 
3.2.4 Topoisomerase inhibitors 
Topoisomerase I (TOP1) enzymes are required to relax DNA supercoiling generated 
by transcription, replication and chromatin remodeling [344]. Anticancer drugs can 
trap TOP1 during their cleavage reaction, thereby reversibly stabilizing the so-called 
“cleavage complex” [345]. The cytotoxic activity of TOP1 inhibitors is related to the 
interference of the trapped complexes with DNA replication and transcription 
(reviewed in [346], Fig. 17).  
 
3.2.4.1 Camptothecin and its derivatives 
Camptothecin is a natural alkaloid extracted from the bark of the Chinese tree 
Camptotheca acuminata [347], with TOP1 as the only cellular target [348, 349]. 
Camptothecin-derivatives are in clinical use: Irinotecan is approved for colon 
carcinomas (usually in combination with 5-fluorouracil and leucovorin), whereas 
topotecan is indicated for the treatment of ovarian cancers. Although both drugs 
target TOP1 in a similar way, empirical values from clinical trials recommend 
different indications.  
One group reported that MMR-deficient human colorectal cancer cells were much 
more sensitive to camptothecin than their proficient counterpart [350]. This study was 
carried out in a non-isogenic system, and indeed, results from our lab obtained with 
the strictly isogenic 293TL cell line [351] did not show any difference between 
MMR-deficient and –proficient background [339].  
However, severe side-effects and other limitations of camptothecins in cancer 
therapy promote the development of new derivatives and non-camptothecin TOP1 
inhibitors [352, 353].  
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Figure 17 Relaxation of DNA 
supercoiling by TOP1-
mediated DNA cleavage 
complexes, and the trapping 
of TOP1 cleavage complexes 
by drugs, DNA modifications 
and during apoptosis. 
a The generation of DNA 
supercoiling by DNA 
replication, transcription and 
chromatin remodelling. The 
unwinding of duplex DNA by 
macromolecular complexes 
tracking along the DNA 
(arrow) without rotating freely 
around the DNA double helix, 
which is also unable to rotate 
freely owing to its length or 
attachment to nuclear matrix 
regions, generates positive 
supercoiling ahead of the 
unwound segment and 
negative supercoiling behind 
(negative supercoiling not 
shown). 
b The introduction of DNA 
single-strand breaks (nicks) 
by TOP1 provides swivel 
points that enable the rotation 
of the intact DNA strand 
around the break and facilitate 
DNA relaxation. The cleavage 
intermediate is referred to as 
a cleavage complex because 
TOP1 cleaves DNA by forming a covalent bond to the 3 DNA terminus that it generates. The 
covalently linked catalytic tyrosine of TOP1 (Y723 for human TOP1) is shown as the yellow circle. 
c An expanded view of DNA relaxation by a TOP1 cleavage complex (TOP1cc). The first step (left) is 
a transesterification reaction whereby the catalytic tyrosine (Y) becomes linked to the 3 DNA end 
(nicking step). In the second step (middle), the torsional strain that results from DNA supercoiling 
drives the rotation of the 5 end of the nicked DNA strand around the intact strand. TOP1 encircles the 
rotating nicked DNA and slows its rotation. This process is referred to as ‘controlled rotation’. In the 
last step (right), the 5 end of the nicked DNA is realigned with the corresponding 3 end, which 
enables DNA religation (the closing step of the ‘nicking–closing reaction’). TOP1ccs are normally 
transient because the closing step is much faster than the nicking step. Drugs and DNA lesions inhibit 
religation by misaligning the ends of the broken DNA. 
d TOP1ccs can be stabilized under three conditions: by drugs such as camptothecin (left), by DNA 
lesions (damage) that misalign the 5 end of the nicked DNA, and by DNA and TOP1 modifications 
that occur during programmed cell death (apoptosis) (from [346]). 
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3.2.5 5-fluorouracil (5-FU) 
The 5-fluoropyrimidine 5-fluorouracil (5-FU) is an antimetabolite drug that is widely 
used for treatment of cancer, particularly for colorectal cancer, with response rates of 
10-20% only.  
 
Figure 18 5-fluorouracil metabolism. 5-
fluorouracil (5-FU; see structure) is 
converted to three main active 
metabolites: 
fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate 
(FUTP). The main mechanism of 5-FU 
activation is conversion to fluorouridine 
monophosphate (FUMP), either directly 
by orotate phosphoribosyltransferase 
(OPRT) with phosphoribosyl 
pyrophosphate (PRPP) as the cofactor, or 
indirectly via fluorouridine (FUR) through 
the sequential action of uridine 
phosphorylase (UP) and uridine kinase 
(UK). FUMP is then phosphorylated to 
fluorouridine diphosphate (FUDP), which 
can be either further phosphorylated to 
the active metabolite fluorouridine 
triphosphate (FUTP), or converted to 
fluorodeoxyuridine diphosphate (FdUDP) 
by ribonucleotide 
reductase (RR). In turn, FdUDP can either 
be phosphorylated or dephosphorylated 
to generate the active metabolites FdUTP 
and FdUMP, respectively. An alternative 
activation pathway involves the thymidine 
phosphorylase catalysed conversion of 5-FU to fluorodeoxyuridine (FUDR), which is then 
phosphorylated by thymidine kinase (TK) to FdUMP. Dihydropyrimidine dehydrogenase (DPD)-
mediated conversion of 5-FU to dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU catabolism 
in normal and tumour cells. Up to 80% of administered 5-FU is broken down by DPD in the liver (from 
[354]). 
 
 
To increase the effectiveness of the therapy, 5-FU is usually combined and 
administered with other chemotherapeutic agents, such as irinotecan and oxaliplatin 
(a platinum-based cross-linker with a different spectrum of action and toxicity than 
cisplatin [355]) [356].  
5-FU exerts its action in the form of three different metabolites: FdUrd-5’-
monophosphate (FdUMP) inhibits DNA synthesis by blocking the activity of 
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thymidylate synthase (TS), 5-fluorouridine-5’-triphosphate (FUTP) is a precursor for 
RNA incorporation, and FdUrd-5’-triphosphate (FdUTP) is incorporated into DNA as 
FdUMP (Fig. 18). 
Human MutS was shown to recognize oligonucleotides containing 5-FU/G in both 
ATPase activity assays [357] and bandshift experiments (Fischer et al., manuscript 
submitted). In contrary to these results, another group published the recognition of 5-
FU/A by the MMR factor hMutS [358]. But the inability of hMutS to recognize 5-
FU/A in vitro may not reflect its ability to recognize the lesion in vivo (see Results, 
Fischer et al., manuscript submitted). In addition, it has been reported that MMR-
deficient cells are resistant to the cytotoxic effects of fluoropyrimidines [357, 359], 
which again emphasizes the important role of the MMR machinery in response to 
DNA-damaging agents. 
 
3.2.5.1 TS inhibition and incorporation of fluoropyrimidines into DNA 
TS directs the de novo synthesis of thymidylate (dTMP) from deoxyuridylate (dUMP) 
by transferring a methyl group from its cofactor (5,10-methylene tetrahydrofolate 
(THF)) to the C5 position of dUMP. In the presence of FdUMP, the ternary complex 
consisting of DNA, TS and THF is greatly stabilized due to the strong carbon-fluorine 
bond in the FdUMP molecule [360]. Consequently, depletion of dTMP induces 
significant perturbations in the levels of the other deoxynucleotides [361, 362], the 
concentrations of which are critical for determining the fidelity of DNA replication 
[363].  
Meyers and colleagues provided evidence that the fluoropyrimidine-induced, MMR-
mediated cytotoxicity is DNA-directed [357], and completed this finding by showing 
that DNA incorporation rather than TS inhibition is the responsible cytotoxic 
mechanism [364]. This is in agreement with results from a group working on the 
glycosylases UNG and SMUG1 and their roles in 5-FU processing [95]. Their most 
recent publication underscores the contribution of 5-FU incorporation into DNA to 5-
FU-mediated toxicity, but ascribe the major role to SMUG1.   
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3.2.5.2 Incorporation of fluoropyrimidines into RNA 
According to a widespread, longlasting notion, the key mechanisms causing 
cytotoxic effects are predominantly RNA incorporation and, to a minor extent, TS 
inhibition, but this idea may have to be reconsidered. The conclusion grew on a 
broad experimental base, with a number of publications providing evidence for the 
toxicity due to exclusive RNA incorporation. Furthermore, 5-FU incorporation into 
DNA is only 10% of the amount incorporated into RNA (reviewed in [365]). 
Taking the complex and multilayered mode of action of fluoropyrimidines into 
account, the most probable scenario may propose pleiotropic effects of the drugs 
within the cell. 
 
3.2.5.3 Clinical applications 
Due to the above described resistance of MMR-deficient cells to 5-FU and its 
derivatives, one would expect that fluoropyrimidine treatment of these cells may is 
detrimental. Indeed, three clinical reports could confirm that 5-FU-based 
chemotherapy given to colon cancer patients with high levels of MSI did not result in 
a significant survival advantage [366-368].  
In general, 5-FU/leucovorin, irinotecan and oxaliplatin are available for treatment of 
advanced colorectal cancer. The coupling of 5-FU with leucovorin, a reduced folate 
that increases thymidylate synthase inhibition, improves clinical outcome; these two 
drugs are therefore generally used in combination [369]. Recent clinical trials 
recommend the so-called FOLFOX regimen, a combination of oxaliplatin and infused 
fluorouracil plus leucovorin as a standard therapy for patients with advanced 
colorectal cancer [370].  
The latest trials combine 5-FU with bevacizumab, an angiogenesis inhibitor, hoping 
for a new avenue in combination therapy. This drug targets VEGF (vascular 
endothelial growth factor), a key mediator of angiogenesis, thus choking off the 
blood supply that is essential for the growth of the tumor and its metastasis [371].  
But as long as we do not know the exact mechanism(s) of MMR-dependent death 
after fluoropyrimidine exposure we are left with hope and a lot of scientific work… 
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Other agents whose cellular response has been shown to be affected by MMR and 
which are not discussed within the scope of this work, include oxidizing agents and 
IR [372, 373] that form 8-oxoguanine adducts in DNA [374, 375] and two additional 
topoisomerase inhibitors, doxorubicin and etoposide [350]. However, in our isogenic 
system, no differences in sensitivity of the 293TL+ and 293TL- cells to mitomycin 
C, chloroethylcyclohexyl nitrosourea (CCNU), melphalan, psoralen-UVA (interstrand 
cross-link agents), camptothecin, etoposide, or IR could be observed [339]. 
 
4. Aim of my studies 
 
The present thesis can be divided into two major projects with different goals. 
On the one hand, we intended to solve the riddle about the scenario “When MMR 
meets O6-methylguanine” by using an in vitro MMR system with heteroduplex 
substrates containing one single O6-methylguanine. Unfortunately, we encountered 
many problems and pitfalls during our work and we could not prove the MMR-
dependent futile cycle hypothesis.  
On the other hand, we exploited our in vitro system to find an answer to the 
contribution of the MMR system to the repair of 5-FU-containing mismatches. Since 
this lesion is addressed by both MMR and BER, we studied the participation of the 
individual candidates. We could nicely demonstrate that TDG is the key player in the 
repair of 5-FU/G mispairs, assisted by UNG. MBD4 did not contribute significantly to 
the repair events and SMUG1 turned out to be inactive under the experimental 
conditions. In the absence of glycosylases, MMR recognized and processed 5-FU/G 
to the same extent as G/T mismatches, implying an active competition between the 
two repair pathways. These findings, although demanding for further in vivo studies, 
may point to new approaches for the treatment of colorectal cancer by regarding the 
presence or absence of the appropriate glycosylases. 
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Abstract 
 
Background & Aims: 5-Fluorouracil (FU) is one of the mainstays of colon cancer 
chemotherapy. Although developed as an inhibitor of thymidylate synthase (TS), its 
mode of action is complex. Thus, in addition to killing cells through thymidine depletion, 
FU cytotoxicity has been linked also to incorporation into RNA. Surprisingly, little is 
known about the consequences of FU incorporation into DNA. 
Methods: Using extracts of human cells and circular DNA substrates containing a single 
FU residue either paired with adenine or mispaired with guanine, we studied the 
efficiency and directionality of FU removal. 
Results: In nicked circular substrates, FU/G mispairs were efficiently repaired by MMR. 
In covalently-closed circular DNA, FU/G repair was initiated by either thymine DNA 
glycosylase (TDG) or uracil DNA glycosylase (UNG), whereas FU/A pairs were 
processed by UNG. Methyl-CpG binding domain protein 4 (MBD4) and single-strand 
selective monofunctional uracil-DNA glycosylase 1 (SMUG1) did not detectably 
contribute to FU removal, however, as these recombinant enzymes process, FU/G and 
FU/A in oligonucleotide substrates, respectively, they too may be involved in FU 
metabolism in vivo. 
Conclusions: The functional redundancy of MMR and DNA glycosylases in FU 
processing should ensure that the drug is efficiently removed from DNA before it can 
interfere with essential metabolic processes. However, in FU-treated cells, the nucleotide 
pools are depleted of thymine. The repair synthesis might thus be inhibited and leave 
cytotoxic gaps or breaks in DNA. Moreover, FU and/or FdUMP removed from DNA will 
increase the intracellular concentration of the drug, and thus exacerbate its cytotoxicity. 
 
Abbreviations: BER, base excision repair; BSA, bovine serum albumin; CRC, colorectal 
cancer; FU, 5-fluorouracil; FdUMP, 5-fluorouracil-2’-deoxy-5’-monophosphate; FdUTP, 5-
fluorouracil-2’-deoxy-5’-triphosphate; MMR, mismatch repair; SMUG1, single-strand 
selective monofunctional uracil-DNA glycosylase 1; TDG, thymine DNA glycosylase; TS, 
thymidylate synthase; UNG, uracil DNA glycosylase;  
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and UBS AG.
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Introduction 
 
Colorectal cancer (CRC) is the third most frequent malignancy in the Western world and 
accounts for 10% of all new cancer cases and cancer-related deaths in the United States (for 
review see 1). 
Developed in the late fifties as inhibitors of thymidylate synthase (TS), a key enzyme of de 
novo pyrimidine biosynthesis2, 3, the fluoropyrimidine 5-fluorouracil (FU) and its nucleoside 
derivative 5-fluoro-2′-deoxyuridine represent the mainstay of chemotherapy of CRC, as well 
as of a variety of other types of cancer. However, although FU is an important 
chemotherapeutic, its mode of action is more complex than originally believed. The 
imbalance of dNTP pools caused by TS inhibition was shown to slow down DNA 
replication4, and because the efficacy of FU therapy is potentiated by leucovorin, which 
stabilizes the FU/TS complex with methylenetetrahydrofolate5, this mode of action is 
believed to be clinically relevant. However, FU was reported to exert its cytostatic effect also 
through incorporation into RNA, where it was suggested to interfere with RNA processing6, 7 
and it has been proposed that incorporation of 5-fluoro-2′-deoxyuridine-5’-monophosphate 
(FdUMP) into DNA is also cytotoxic8.  
 When attempting to elucidate the mode of action of a cancer chemotherapeutic, 
invaluable lessons can be learned from the study of drug resistance, both inherent and 
acquired. Tumors resistant to FU are commonplace, as are FU-resistant tumor-derived cell 
lines (see ref. 1 for review). Analysis of these cells showed that FU resistance is often linked 
to an upregulation of expression of TS, which means that higher drug concentrations are 
required to inhibit the larger cellular TS pool, or to elevated levels of dihydropyrimidine 
dehydrogenase (DPD), which catabolises the drug. An alternative path to resistance is to 
express low levels of thymidine kinase (TK), which will result in low FdUMP levels and thus 
in low TS inhibition. However, FU resistance was correlated also with low uridine-cytidine 
monophosphate kinase (UMPK) levels. This enzyme converts FdUMP and FUMP into the 
corresponding diphosphates, which are then further phosphorylated to the triphosphates 
FdUTP and FUTP, substrates of DNA and RNA polymerases, respectively. The link between 
low UMPK levels and FU resistance confirmed the hypothesis that incorporation into nucleic 
acids is harmful. However, recent reports describing the lack of response to FU therapy in 
patients with tumors displaying microsatellite instability (MSI), a hallmark of mismatch 
repair (MMR) deficiency, implied that removal of FU from DNA by the MMR system is 
more toxic than when the base remains unrepaired. 
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 MMR improves the fidelity of DNA replication by several orders of magnitude, 
through correcting biosynthetic errors in newly synthesized DNA. It also controls DNA 
recombination by helping to abort strand exchange between non-identical sequences. More 
recently, MMR has been implicated also in the processing of modified nucleotides and DNA 
damage signaling and apoptosis, as MMR-deficient cells are more resistant than matched 
MMR-proficient ones to several different classes of chemicals (recently reviewed in 9, 10). 
As noted above, the MMR system was suggested to play a role also in the cellular response to 
FU treatment11-14. In three of these publications, patients with MSI+ CRCs were reported not 
to benefit from FU-based chemotherapy, and these findings appeared to be confirmed by in 
vitro studies8, 15, 16, which showed MMR-deficient cells to be more resistant to FU than 
matched MMR-proficient ones. What these studies implied is that removal of FU from DNA 
by the MMR system is deleterious to the cells, which runs contrary to the above hypothesis. 
However, the reason underlying the apparent lack of response of MMR-deficient tumors and 
cells to FU was not investigated in detail in these publications. One study ascribed it to a 
higher expression of TS in MMR-deficient cancers17, but this was not confirmed in another 
laboratory18. Moreover, clinical data from Finland19 suggest that MSI+ tumors respond better 
to FU treatment than MSI- CRCs. In an attempt to learn more about the role of MMR in the 
cytotoxicity of FU, we set out to study the processing of this base analogue in DNA. 
 Unlike the other halogenated pyrimidines 5-bromouracil and 5-iodouracil, FU does 
not readily undergo a tautomeric shift to the enol form (Fig. 1A) and is therefore unlikely to 
be misincorporated into DNA opposite guanosine during replication with appreciable 
frequency. We anticipated that, in the event of this happening, the resulting FU/G mispair 
would be corrected by the MMR system to a C/G. However, given that FU will 
predominantly form FU/A pairs, which very closely resemble T/A pairs, we wanted to test 
whether these latter structures were also recognized and processed by the MMR system. 
Moreover, given that the fluorine atom at the 5-position of the pyrimidine has a van der Waals 
radius similar to a proton, FU is a substrate for all four known human DNA glycosylases that 
remove uracil from DNA: uracil-DNA glycosylase (UNG)20, thymine-DNA glycosylase 
(TDG)21, 22, single-strand selective monofunctional uracil-DNA glycosylase 1 (SMUG1)23 and 
methyl-CpG binding domain protein 4 (MBD4)24, 25 (reviewed in 26). However, the relative 
efficiency of FU processing by these glycosylases has not been tested in a system where all 
four were present at the same time and where also the MMR system was functional. 
 In this study, we show that FU/G and, to a lesser extent, FU/A base pairs incorporated 
into circular DNA substrates are addressed by the MMR system in extracts of human cells. In 
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addition, the former substrate is very efficiently repaired to C/G by base excision repair 
(BER). In this processing, TDG plays the predominant role. The processing of FU/A by BER 
could be shown to involve UNG, but SMUG1 and TDG may also play important roles in the 
processing of this most frequent lesion. 
 
Materials and Methods 
Substrates, nuclear extracts and in vitro mismatch repair (MMR) assays 
The detailed procedure has been described previously27. Briefly, heteroduplex DNA 
substrates containing a FU/A or a FU/G mismatch within an AclI restriction site in the 46 bp 
polylinker of a pGEM13Zf(+) derivative were constructed by primer extension, using an FU-
containing oligonucleotide as the primer and the single-stranded phagemid DNA as template. 
The desired supercoiled heteroduplex substrates were purified by caesium chloride 
centrifugation. The strand discrimination signal was introduced by incubation with N.BstNBI, 
which introduced a specific nick in the complementary strand (3’ from the mismatch) at 
position 352 of the duplex. The mismatch repair assays were performed in 20 mM Tris-HCl 
pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM glutathione, 50 µg/ml BSA, 0.1 mM each dGTP, 
dCTP, dTTP and dATP, 1.5 mM ATP, 100 ng (47.5 fmol) heteroduplex DNA substrate and 
50 µg of nuclear extract from 293T-Lα+ (MLH1+), or 293T-Lα- (MLH1-)28 cells in a total 
volume of 25 µl. After 30 min incubation at 37°C, the reactions were terminated by the 
addition of a stop solution and further incubation for 30 min at 37°C (final concentrations: 25 
mM EDTA, 0.67% SDS, 50 µg/ml proteinase K). The DNA was purified using Qiagen 
MinElute Reaction Cleanup Kit, digested with the appropriate mismatch-discriminating 
restriction enzyme and treated with 50 µg/ml RNase A, followed by proteinase K (60 µg/ml) 
in the presence of 0.2% SDS. The DNA was then precipitated in 0.3 M NaOAc pH 5.5/70% 
ethanol, and resuspended in 10 mM Tris-HCl. The efficiency of the repair reactions was 
monitored on 1% TAE agarose (Invitrogen) gels stained with ethidium bromide. 
 Some assays contained also 1.7 pmol [α-32P]dATP (8.5 µCi). To monitor 
incorporation of the radiolabeled nucleotide, the agarose gels were vacuum-dried and exposed 
to a PhosphoScreen (Molecular Dynamics, Inc.).  
 
Immunodepletion of nuclear extracts 
DynabeadsProtein A (Dynal Biotech, Invitrogen) were washed twice with 30 mM Hepes-
KOH pH 7.5, 7 mM MgCl2 and incubated for 2 h at 4°C with either anti-MBD4 (Sigma, 
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1:2000) or anti-TDG (rabbit polyclonal, a kind gift of Primo Schär, 1:10000) antibodies.  
After washing three times with the above buffer, the pre-adsorbed beads were stored at 4°C 
until required. 50 µg of nuclear extracts were incubated for 30 min at 4°C with 6.25 µl of the 
antibody-pre-adsorbed Dynabeads and subsequently used for in vitro MMR assays or Western 
Blots. 
 
Bandshift assays 
40 fmol (2 nM) of annealed 5’- [32P]-labeled oligonucleotides (TTT CTG ACT TGG ATA 
CCA FUCT ATC TAT CTA TAA AAT AT, TTT CTG ACT TGG ATA CCA TCT ATC 
TAT CTA TAA AAT AT, ATA TTT TAT AGA TAG ATA GAT GGT ATC CAA GTC 
AGA AA, or ATA TTT TAT AGA TAG ATA GGT GGT ATC CAA GTC AGA AA (all 
written 5’ to 3’ – see ref. 29) were incubated with 100 mM KCl, 25 mM Hepes-KOH pH 7.5, 1 
mM DTT, 0.5 mM MgCl2, 0.1 mM ADP, 10% glycerol, 75 µg/ml BSA and 60 ng poly(dI-
dC)•poly(dI-dC) competitor (Amersham Pharmacia Biotech) in the presence of 40, 70, or 100 
nM purified human MutSα in a final volume of 20 µl. After 20 min at 37°C, 10 µl were 
loaded onto 9x8 cm 5% native polyacrylamide (29:1) gels (ATTO system) eluted with 1x 
TAE buffer and run 30 min at 19 V/cm. The vacuum-dried gels were exposed to 
PhosphoScreens (Molecular Dynamics, Inc). 
 
Nicking assay 
50 fmol (2.5 nM) of annealed  5’-[32P]-labeled oligonucleotides (TTT CTG ACT TGG ATA 
CCA FUCT ATC TAT CTA TAA AAT AT, ATA TTT TAT AGA TAG ATA GAT GGT 
ATC CAA GTC AGA AA, ATA TTT TAT AGA TAG ATA GGT GGT ATC CAA GTC 
AGA AA, all written 5’ to 3’ – see ref. 29) were incubated either under MMR conditions [20 
mM Tris-HCl pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM glutathione, 50 µg/ml BSA, 0.1 mM 
each dGTP, dCTP, dTTP and dATP, and 50 µg of nuclear extract from 293T Lα- (MLH1-)] or 
under standard conditions (20 mM Tris-HCl pH 8, 1 mM EDTA, 1 mM DTT, 0.1 mg/ml 
BSA) in the absence or presence of UGI (1U) and/or SMUG1 (4U) in a final volume of 20 µl. 
Reactions were incubated for 1 h at 37°C followed by a denaturing step for 5 min at 95°C in 
the presence of 0.1 M NaOH. After adding 20 µl 8 M urea/1xTBE loading buffer, 10 µl were 
loaded onto a pre-run 15% denaturing PAGE (8 M urea) and ran at approximately 45 V/cm 
for 20 min. Finally, the gels were exposed to a PhosphoScreen (Molecular Dynamics, Inc.). 
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Results 
Binding of MutSα to FU/G and FU/A 
To test the ability of the MMR machinery to recognize FU-containing base pairs in DNA, we 
incubated 38-mer oligonucleotides containing a T/A, T/G, FU/A or FU/G base pair at position 
1929 with varying concentrations of the purified recombinant human mismatch binding factor 
MSH2/MSH6 (MutSα). As anticipated, these experiments revealed that MutSα binds the 
FU/G substrate with an affinity similar to T/G. In contrast, FU/A and T/A substrates failed to 
form stable protein/DNA complexes in this assay, even at high concentrations of MutSα (Fig. 
1B). Our findings agree with the data of Meyers et al.16, 26, but are in sharp contrast to those of 
Tajima and colleagues29, even though both sets of experiments were carried out with identical 
oligonucleotide sequences.  
 
Processing of FU-containing base pairs in nuclear extracts of human cells 
Our previous experience showed that mismatches that are efficiently bound by MutSα in 
bandshift experiments are efficiently repaired by the MMR system in in vitro MMR assays. 
However, the contrary is not necessarily true. We therefore wanted to test the efficiency with 
which the FU/A and FU/G pairs are addressed in a mismatch repair assay. To this end, we 
constructed circular heteroduplex substrates, in which the FU/A or FU/G base pairs were 
embedded within the recognition site of the AclI endonuclease (Fig. 2A). In order to be able 
to follow the progress of the in vitro repair process, the presence of the modified base or 
mismatch has to inhibit the cleavage of this site by the restriction enzyme. Successful MMR 
outcome is then scored as the amount of DNA converted to an AclI-susceptible form. 
 As shown in Fig. 2B, the presence of a T/G or FU/G mispair at this site rendered the 
substrates refractory to cleavage with the enzyme. Thus, these substrates can be used in the in 
vitro MMR assays with AclI. In contrast, the FU/A substrate was as efficiently cleaved by the 
enzyme as the control T/A plasmid. Taken together with the result of the bandshift assay 
shown above, this result confirmed that the FU/A base pair structurally resembles a T/A. As 
this result precluded the use of AclI digests as readout of FU/A repair efficiency, the repair 
assays with the latter substrates had to be followed by incorporation of radiolabeled 
nucleotides.  
 Successful mismatch correction in human cell extracts requires that the circular 
heteroduplex substrates carry also a strand discontinuity within ~1 kb upstream or 
downstream from the mispair. This is the site where the exonucleolytic mismatch correction 
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process initiates. Our plasmids contain a single N.BstNBI site 297 base pairs from the 
mismatch. This enzyme recognizes the sequence GAGTC/CTCAG, but cleaves the DNA only 
in the top strand. Covalently-closed circular heteroduplex substrates, which are refractory to 
mismatch correction in vitro, were used as controls where appropriate.  
 When the G/T substrate was incubated with mismatch repair-deficient extracts of 
293T-Lα cells, no repair was observed. In contrast, in the presence of mismatch-repair 
proficient extracts, approximately 60% of the heteroduplex substrate were converted into an 
AclI-cleavable form that is indicative of G/T to A/T repair, as shown by the appearance of the 
1.5 and 1.3 kb bands in the agarose gel (Fig. 2C, lanes 5 and 6, respectively). As anticipated, 
the FU/A plasmid was completely cleaved after incubation with the extracts (lanes 1 and 2), 
and this result was therefore uninformative (but see Fig. 5). The efficiency of FU/G to C/G 
repair was similar to G/T in the MMR-proficient extract (compare lanes 4 and 6). 
Surprisingly, however, we observed an appreciable extent of FU/G repair also in the MMR-
deficient 293T-Lα extract (lane 3). As the FU/G mispair was addressed to a similar extent 
also in a covalently-closed substrate that is refractory to MMR (data not shown), we assumed 
that the FU residue was recognized and repaired by BER.  
 
Contribution of UNG and MBD4 to FU/G repair in vitro 
FU was reported to be processed by UNG30 and MBD431. As the latter studies were carried 
out with synthetic oligonucleotide substrates and purified glycosylases in isolation, we set out 
to test, which of these enzymes was responsible for processing of the FU/G mismatch in a 
circular plasmid substrate in the 293T-Lα extracts.   
 We incubated the MMR-deficient nuclear extract of 293T-Lα- cells with increasing 
concentrations of the uracil glycosylase inhibitor (UGI) (Fig. 3A). Although the tested 
amounts of UGI were sufficient to inhibit the UNG activity in these nuclear extracts when 
tested on radiolabeled oligonucleotides in nicking assays (data not shown), the inhibition of 
FU/G processing in our circular substrate was barely detectable. We therefore concluded that 
UNG was either not required for FU processing, or that another activity in the extracts, 
possibly MBD4, was compensating for the lack of active UNG. 
 When we immuno-depleted the 293T-Lα- nuclear extract of MBD4 by a procedure 
(see Materials and Methods) that reduced the amount of MBD4 in the extracts to an almost 
undetectable level (Fig. 3B, left panel, lanes 1 and 2), the efficiency of MMR did not 
diminish, as witnessed by the unchanged efficiency of G/T repair (right panel, lane 6). In 
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these extracts, the FU/G mispair processing (right panel, lane 3) was similarly efficient to that 
seen in undepleted extracts (right panel, lane 1), which indicated that MBD4 was either not 
responsible for FU repair under our experimental conditions, or that it was not active in the 
cell extracts. 
 
TDG depletion reduces the efficiency of FU/G repair to C/G 
TDG is known to remove U or T from U/G or T/G mispairs32 and has been reported to 
efficiently remove FU residues from oligonucleotide substrates33. We set out to test whether 
this latter enzyme might be responsible for the observed FU/G processing in the circular 
substrates in the 293T-Lα extracts, by immuno-depleting them of TDG, using a rabbit 
polyclonal anti-TDG serum (a kind gift of Primo Schär). TDG exists in two different forms: 
the unmodified protein, which migrates in SDS-PAGE gels with an apparent molecular size 
of 55-60 kDa and the SUMOylated variant with an apparent molecular size of ~80 kDa34. The 
efficiency of FU/G repair in cell extracts depleted of both these TDG forms (Fig. 3C, left 
panel, lanes 1 and 2) was somewhat reduced (Fig. 3C, right panel, lane 3), indicating that 
TDG is at least partially involved in the repair of FU residues mispaired with G. 
 
Lack of TDG, UNG and MMR abolishes repair of FU/G in vitro 
Having observed that TDG and, to a lesser extent, UNG, contribute to the repair of FU/G 
mispairs, we postulated that these enzymes might be functionally redundant in FU processing. 
This indeed appears to be the case. In MMR-deficient extracts depleted of TDG (Fig. 4, left 
panel, lane 1), in which UNG was inhibited by the addition of UGI, a nearly complete 
abrogation of FU/G repair was observed (right panel, lane 3). Importantly, in the absence of 
TDG and UNG, the MMR machinery processes the FU/G mismatch with efficiency similar to 
that of the G/T control (right panel, lanes 4 and 6). 
 In summary, in our in vitro system, human TDG, UNG and MMR can all process 
FU/G mispairs. The base excision repair process initiated by TDG and UNG always converts 
the FU/G to a C/G. Unlike BER, MMR-mediated repair is directed to the strand carrying the 
nick, which is required for initiation of the excision. In the substrates shown in Figs. 2-4, 
which contained a nick 297 nucleotides 3’ from the FU/G mispair in the FU strand, MMR 
catalyzed the conversion of the FU/G mismatch to C/G, similarly to BER. This reflects the 
situation when the FU is incorporated opposite G during replication. However, should a G be 
incorporated opposite an FU residue in the template strand, then the G/FU mispair would be 
repaired by MMR to an A/FU.  
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FU/A repair in human cell extracts 
As shown in Fig. 2B (lane 1), the restriction enzyme AclI is insensitive to the presence of FU 
in its recognition site. Given that the FU/A heteroduplex is completely cleaved by the 
enzyme, it cannot be used as a substrate to study the processing of FU/A by the above-
described assays. However, by carrying out the repair reactions in the presence of [α-
32P]dATP, we could monitor the extent of enzymatic processing by the amount of 
radioactivity incorporated into the three restriction fragments generated by the AclI digests. In 
the control experiment, we incubated the G/T substrate with MMR-deficient and –proficient 
cell extracts and confirmed that MMR-dependent G/T to A/T processing took place solely in 
the latter extracts (Fig. 5B, lanes 5 and 6, respectively). The autoradiograph of the same 
agarose gel revealed that most of the radioactivity was incorporated into the 1.5 and 1.3 kb 
fragments generated by the AclI digest upon successful MMR-catalysed G/T to A/T repair. 
The fact that both these fragments were labeled with similar efficiency confirms the results of 
previous studies, which showed that the MMR repair tracts span the distance between the 
strand discontinuity (a nick situated in the G strand 297 nucleotides 3’ from the mismatch in 
our case) and ~150 nucleotides past the mismatch35. The radioactivity incorporated into the 
uncleaved 2.8 kb fragment most likely represents a small amount of strand displacement 
commencing at the nick. In a MMR-deficient extract, G/T to A/T processing was hardly 
detectable (Fig. 5B, lane 5) and radioactivity was incorporated predominantly into the 
uncleaved 2.8 kb fragment, presumably also through strand displacement. 
 As anticipated, the FU/A substrates were completely cleaved by AclI into the 1.5, 1.3 
and 0.3 kb fragments. Although no differences between the assays using MMR-deficient and 
–proficient extracts could be seen in ethidium bromide-stained gels (Fig. 5B), 
autoradiography of the gels revealed interesting differences. When the MMR-deficient extract 
was used (Fig. 5C, lane 1), the radioactivity was incorporated predominantly into the 1.5 and 
1.3 kb fragments in an approximate ratio of 3:1. When the same extract was depleted of TDG 
(Fig. 5A, lane 1) and supplemented with UGI to inhibit also UNG, the incorporation of 
radioactivity into the 1.5 kb fragment increased (Fig. 5C, lane 3). This suggests that the 
radioactivity was incorporated through DNA synthesis starting at the nick and proceeding 
away from the FU/A pair. This strand displacement reaction was inhibited by the presence of 
the two glycosylases. 
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 In MMR-proficient extracts, both the 1.5 and 1.3 kb fragments contained similar 
amounts of incorporated radioactivity, which shows that the FU/A mispair was processed by 
the MMR system, giving rise to long repair tracts that flank the mispair on either side. 
Although the amount of radioactivity in these fragments (Fig. 5C, lanes 2 and 4) was 
substantially lower than that seen in the G/T substrate (Fig. 5C, lane 6), and although the 
MMR system was somewhat inhibited by the presence of TDG and UNG (Fig. 5C, compare 
lanes 2 and 4), our results clearly show that the MMR system recognizes and processes the 
FU/A substrate, albeit with low efficiency. This finding was unexpected, given that the FU/A 
oligonucleotide duplex was not appreciably bound by MutSα in the bandshift assay (Fig. 1B) 
and that the FU/A base pair apparently closely resembles a T/A; indeed, we failed to find a 
restriction enzyme capable of distinguishing between FU/A- and T/A-containing 
oligonucleotide substrates (data not shown).     
 
 The role of SMUG1 in the repair of FU-containing substrates 
Mammalian cells possess, in addition to UNG, TDG and MBD4, one additional DNA 
glycosylase capable of processing uracil residues in DNA: SMUG1. This enzyme was 
initially believed to be specific for uracil in single-stranded DNA, hence its name - single-
strand selective monofunctional uracil DNA glycosylase. However, it is now known to 
efficiently process also A/U and G/U substrates, at least at low salt concentrations in vitro36. 
 As shown above (Figs. 2-5), inhibition of TDG and UNG activities in the absence of 
MMR was sufficient to abolish processing of the FU/G substrate in our in vitro assays. These 
results therefore suggested that, like MBD4, SMUG1 did not contribute significantly towards 
the processing of FU in DNA in our system. However, the protein was shown to be present in 
the 293T-Lα extracts in relatively high amounts, as shown by western blotting (Fig. 6A), so 
some processing of the FU-containing substrates was anticipated if SMUG1 were able to act 
on them. Indeed, when the recombinant enzyme was incubated with FU-containing 
oligonucleotide substrates, it processed both the FU/G and the FU/A substrates rather 
efficiently (Fig. 6B, lanes 6 and 7, 9 and 10). We therefore suspected that SMUG1 might be 
inactive under the conditions of our in vitro MMR assay. This was indeed the case, as the 
enzymatic activity of the recombinant enzyme observed in the buffer recommended by the 
supplier was lost when the experiment was carried out in our MMR buffer (Fig. 6B, lanes 1-4; 
see Materials and Methods). As we cannot change the composition of this buffer without 
losing MMR activity, we are currently unable to test the contribution of SMUG1 towards FU 
processing in human cell extracts. However, we postulate that its activity in vivo would 
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contribute, together with UNG, TDG and, possibly also MBD4, towards the efficient removal 
of FU from DNA (see below). 
 
Discussion 
In spite of the fact that FU has been in daily use in clinical practice as an antimicrobial and 
anticancer agent for 50 years now, it’s mode of action is still poorly understood, principally 
due to the complexity of its metabolism. Its function as an inhibitor of thymidylate synthase 
(TS) is beyond doubt; it has been shown to irreversibly inhibit this enzyme by forming a 
covalent intermediate between its deoxyribonucleotide FdUMP and TS, trapping thus also 
methylenetetrahydrofolate in the complex. Moreover, its clinical efficacy in colon cancer 
therapy is somewhat increased by leucovorin, which stabilizes this ternary complex. FU can 
be also metabolized to the ribonucleotide and be incorporated into RNA in the form of 
FUMP, where it is believed to interfere with the function of tRNA and rRNA, as well as with 
mRNA metabolism. Although it has been known for several years that substantial amounts of 
FdUMP are incorporated into DNA, the contribution of this component to FU cytotoxicity has 
been little studied to date. We now show that this base analogue is efficiently removed from 
DNA, irrespective of whether it is base paired with adenine or guanine. In the latter case, the 
FU/G mispairs are addressed by the MMR system, by TDG, UNG and most likely also by 
SMUG1. FU/A pairs are poor substrates for MMR, but are addressed by UNG and most likely 
also by TDG and SMUG1. Indeed, while this manuscript was in the last stages of preparation, 
a report from the Lindahl laboratory37 showed that FU treatment of mammalian cells results 
in substantial levels of incorporation of this nucleoside analogue into DNA and that knock-
down of SMUG1 by siRNA leads to some two-fold sensitization to the drug. These results 
demonstrate not only that FU residues are addressed by the latter enzyme, but also that the 
removal of FU from DNA by SMUG1 has a protective effect – in contrast to UNG deficiency, 
which does not alter the sensitivity of the cells to the drug38. 
 What are the implications of these findings for FU-therapy? The first conclusion that 
could be made on the basis of our experiments is that FU would not reside in DNA for long, 
given that it can be removed by at least four enzymatic pathways. As it would be incorporated 
into newly-synthesized DNA predominantly opposite A, most of the removal would be 
expected to be catalyzed by SMUG1 and possibly also by UNG and TDG. Given that these 
enzymes process identical substrates, their functional redundancy would ensure that loss of 
one of these enzymes, e.g. through mutation or transcriptional silencing, would not carry 
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serious phenotypic consequences. Indeed, as mentioned above, UNG-deficient murine Ung-/- 
cells are not hypersensitive to FU38. In the case of FU incorporation opposite G, the resulting 
FU/G mispair would be efficiently processed by the MMR system. In its absence, it would be 
removed by the glycosylases TDG, UNG and probably also by MBD4 and SMUG1. In all 
these cases, the removal would not give rise to mutations, as the FU/G mispairs would be 
converted to C/G. Similarly to the case of the FU/A base pairs, it could be argued that the 
redundancy of the repair pathways addressing FU/G would make it unlikely that inactivation 
of any one would result in an increased sensitivity to the drug. However, this does not appear 
to be the case, given that SMUG1 deficiency sensitizes cells to FU. This implies that the 
different glycosylases contribute differently towards the removal of the halogenated base 
from DNA, as seen also in our assays, where TDG was shown to be notably more active on 
FU/G than UNG (compare Fig. 3A and 3C). Moreover, it also conceivable that the removal of 
FU from different genomic regions or during an inappropriate stage of the cell cycle may 
affect the cytotoxicity of the drug. Thus, UNG is believed to be associated predominantly 
with replication foci, while SMUG1 appears to be found predominantly in nucleoli36 and 
TDG is degraded prior to S-phase34. In the absence of SMUG1, ribosomal DNA might be left 
largely unrepaired, which would cause inefficient synthesis of rRNA and inhibition of 
translation. In the absence of TDG, FU-containing DNA might persist until the following 
replication cycle, where removal of FU residues from the single stranded template DNA 
might result in replication fork collapse and subsequent apoptosis. 
 There is one more point worth considering. Our experiments were carried out in an in 
vitro system, in which the FU-containing substrates were incubated with nuclear extracts of 
human cells supplemented with all four nucleoside triphosphates. In this scenario, the 
excision of FU residues mediated by MMR or BER could be followed by DNA synthesis, 
where the repair tracts were filled-in by polymerase-δ or –β, respectively. In a cell treated 
with FU, however, the nucleotide pools are depleted of dTTP, which has two important 
consequences: first, the replicating polymerases will incorporate large amounts of FdUMP 
into nascent DNA, and second, the repair polymerases will be unable to replace FdUMP 
residues removed by MMR or BER with TMP and will thus re-incorporate FdUMP into the 
repair tracts, triggering thus further rounds of futile repair. Moreover, FU excised by BER, or 
FdUMP excised by MMR, would be recycled to find their way back into a complex with TS, 
or into the DNA. In this way, the DNA repair processes would continuously replenish the FU 
levels in the cells and thus augment the toxicity of the drug. 
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   In conclusion, our experiments demonstrate that FU residues in DNA are efficiently 
removed by several redundant enzymatic systems. This processing could contribute 
substantially towards the toxicity of the drug. It could be argued that because the MMR repair 
tracts are substantially longer that those resulting from base excision, the absence of the 
MMR system would reduce the amount of repair DNA synthesis and thus attenuate the 
toxicity of FU through limiting all repair events to BER. However, MMR would be acting 
predominantly on FU/G mispairs, which would be expected to arise only rarely and the 
toxicity associated with MMR repair tracts would therefore be minimal. The differential 
sensitivity of the MMR-proficient and –deficient cell lines described in the literature8, 15, 16 is 
thus likely to be the result of other genetic differences between the cell lines. Indeed, in our 
hands, the MMR-deficient cell lines HCT116 and 293T-Lα-28 are as sensitive to FU as the 
matched MMR-proficient lines HCT116+chr3 and 293T-La+ (data not shown). The open 
question concerns the in vivo role of TDG, which would be expected to participate in the 
removal of FU from both, FU/G and FU/A pairs. If this enzyme were as active in cells as in 
our in vitro assays, it would be expected to exert a substantial protection against FU 
cytotoxicity. Given that Tdg knock out mice are embryonic lethal and that no isogenic TDG-
proficient and -deficient cell pairs exist, these experiments will have to await generation of 
such stable cell lines by, for example, shRNA technology. 
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Legends to Figures 
Fig.1 Chemical structures of halogenated pyrimidines and the recognition of FU in DNA by 
the human mismatch binding factor MutSα. A, Keto-enol tautomerism of uracils substituted 
with fluorine (FU), bromine (BrU) and iodine (IU). The question mark indicates the 
uncertainty regarding the prevalence of the enol form of FU. B, Binding of MutSα to FU/G 
and FU/A oligonucleotide substrates. The 5’-[32P]-labeled oligonucleotides (A/T, G/T, FU/A, 
FU/G) were incubated with 40 nM (lanes 1-4), 70 nM (lanes 5-8) or 100 nM (lanes 9-12) of 
purified human MutSα. The figure is an autoradiogram of a 5% native polyacrylamide gel. 
 
Fig.2 Processing of FU-containing base pairs in nuclear extracts of human cells. A, Schematic 
representation of the construction of the FU-containing DNA substrates and of the in vitro 
MMR assay. B, Susceptibility of FU-containing heteroduplex substrates to cleavage with 
AclI. The FU/A (lane 1) substrate was cleaved at position 46 (see panel A above), whereas the 
FU/G (lane 2) and G/T (lane 3) substrates were refractory to cleavage at this position. C, In 
vitro MMR assays performed with the FU/A (lanes 1 and 2), FU/G (lanes 3 and 4) or G/T 
(lanes 5 and 6) substrates. The 1516 bp and 1307 bp restriction fragments are indicative of 
repair (for details see 2A). The reactions were carried out in nuclear extracts of MLH1-
proficient (+), or MLH1-deficient (-) 293T-Lα cells. 
 
Fig.3 Contribution of different glycosylases to the repair of FU/G mispairs. A, mismatch 
repair assay in the presence of different concentrations of uracil DNA glycosylase inhibitor 
(UGI). The reactions were performed in nuclear extracts of MLH1-proficient (+), or MLH1-
deficient (-) 293T-Lα cells, with the nicked FU/G (lanes 1-5) or G/T (lane 6) substrates. The 
used UGI concentrations [U] are indicated in units defined by the manufacturer. B, Effect of 
MBD4 depletion on FU/G repair. Efficiency of MBD4 immunodepletion from 293T-Lα 
nuclear extracts was confirmed by Western blot analysis  (MBD4-, left panel, lanes 1 and 2). 
The MMR assays (right panel) were performed with undepleted (lanes 1 and 2) or MBD4-
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depleted nuclear extract (lanes 3-6). The DNA bands representing the repaired fragments 
were quantified using ImageQuant TL, Amersham Biosciences (right bottom panel). C, Effect 
of TDG depletion on FU/G repair. The reactions are identical to those shown in panel B, 
except that both SUMOylated and unmodified forms of TDG (arrows) were immunodepleted. 
 
Fig.4 Lack of TDG, UNG and MMR abolishes FU/G repair in vitro.  
The immunodepletion and Western blot analyses are identical to those shown in Fig. 3 BC 
(left panels). The MMR assay (right panel) was performed in the presence of UNG and TDG 
(lane 1), in the absence of UNG only (lane 2) or in the absence of both UNG and TDG (lanes 
3-6). 
 
Fig.5 FU/A repair in human cell extracts. A, Immunodepletion and Western blot analyses 
were identical to those shown in Fig. 3 BC. B, In vitro MMR assays supplemented with 
[α-32P] dATP were performed in the presence (lanes 1 and 2) or absence of UNG and TDG 
(lanes 3-6). Radioactive incorporation was visualized with a PhosphorImager (C).  
 
Fig.6 Processing of FU-containing substrates by SMUG1. A, SMUG1 is present in the 
extracts of 293T-Lα cells in large amounts, as shown by Western blot analysis. LoVo 
extracts, which express lower amounts of SMUG1 mRNA than 293T-Lα cells as judged by 
microarray experiments (J. Sabates-Bellver, unpublished) contain correspondingly lower 
amounts of the protein. B, In vitro activity of SMUG1 on FU-containing oligonucleotides. 
The FU/A and FU/G substrates were incubated either under MMR conditions (10xMMR 
buffer, lanes 1-4) or in buffer recommended by the manufacturer (10xDDR buffer, lanes 5-10, 
see Materials and Methods) in the presence (+) or absence (-) of MLH1-deficient nuclear 
extract of 293T-Lα cells (NE MLH1-). As shown, the recombinant enzyme is inactive in the 
MMR buffer, which might explain the absence of processing of FU-containing substrates in 
the cell extracts. The figure is an autoradiograph of a 12% denaturing polyacrylamide gel. 
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Abstract 
 
O6-methylguanine (mG) is the principal mutagenic and cytotoxic 
modification induced in DNA by SN1-methylating agents, such as N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG). The exact mechanism by 
which O6-methylguanine triggers cell death is unknown. One model 
suggests that mismatch repair (MMR) recognizes mG base pairs in the 
template strand and initiates several iterative excision-resynthesis 
cycles, finally resulting in persistent discontinuities, such as long 
single-stranded DNA regions. In an attempt to substantiate this 
hypothesis, we incubated heteroduplex substrates containing a single 
mG lesion with either MMR-proficient or –deficient nuclear extracts from 
293TL  cells. Pulse chase experiments in the presence of radiolabeled 
nucleotides permitted the direct visualization of repair events and 
putative iterative cycles on the substrates. We could show that mG-
containing mispairs are recognized and processed by MMR, albeit 
inefficiently, probably resulting in the formation of gapped regions 
opposite mG. Unfortunately, the recognition of the substrates by MMR 
was too weak to allow the detection of possible futile repair cycles and 
DNA intermediates in the systems we used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103
Metabolism of O6-methylguanine in DNA  Fischer et al. 
Introduction 
 
By treating DNA with methylating drugs, a plethora of modifications can be 
created. It is generally believed that agents inducing predominantely N-
methylations (SN2-type agents) such as methylmethanesulfonate (MMS) and 
dimethyl sulphate (DMS) provoke high chromosome breakage (clastogenic) 
effects but exhibit low mutagenic potency. On the other hand, agents inducing 
higher levels of O-methylations (SN1-type agents) such as N-methyl-N-
nitrosourea (MNU) and N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) are 
both clastogenic and mutagenic. The critical lesion responsible for the 
cytotoxicity of SN1-methylating agents is O6-methylguanine (mG) [1], which is 
induced in minor amounts (7% of the alkylation burden) in the DNA of 
exposed cells [2]. mG is repaired by O6-methylguanine-DNA methyltransferase 
(MGMT) [3], and, consequently, cells lacking this repair protein are highly 
sensitive to O6-methylating agents compared to MGMT containing cells [4].  
In vitro MNU-methylated plasmids exhibited mG processing in the form of 
unscheduled DNA synthesis [5] and this aberrant repair event could be linked 
to the presence of an intact mismatch repair (MMR) system [6]. Consistent 
with these results, mG -containing oligonucleotides are recognized by the 
human mismatch repair recognition factor hMutS in bandshift experiments 
[7]. The finding that cell lines defective in mismatch correction tolerate DNA-
methylation damage induced by SN1-type drugs [8, 9] confirmed the 
participation of MMR machinery in mG-directed cytotoxicity. 
Several models speculating about the mode of action of methylating agents 
and their ability to induce apoptosis have evolved, but none could be 
convincingly substantiated so far.  
The “futile repair” hypothesis [10] assumes that upon encountering mG in the 
template strand, MMR recognizes the lesion, but fails to repair it since the 
methylated base does not reside in the newly synthesized strand and thus 
cannot be addressed by the MMR system. The unsuccessful processing 
comprises several rounds of excision and re-synthesis steps, finally resulting 
in aberrant DNA intermediates, which could be converted into harmful double-
strand breaks in the following replication round.   
104
Metabolism of O6-methylguanine in DNA  Fischer et al. 
Alternatively, the “sliding-clamp signaling” model suggests a new role for 
MMR as a general DNA damage detector: upon recognition of specific types 
of DNA damage, MMR proteins directly signal to the apoptotic machinery [11].  
Using an isogenic system developed in our laboratory [12], we could recently 
show that an MNNG-induced G2 arrest in the second cell cycle is absolutely 
dependent on a functional mismatch repair system and persistence of single-
stranded DNA intermediates after the first S-phase could be exclusively 
detected in MMR-proficient cells [13]. This delayed damage response and 
preliminary data from electron microscopy studies that reveal single-stranded 
regions behind yeast and mammalian replication forks (Massimo Lopes, 
unpublished data) rather support a “futile repair” scenario. Furthermore, Paul 
Modrich’s lab succeeded in providing evidence for iterative repair cycles 
opposite mG in vitro [14], endorsing the first model. 
But also the “sliding-clamp signaling” model is based on experimental 
references. Recently, the MMR-dependent recruitment of ATR/ATRIP to mG/T 
mismatches in vitro and the concomitant phosphorylation of CHK1 was 
shown, implying a role of MMR proteins as direct sensors of alkylation 
damage [15]. This is consistent with previous studies, showing that murine 
MSH2 carrying a missense mutation in the ATPase domain provokes 
mismatch repair deficiency while retaining apoptotic signaling function in 
response to DNA-damaging agents. Although the mutated MutS was 
resistant to ATP-induced release, the mismatch binding capacity was not 
affected. From this, the authors concluded that processing of the lesion is not 
necessary for damage response, thus supporting the “sliding-clamp signaling” 
model [16]. Similar results were obtained with a dominant missense mutation 
in the MSH2-MSH6 heterodimer interface of murine MSH6 [17].  
In summary, although methylating agents are an integral part of 
chemotherapeutic regimens for various cancers, the mechanisms of these 
drugs in eliciting a cytotoxic response in tumour cells are still not fully 
understood and resistance to chemotherapies remains a major obstacle in 
cancer treatment.    
In an attempt to detect iterative repair opposite mG and to prove the existence 
of MMR-dependent single-stranded regions after processing of methylation 
damage, we incubated heteroduplex substrates containing one single O6-
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methylguanine with nuclear extracts from either MLH1-proficient or –deficient 
cells, and monitored the repair efficiency with an in vitro assay using 
restriction endonucleases. 
 
Materials and Methods 
 
Substrates, nuclear extracts and in vitro mismatch repair (MMR) assays 
The detailed procedure has been described previously [18]. Briefly, 
heteroduplex DNA substrates containing a G/T, a mG/T or a mG/C mismatch 
within an overlapping AclI/SalI restriction site in the 46 bp polylinker of a 
pGEM13Zf(+) derivative were constructed by primer extension, using 
oligonucleotides containing either a G or a mG  as primers and the single-
stranded phagemid DNA as template. 
The desired supercoiled heteroduplex substrates were purified by caesium 
chloride centrifugation. The strand discrimination signal was introduced by 
incubation with N.BstNBI, which specifically nicks the substrates either 3’ from 
the mismatch in the mG-containing strand (top strand) or 5’ from the mismatch 
in the viral strand (bottom strand) at position 352 of the duplex. The mismatch 
repair assays were performed in 20 mM Tris-HCl pH 7.6, 110 mM KCl, 5 mM 
MgCl2, 1 mM glutathione, 50 g/ml BSA, 0.1 mM each dGTP, dCTP, dTTP 
and dATP, 1.5 mM ATP, 100 ng (47.5 fmol) heteroduplex DNA substrate and 
50 g of nuclear extract from 293T-L+ (MLH1+), or 293T-L- (MLH1-) [12] 
cells in a total volume of 25 l. After 30 min incubation at 37°C, the reactions 
were terminated by the addition of a stop solution and further incubation for 30 
min at 37°C (final concentrations: 25 mM EDTA, 0.67% SDS, 50 g/ml 
proteinase K). The DNA was purified using Qiagen MinElute Reaction 
Cleanup Kit, digested with the appropriate mismatch-discriminating restriction 
enzyme and treated with 50 g/ml RNase A, followed by proteinase K (60 
g/ml) in the presence of 0.2% SDS. The DNA was then precipitated with 0.3 
M NaOAc pH 5.5 and ethanol, and resuspended in 10 mM Tris-HCl. The 
efficiency of the repair reactions was monitored on 1% TAE agarose 
(Invitrogen) gels stained with ethidium bromide. 
Most of the assays were performed in the presence of 1.7 pmol [-32P]dATP 
(10 Ci). To monitor incorporation of the radiolabeled nucleotide, the agarose 
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gels were vacuum-dried and exposed to a PhosphoScreen (Molecular 
Dynamics, Inc.). 
For pulse chase experiments, MMR reactions were incubated 10 min at 37°C 
in the presence of 1.7 pmol [-32P]dATP (10 Ci) and 250 pmol unlabeled 
dATP (Pulse), followed by addition of 5 nmol of unlabeled dATP (Chase). 
Samples were usually taken after 10, 20 and 40 min, or as indicated. 
 
Bandshift assays 
40 fmol (2 nM) of annealed [-32P] 5’-labeled oligonucleotides (see Fig. 1A for 
details) were incubated with 100 mM KCl, 25 mM Hepes-KOH pH 7.5, 1 mM 
DTT, 0.5 mM MgCl2, 0.1 mM ADP, 10% glycerol, 75 g/ml BSA and 60 ng 
poly(dIdC)•poly(dI-dC) competitor (Amersham Pharmacia Biotech) in the 
presence of different concentrations of purified human MutS in a final 
volume of 20 l. The binding reaction was performed at 37°C for 20 min. 
Where indicated, oligonucleotides were first incubated for 10 min at 37°C with 
0.2U of the human methylguanine methyltransferase MGMT (Sigma) before 
adding MutS and incubation for another 15 min at 37°C. 
Finally, 10 l were loaded onto 9x8 cm 5% native polyacrylamide (29:1) gels 
(ATTO system) eluted with 1x TAE buffer and run 30 min at 19 V/cm. The 
vacuum-dried gels were exposed to PhosphoScreens (Molecular Dynamics, 
Inc.). 
 
MGMT treatment of heteroduplex mG substrates 
MGMT treatment of mG-containing heteroduplex substrates was performed in 
25 mM Hepes-KOH pH 7.5, 1 mM DTT, and 75 g/ml BSA in the presence of 
0.2U of the human methylguanine methyltransferase MGMT (Sigma) in a final 
volume of 20 l. After 15 min incubation at 37°C, reactions were 
supplemented with appropriate amounts of BSA and restriction buffer and 
subsequently digested with AclI or SalI/BanI endonucleases, respectively. 
 
Dot Blot 
DNA was spotted under vacuum onto a Zeta-membrane (Zeta-Probe GT 
Genomics, Biorad), incubated in 2x SSC for 5 min and cross-linked to the 
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membrane with UV Stratalinker 1800 (Stratagene). The 6x SSC-wetted 
membrane was pre-hybridized for 2 hours at 45°C with hybrisol I (Chemicon 
International) in rotating glass tubes.  
Subsequently, the membrane was incubated overnight with 10 pmol of a [-
32P] 5’-labeled probe (5’ CAA TTC TCA AGC TTC CCA ACG TCG ACA GAC 
GTC TGG 3’) in hybrisol I solution. Finally, the dot blot was washed 
consecutively with 2x SSC/0.1% SDS, 0.5x SSC/0.1% SDS and 0.1x 
SSC/0.1% SDS (15 min for each washing step) and exposed to a 
PhosphoScreen (Molecular Dynamics, Inc.). 
As a positive control, the [-32P] 5’-labeled probe was annealed to 10 pmol of a 
complementary oligonucleotide, and 100 ng of non-complementary closed-
circular single-stranded DNA served as a negative control. 
 
Results 
 
Recognition of mG-containing mispairs by human MutS  
To confirm the ability of the human mismatch recognition factor MutS to 
detect and bind to O6-methylguanine (mG) in double-stranded DNA [7], we 
performed bandshift experiments with oligonucleotides harboring different 
mispairs (Fig. 1A). 
In contrast to G/T mismatches that are efficiently recognized and bound by 
MutS, mG/T and mG/C mispairs, at least in our sequence context, were no 
better substrates than a G/C homoduplex control (Fig. 1B). Observations with 
different oligonucleotides made by Hsieh et al. [15], where the mG/T and G/T 
substrates were bound with comparable efficiency suggested that the binding 
of MutS to mG/T may be affected by flanking sequences. However, in our 
hands, no appreciable binding could be detected even in a different sequence 
context (data not shown). As the sequences used in our experiment were 
bound as strongly as the G/T substrate by yeast MutS, we concluded that 
the human mismatch binding protein recognizes the methylated G/T and G/C 
substrates with low efficiency. The quantification of the bandshifts shown in 
Fig. 1B is depicted in Fig. 1C. In order to ensure the integrity of our 
substrates, we pretreated our mG/T oligonucleotides with human 
methylguanine methyltransferase (MGMT) prior to incubation with MutS, 
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thereby restoring a G/T mismatch that is strongly bound by human MutS 
(Fig. 1D).  In summary, human MutS recognizes both mG/T and mG/C 
mispairs equally weakly and to a similar extent as homoduplex DNA in 
bandshift assays. 
 
Endonuclease susceptibility of mG-containing mispairs in heteroduplex 
DNA substrates 
To study mismatch repair-dependent processing of mG in more detail in vitro, 
we constructed heteroduplex DNA substrates containing a mG either opposite 
C or T. The former mispair resides within an AclI restriction site, the latter lies 
within an overlapping AclI/SalI sequence (see Fig. 3A). Because the MMR 
assay is based on conversion of the restriction-endonuclease resistant, 
mismatch-containing vector, to a cleavage-susceptible form, we first had to 
test whether our mG/C and mG/T substrates are indeed resistant to the 
respective endonucleases. As shown in Fig. 2, mG/C mispairs are indeed AclI-
resistant (lane 2), while a considerable portion of mG/T mismatches, although 
resistant to SalI (lane 8), can be cleaved by AclI (lane 5). The presence of mG 
was confirmed by treating the mG/T and mG/C substrates with MGMT (lanes 3, 
6 and 9), thereby restoring G/T and G/C base pairs, respectively. G/T and 
G/C substrates served as controls (lanes 1, 4 and 7). These results confirm 
that mG/T resembles more closely a Watson-Crick base pair than mG/C [19] 
and provide an explanation for the observed AclI sensitivity of mG/T 
substrates. 
 
 
Processing of mG-containing base pairs in nuclear extracts of human 
cells 
With the aid of an in vitro MMR assay (Fig. 3A), we addressed MMR-
dependent processing of mG residues located either in the template 
(unnicked, circular) or the newly synthesized (N.BstNBI nicked) strand. Upon 
incubation of heteroduplex substrates containing single G/T, mG/T or mG/C 
mismatches with nuclear extracts from MLH1-proficient (+), or MLH1-deficient 
(-) 293T-L cells, we could examine the repair process in some detail. As 
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shown in Fig. 3B, the MMR machinery clearly recognized and repaired mG 
lesions from the nicked strand, although substantially less efficiently than G/T 
mismatches (left panel, compare lane 2 with lanes 4 and 6) [7], consistent 
with our bandshift results. A different situation arises when the MMR system 
encounters a mG in the template strand. Since such a lesion cannot be 
removed, we expected it to be left unrepaired in our MMR assay. Indeed, no 
indication of repair of heteroduplex substrates containing mG in the unnicked 
strand could be observed (Fig. 3B, right panel, lanes 4 and 6).  
Recently, Modrich and colleagues [20, 21] reported that repair of the 5’-G/T 
heteroduplex in their reconstituted system with purified proteins occurred 
efficiently in the absence of human MutL, although MutS and EXOI were 
required for the reaction. We agree with these findings, since also in our 
hands 5’-G/T shows significant background repair in the absence of MutL, 
which can be abolished by performing MMR assays with MSH2-deficient 
LoVo nuclear extract. Furthermore, aphidicolin inhibited both background 
repair in MLH1-deficient and MMR-specific repair in MLH1-proficient nuclear 
extract, thus supporting the idea that MutS and probably both EXOI and 
polymerase  are responsible for the observed 5’3’ activity (data not 
shown). It is however noteworthy that the extent of background repair was 
dependent on the batch of substrate and/or the nuclear extract preparation, 
since this phenomenon was not reproducible (compare Fig. 3, right panel, 
lanes 1 and 2 with Fig. 5D, lanes 5 and 6). 
In summary, MMR machinery recognizes and repairs mG, albeit with low 
efficiency, provided that the lesion resides in the nick-containing strand. 
 
Futile repair opposite mG lesions  
In an attempt to contribute to the longstanding hypothesis of futile repair 
events opposite a template mG, we set out to take advantage of our in vitro 
MMR assay and performed pulse chase experiments. The idea behind these 
experiments was to incubate our mG substrate with nuclear extracts in the 
presence of radiolabeled dATP, which is supposed to be incorporated mainly 
in the excision tracts formed upon repair attempts. By the addition of excess 
non-radioactive dATP after some minutes, we hoped to detect a decrease in 
110
Metabolism of O6-methylguanine in DNA  Fischer et al. 
the amount of incorporated radioactivity due to the proposed futile cycling 
opposite mG (Fig. 4A). In contrast to recently published data [14], we could 
never observe a mG-provoked and MMR-dependent decrease in radioactivity 
after cold-chasing the reaction. Moreover and unexpectedly, the most 
pronounced effect could be seen with the G/T substrate (Fig. 4B and 4E). 
Although mG/T substrates revealed a MMR-specific decrease of radioactivity 
of 20% (Fig. 4D and 4E), mG/C substrates did not show any difference 
between MMR-deficient and –proficient backgrounds (Fig. 4C and 4E).  
In another approach we separated MMR reactions containing radioactive 
dATP by means of Thin Layer Chromatography (TLC) and tried to detect the 
side-product dAMP, which should arise during the excision step of putative 
futile repair cycles (data not shown). Unfortunately, dATP was already 
hydrolyzed by solely adding nuclear extract, thereby masking MMR-
dependent hydrolysis. 
Thus, we cannot confirm the futile cycling scenario opposite mG, but rather 
observe a general decrease of radioactivity within our DNA substrates over 
time.  
 
Incorporation of C or T opposite mG remains ambiguous 
Which base is chosen to complement mG in the template strand ? To find an 
answer to this question we tried to exploit our mismatch-discriminating 
restriction enzymes AclI and SalI once more. After incubation of mG/T 
substrates with a nick in the T-containing strand and in the presence of all 
MMR proteins, three different situations opposite mG came into play: 
incorporation of either T or C, or formation of a gap due to unsuccessful 
processing. To leave aside the latter and by assuming that either mG/T or 
mG/C are formed, we theoretically end up with G/T and G/C base pairs 
exhibiting characteristic endonuclease susceptibility after MGMT treatment 
(Fig. 5A). 
However, the outcome of the experiments was not clear. Our results 
suggested that both mG/T and mG/C maintained (or restored) the original base 
pair conformation: mG/T showed AclI and SalI resistance upon MGMT 
treatment, implying the existence of a G/T mismatch (Fig. 5B and 5C), and 
mG/C turned out to be AclI-sensitive after incubation with MGMT, a proof for 
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the presence of a G/C base pair and an argument against the formation of 
gaps (Fig. 5D). The fact that only 10% of the molecules retained the AclI-
resistant phenotype (fragments indicated by an asterisk) in a MMR-
independent way further substantiates this conclusion. On the other hand, we 
cannot fully exclude the possibility of gaps arising, especially for mG/T 
mismatches (see also Fig. 6A).  
 
No gaps are detected upon repair events opposite mG 
Since mG/T substrates are clearly processed in the presence of nuclear 
extract, thereby becoming considerably AclI-resistant (Fig. 6A), we wanted to 
have a closer look at possible gaps arising during the repair trial. To this end 
we spotted purified MMR reactions on a membrane and hybridized a 
radiolabeled probe to the samples. Although MMR on a G/T substrate worked 
properly in this approach (Fig. 6B, right panel), no signal could be detected in 
any of the tested substrates (Fig. 6B, left panel, lanes 1-8).  
Fill-in assays with Klenow polymerase 3’5’ Exo- (deficient in both 3’5’ and 
5’3’ exonucleolytic activities) after MMR reactions could not show MMR-
dependent gap formation (data not shown, see Discussion). 
 
Discussion 
 
A functional mismatch repair system (MMR) in combination with mG moieties 
in DNA yields a cytotoxic composite causing cells to arrest in the G2/M phase 
of the second cell cycle [13]. Although we and others provided pieces of 
evidence for the formation of processed DNA intermediates due to repeated 
but unsuccessful attempts of MMR to correct the lesion, the exact mechanism 
of the observed cytotoxicity remains speculative. 
To confirm the hypothesis predicting “futile repair” events opposite mG in the 
template strand thereby leading to single-stranded DNA intermediates, we 
used an in vitro MMR system with heteroduplex substrates containing one 
single O6-methylguanine in the parental (unnicked) strand and nuclear 
extracts from the isogenic 293TL cell line, being either MLH1-proficient or 
MLH1-deficient [12]. We established an assay to detect incorporation of 
radiolabeled nucleotides and repair efficiency on our substrates (Fig. 3B), but 
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neither pulse-chase experiments (Fig. 4) nor thin layer chromatography to 
monitor the excised dAMP (data not shown) could prove the futile repair 
scenario in our hands. However, we cannot exclude the existence of the latter 
phenomenon, for reasons that will be briefly discussed.  
As shown in bandshift and MMR assays, our mG-containing substrates were 
poorly recognized by hMutS using two different sets of oligonucleotides (Fig. 
1B, 3B and data not shown). This has been ascribed to a certain sequence-
dependence of MMR factors, and other groups indeed reported that hMutS 
bound mG/T mismatches as well as G/T mismatches ([15]; Paul Modrich, 
personal communication) in a specific sequence environment. Interestingly, 
yeast MutS efficiently recognized mG/T mismatches in our sequence context 
(data not shown). 
To monitor radioactive incorporation and MMR efficiency, we’ve used 
standard agarose gels for our assays. Although eminently suitable for 
standard MMR assays, agarose gels may lack the resolution necessary to 
detect the small differences occurring in these reactions. Moreover, assuming 
that the inherently weak recognition of our mG-substrates will not result in a 
large amount of the desired DNA intermediates, the detection of these 
aberrant structures might need more sensitive read-outs. Indeed, working on 
the same topic, Paul Modrich’s laboratory recently demonstrated futile repair 
events opposite mG with the aid of alkaline agarose and polyacrylamide gels 
[14].  
The elegant idea to show in vitro futile repair cycles by iteratively excised 
nucleotides in the form of radiolabeled dAMP with thin layer chromatography 
failed due to the fact that dATP is hydrolyzed to dAMP in the mere presence 
of nuclear extract, thus masking the effect of mG-induced hydrolysis (data not 
shown). 
To visualize the hypothesized single-stranded gaps presumably formed upon 
mG processing, we performed fill-in assays after MMR reactions by using 
Klenow polymerase 3’5’ Exo-. The residual 5’3’ polymerase activity was 
expected to fill the presumable gaps and replicate across mG [22] without 
exonucleolytic side reactions. Unfortunately, we encountered a major obstacle 
in the purification step and we fear that the commercially available columns as 
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parts of DNA purification kits are not suitable for the recovery of special DNA 
intermediates. We are currently trying to optimize the protocol by phenol-
chloroform purification of the DNA.  
Another approach, called Dot Blot, was tested to gain more insight into 
gapped structures by spotting DNA on a special membrane after MMR 
reaction on mG-substrates, followed by hybridization with a radiolabeled probe 
that is complementary to the mG-containing strand (Fig. 6B). We could not 
detect a signal so far, and this could be for several reasons: 1) the amount of 
generated gaps due to futile repair cycles is too low to be detected, or, in 
other words, the amount of DNA has to be increased to see an effect; 2) the 
size of the gap is shorter than our probe and thus cannot be detected; 3) the 
gaps within the substrates are not accessible for the probe; 4) there are no 
gaps. Since the controls worked very nicely, we shall try to optimize the 
conditions in order to find an answer. 
Since tolerant cells remain sensitive to the mutagenic effect of alkylating 
agents, questions about the replication across mG arise. Several studies in 
vitro [23-25] and in vivo [26-28] demonstrated a preferential, albeit quite 
inefficient, incorporation of dTMP opposite a mG template, for this lesion 
blocks synthesis by prokaryotic and eukaryotic DNA polymerases in general. 
This applies also to the repair polymerase  [22], although the latter can 
catalyze the mG bypass in vitro, provided that the lesion resides in single- or 
short nucleotide gapped substrates [29]. DNA polymerase , required for 
lagging strand synthesis, is strongly blocked one base before mG [30]. The 
human and yeast translesion polymerases  (also called Rad30 in yeast) are 
very efficient in bypassing mG and inserting nearly equally well a C or a T 
opposite the lesion ([19], reviewed in [31]). The replicative human and yeast 
polymerase  can bypass mG as well, but this lesion presents a strong block 
and favors the error-prone incorporation of a T [19]. Another translesion 
polymerase, the yeast polymerase , was shown to act as an extender from 
the nucleotides inserted opposite mG by polymerase  [32]. But which 
nucleotide is incorporated in the presence of the full complement of 
polymerases ? In an attempt to find an answer to this question, we took 
advantage of the different endonuclease sensitivities of our mG substrates 
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(Fig. 5). But once more: the weak recognition of our substrates by the MMR 
system failed to yield a conclusive result. mG/Tb clearly became AclI- and SalI-
resistant (Fig. 5B, left panel, lanes 1-4; middle panel, lanes 1-4) after the 
MMR reaction and MGMT treatment, implying the formation of a G/T 
mismatch. The weak persistence of the two repair fragments (left panel, lane 
4) can be explained by the spontaneous generation of unspecific nicks in the 
top strand and concomitant repair by the MMR to restore an AclI-susceptible 
A/T site. On the other hand, mG/Cb became AclI-sensitive after MMR reaction 
and MGMT treatment, suggesting the maintenance of the original base-pair 
(Fig. 5, right panel, lanes 1-4). Three conclusions can be drawn: 1) the 
complex interplay between several different polymerases incorporating 
distinct nucleotides concealed the outcome, 2) our system is not sensitive 
enough to reveal the MMR-directed incorporation of the favored nucleotide 
opposite mG due to the weak recognition of the lesion, or 3) the arising gaps 
predominate and cannot be detected by this approach.  
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Legends to Figures 
 
Fig. 1 Recognition of mG-containing mispairs by MutS in bandshift assays. 
A, Oligonucleotide substrates G/T, mG/C, mG/T or G/C. B, Binding of MutS to 
mG/T and mG/C mismatches. The [-32P] 5’-labeled oligonucleotides (G/C, 
G/T, mG/C, mG/T) were incubated with increasing concentrations of purified 
human MutS, as indicated. C Quantification of the gels. The shifted bands 
were quantified using the ImageQuant TL (Amersham Biosciences) software. 
D, Methylguanine methyltransferase (MGMT) efficiently converts mG to G. G/T 
and mG/T oligonucleotides were incubated with 103.5 nM MutS in the 
absence (lanes 1 and 2) or presence (lanes 3and 4) of MGMT (0.2U). The 
panels B and D are autoradiograms of 5% native polyacrylamide gels. 
 
Fig. 2 Susceptibility of mG-containing heteroduplex substrates to cleavage 
with the endonucleases AclI and SalI.  
The heteroduplex DNA substrates (see Materials and Methods and Fig. 3) 
containing a mG/C mismatch were tested for AclI-sensitivity only (lanes 2 and 
3), whereas the mG/T substrates were tested with both endonucleases, AclI 
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and SalI (lanes 5 and 6, 8 and 9) in the presence (lanes 3, 6 and 9) or 
absence of 0.2 U MGMT. The resulting fragments are labeled a-g. 
 
Fig. 3 Processing of mG-containing base pairs in nuclear extracts of human 
cells. 
A, Schematic representation of the construction of the mG-containing DNA 
substrates and of the in vitro MMR assay. B, In vitro MMR assays performed 
with G/T, mG/T or mG/C substrates. The 1516 bp and 1307 bp AclI restriction 
fragments indicate repair of G/Tt, mG/Tt, mG/Ct and mG/Cb, the 422 bp and 
141 bp (not visible) restriction fragments generated by SalI/BanI monitor 
repair of G/Tb and mG/Tb. The reactions were carried out in nuclear extracts 
of MMR-proficient (+), or MMR-deficient (-) 293T-L cells in the presence of 
[-32P]dATP, separated on a 1% TAE agarose gel (upper panel) and finally 
exposed to a PhosphoScreen (lower panel). t, substrate containing a specific 
nick in the complementary (“top”) strand; b, substrate containing a specific 
nick in the viral (“bottom”) strand. 
 
Fig. 4 Pulse chase experiments fail to provide evidence of futile cycling.  
A, Experimental design of the pulse chase experiments. NE: nuclear extract of 
MMR-proficient 293T-L cells. B, Pulse chase with the G/T substrate. The 
heteroduplex DNA was incubated with either MMR-deficient (L-) or MMR-
proficient (L+) nuclear extract in the presence of [-32P]dATP. Aliquots were 
withdrawn after 10, 20 and 40 minutes. After the10 minute pulse, an excess of 
cold dATP was added to the reaction (chase), indicated by black arrows. The 
1% TAE agarose gel showing the AclI digest of the repair reactions (upper 
panel) was finally vacuum-dried and exposed to a PhosphoScreen (lower 
panel). C, Pulse chase with the mG/C substrate. The procedure was as 
described in B. D, Pulse chase with the mG/T substrate. The procedure was 
as described in B, with the exception that aliquots were withdrawn after 10, 
15, 25 and 40 minutes. E, Quantification of the pulse chase experiments. For 
each time point, the total incorporation of radiolabeled dATP within the 
substrate was quantified. The level of radioactive incorporation after 10 
minutes (pulse) was taken as 100%. 
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Fig. 5 Processing of mispairs containing mG in the template strand.  
A, Schematic representation of the possible outcomes of MMR-dependent in 
vitro processing and subsequent MGMT treatment of substrates containing 
the mG residue in the continuous strand, as measured by susceptibility to the 
endonucleases AclI and SalI after. , endonuclease-resistant; , 
endonuclease-sensitive. B, C, The mG/T substrate was incubated with either 
MMR-deficient (-) or MMR-proficient (+) nuclear extracts, followed by MGMT 
treatment (n: no MGMT; y: MGMT-treated) and restriction digest with the 
appropriate endonucleases AclI (B, lanes 1-4) or SalI/BanI (C, lanes 1-4)). 
The repair efficiency was compared to that of the G/T substrate (B and C, 
lanes 5 and 6). The upper panels show agarose gels, which were vacuum-
dried and exposed to PhosphoScreens (middle panels). On the bottom, 
formation of fragments that are indicative of repair was quantified (compare 
Fig. 3). D, Procedure identical to B and C, exception that the mG/C substrate 
was used. The G/T substrate containing the nick in the viral strand meaning 
the restoration of the SalI restriction site upon repair was used as the positive 
control (lanes 5 and 6). 
 
Fig. 6 Nuclear extracts of 293T-L cells processes mG-containing 
heteroduplexes independently of their MMR status.  
A, AclI susceptibility of the mG/T substrate after incubation with the 
endonuclease alone (left) or with nuclear extract from MMR-deficient (-) or 
MMR-proficient (+) 293T-L cells (centre). AclI fragments arising due to 
cleavage at the mismatch site are marked with an asterisk. Quantification of 
the AclI cleavage is depicted on the right. B, Left panel: Dot Blot with mG/Tb 
(lanes 1 and 2), mG/Cb (lanes 3 and 4), G/Tb (lanes 5 and 6) and G/Tt (lanes 
7 and 8) substrates, which were incubated with nuclear extract from MMR-
deficient (-) or MMR-proficient (+) 293T-L cells, subsequently spotted onto a 
Zeta-membrane and hybridized with a radiolabeled probe complementary to 
the O6-methylguanine- (lanes 1-4) or guanine-containing (lanes 5-8) strands, 
respectively. A complementary 31-mer oligonucleotide served as the positive 
control (Positive C.), non-complementary single-stranded DNA was used as 
the negative control (Negative C). Right panel: MMR reaction with a G/Tt 
substrate was used to check the repair efficiency of the experiment. 
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  Results 
 
6.3 Characterization of the “mismatch repairosome” and its role in the 
processing of modified nucleosides in vitro 
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Abstract
The process of postreplicative mismatch repair (MMR) increases the
fidelity of DNA replication by eliminating biosynthetic errors from newly
synthesized DNA. In addition, MMR proteins are also involved in the
processing of intermediates of mitotic and meiotic recombination and, in
mammalian cells, play a role in DNA damage signaling. As mismatches
cannot be induced in the DNA of living cells, the study of the molecular
transactions during MMR is restricted to in vitro systems. This chapter
describes the construction of heteroduplex substrates that can be used
for DNA affinity purification of MMR protein complexes and for the study
of the role of eukaryotic MMR proteins in the processing of modified
nucleosides.
Introduction
The mismatch repair (MMR) system can increase the fidelity of DNA
replication by up to three orders of magnitude. It accomplishes this task by
recognizing base/base mismatches and strand misalignments (insertion/
deletion loops, IDLs) that have escaped the proofreading function of
the replicative polymerase and by catalyzing a regional degradation of
the mismatch‐containing DNA strand, which results in removal of the
non‐Watson–Crick structures. Resynthesis of the degraded region res-
tores the integrity of the replicated duplex (Modrich and Lahue, 1996).
As it is the newly synthesized DNA strand that carries the erroneous
genetic information, the correction process has to be directed to this strand
(Modrich, 1997). In eukaryotes, the directionality of MMR is made possi-
ble by an intimate coupling of the replication and repair processes,
mediated most likely by proliferating cell nuclear antigen, the processivity
factor of DNA polymerases (Jiricny and Marra, 2003). Because the eu-
karyotic MMR system lacks detectable endonuclease activity (Holmes
et al., 1990; Thomas et al., 1991), degradation of the error‐containing strand
must begin at a preexisting strand discontinuity, such as either end of an
Okazaki fragment or the 30 terminus of the primer strand (Modrich, 1997).
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The mammalian MMR reaction works extremely well in cell‐free sys-
tems. To date, the tested substrates have been heteroduplexes based on
fd phage (Holmes et al., 1990) or M13 (Thomas et al., 1991), which were
obtained by annealing of a linearized double‐stranded DNA of one phage
with the single‐stranded circular (viral) form of another phage that differed
from the first in a defined position. Isolation of circular double‐stranded
molecules yielded a substrate containing a mismatch at a defined site,
together with a nick a given distance 50 or 30 from the mispair. The disad-
vantage of this approach was the large size of the DNA used (fd phage and
M13 are 6–7 kb in length), which limits the yields, and the fact that the nick
could only be positioned in the complementary strand.
We are interested primarily in isolating the ‘‘mismatch repairosome’’
by DNA affinity purification, which requires considerable amounts of
heteroduplex DNA. To this end, we have modified the construction meth-
od of the heteroduplex substrate. We make use of phagemid DNA, which
is 3 kb in size and can be isolated in large amounts in both single‐ and
double‐stranded forms. Our second field of study is concerned with the
investigation of the role of MMR proteins in the processing of modified
nucleosides. In this experimental system we need to introduce site‐specific
modifications into either strand of the heteroduplex. To achieve this goal,
we have modified the pGEM‐13Zf(þ) vector, such that it carries only a
single recognition site for N.BstNBI, an enzyme, which cleaves only a
single strand of this asymmetric sequence and thus introduces only a single
nick into our duplex DNA molecules (see also Wang and Hays, 2001,
2002).
The following paragraphs describe the preparation of both these
substrates and include also some pilot experiments with extracts of
human cells.
Construction of Substrates Containing Insertion/Deletion Loops
The heteroduplex substrates containing an insertion/deletion loop
(IDL) of a single extrahelical nucleotide are constructed from two different
plasmids, one of which is 1 bp longer than the other. To produce these, two
oligonucleotides, 50‐GGCCGCTCCATGCAAGCCTAGAGATCTCCC-
TCAAGTAGTA‐30 and 50‐GGCCGCTCCATGCAAGCCTAGGATC-
TCCCTCAAGTAGTA‐30, differing in one position (denoted in bold),
are cloned between the HindIII and the NotI restriction sites of the pha-
gemid pGem‐13Zf(þ). The first of the resulting plasmids, pGem_IDLin-
ker40, contains a unique BglII restriction site, whereas the second,
pGem_IDLinker39, contains a unique AvrII site. By linearizing the two
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double‐stranded DNAs with different restriction enzymes, denaturing and
reannealing, a mixture of two circular heteroduplexes can be obtained,
50% of which contain an extrahelical adenosine in one strand and the
other 50% an extrahelical thymidine in the other strand (Fig. 1A). This
substrate, which is referred to as the (þ/) substrate, is simple to obtain in
large amounts and is used for DNA affinity purifications. The second
heteroduplex can be obtained by annealing a linearized double‐stranded
DNA of one phagemid with the circular single‐stranded DNA of the other
(Fig. 1B). In this way, heteroduplexes containing either a single extraheli-
cal thymidine in the viral strand or a single extrahelical adenosine in the
complementary strand can be obtained. By using different phagemids,
heteroduplexes carrying any type of base/base mismatch or any size IDL
can be obtained.
Construction of the (þ/) Substrate
Linearization. To produce the (þ/) heteroduplex substrate, 100 g
pGem_IDLinker39 is digested with BsaI (New England Biolabs) and 100 g
pGem_IDLinker40withBanII (1U enzyme/gDNA in 500 l volume) (New
England Biolabs). To produce the (þ/) homoduplex substrate, 100 g
pGem_IDLinker39 is digested withBsaI and 100 g pGem_IDLinker39 with
BanII. Completeness of the digest is checked on a 1%agarose gel (Fig. 2, lane
1) and, if complete, theDNA is ethanol precipitated and then dissolved in 500
l 10 mM Tris–HCl, pH 8.0.
Annealing. The annealing is performed in 3 ml total volume containing
10 mM NaCl, 1 mM EDTA, 50 mM Tris–HCl, pH 7.6, 100 g pGem_
IDLinker40 (BanII), and 100 g pGem_IDLinker39 (BsaI) to produce
FIG. 1. Schematic representation of the production of (þ/) substrates (A) and 30 and 50
substrates (B).
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the (þ/) heteroduplex substrate or 100 g pGem_IDLinker39 (BanII)
and 100 g pGem_IDLinker39 (BsaI) to produce the (þ/) homoduplex
substrate. Ninety microliters of freshly prepared 10 N NaOH (200 mg in
500 l H2O) is added, and the solution is mixed gently and left at room
temperature for 5 min. The following solutions are then added sequential-
ly: 300 l 2.9 M acetic acid, 135 l 3 M KCl, 372 l 1 M potassium
phosphate, pH 7.4. The solution is incubated for 30 min at 65, then for
3 h at 37, and finally left to stand at room temperature while 2 l of the
reaction mix are loaded onto a 1% agarose gel to check for annealing
efficiency (Fig. 2, lane 2). The nicked (þ/) substrates run slightly slower
than the linearized DNA.
Purification. The annealing mixture is dialyzed for 2 1 h against 1 liter
of 10 mM Tris–HCl, pH 8, 0.1 mM EDTA. The linear side product of the
reaction is removed by the addition of DNase V and incubation at 37
overnight in 33 mM Tris–acetate (stock solution: 1 M, pH 7.8), 66 mM
potassium acetate (stock solution 3M, pH 7.7), 10 mM magnesium acetate
(stock solution 1 M), 1 mM ATP, 0.5 mM dithiothreitol (DTT), and 50 U
Plasmid‐Safe ATP‐Dependent DNase (Epicentre). The efficiency of the
digest is checked on a 1% agarose gel (Fig. 2, lane 3). If the faster migrating
band of linearized DNA has disappeared completely, the DNase V is heat
inactivated by incubation at 70 for 30 min. The formerly clear solution
now becomes turbid and has to be filtered prior to DNA precipitation. If
the filtration step is omitted, the DNA will be only partially soluble after
the precipitation. The filtration is performed with PD‐10 desalting columns
(Amersham Biosciences), which contain Sephadex G‐25 (two columns/
reaction). The eluate is precipitated with 0.2 M NaCl and 2 total volume
of ice‐cold ethanol, left at 20 for at least 90 min, centrifuged at 20,000g
for 30 min at 4, washed with 6 ml 70% ethanol, and centrifuged again at
20,000g for 10 min at 4. The pellets, which may not be visible, are dried at
room temperature and then dissolved in about 250 l 10 mM Tris–HCl, pH
FIG. 2. Production of the (þ/) substrate. Aliquots of the various steps in the preparation
of this substrate were separated on a 1% agarose gel containing 0.5 g/ml ethidium bromide
and visualized on a UV transilluminator. M, 1‐kb DNA ladder; lane 1, 1 l before annealing;
lane 2, 2 l after annealing; lane 3, 40 ng after DNase V digest and precipitation; lane 4, 40 ng
after NdeI digest; lane 5, 40 ng after Klenow fill in and Sephadex purification; lane 6, double
volume of DNA sup; and lane 7, 40 ng linearized pGemIDLinker40. The mobilities of open
circular (oc) and linearized DNA molecules are shown on the right.
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8.0. The concentration and quality of the DNA are determined by analyti-
cal agarose gels and/or on a Nanodrop. The yield is between 25 and 40 g
(25–40%). If the DNA is to be used in mismatch repair assays, it is purified
further by gel extraction.
Biotinylation. If the DNA is to be used as an affinity matrix, it has to be
labeled with biotin, such that it will bind onto magnetic, streptavidin‐
coated beads. To this end, the DNA is first cut with NdeI (4 U/g DNA;
New England Biolabs), which creates the required TA‐50 overhangs. The
digest is checked on an agarose gel (Fig. 2, lane 4) and, if complete, the
enzyme is heat inactivated by incubation at 65 for 30 min. The ends
are filled in with Klenow polymerase under the following conditions:
10 g (þ/) substrate (NdeI), 10 U Klenow polymerase (Roche), 33 M
biotin‐16–20‐deoxyuridine‐50‐triphosphate (Biotin‐16‐dUTP; Roche), 33 M
of each dATP, dGTP, and dCTP. The reaction is allowed to proceed at
25 for 30 min and is then stopped by the addition of EDTA to a final
concentration of 10 mM and heating to 75 for 20 min. The biotinylated
substrate is then purified from the excess of free biotin‐16‐dUTP on a
Sephadex G‐25 or G‐50 filtration column (self‐packed). The flow through
will contain the purified, biotinylated and nicked (þ/) substrate (Fig. 2,
lane 5).
Coating of Magnetic Beads with the (þ/) Substrate DNA. To obtain
complete binding of the biotinylated DNA to Dynabeads M‐280 streptavi-
din (Dynal), 30 l of the bead suspension is used per microgram of (þ/)
substrate. The beads are agitated and the desired amount is taken out and
aliquoted into 1.5‐ml Eppendorf tubes. These are put into a magnetic
particle concentrator (MPC; Dynal MPC‐E‐1) and allowed to attach for
about 2 min. The storage buffer is removed. An equal volume of wash
buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 M NaCl, 0.003% [v/v]
NP‐40) is added and the beads are resuspended by flicking the side of the
tube. They are then allowed to attach to the wall in the MPC for about
2 min. This procedure is repeated twice. The beads are then washed once
with B&W buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA, 2 M NaCl,
0.003% [v/v] NP40).
The DNA is attached to the beads as follows: the desired amount
of DNA and an equal volume of B&W buffer are added to the beads and
the mixture is incubated at 43 for 1 h. The supernatant (DNA superna-
tant) is then removed from the beads using the MPC. To ensure complete
binding of the DNA, the DNA supernatant should be analyzed on an
agarose gel (Fig. 2, lane 6). The beads are then washed twice with wash
buffer and once with B&W buffer by resuspension and immobilization in
the MPC at each step and are now ready to be used for DNA affinity
purification.
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Construction of 30 and 50 Substrates
By definition, the 50 substrate contains a single‐strand nick upstream
from the mismatch. On this substrate, the mismatch is removed by a 50!30
exonuclease, which starts at the nick. In contrast, the 30 substrate, which
contains the nick downstream from the mispair, has to be processed first
by a 30!50 exonuclease. The key difference between these substrates
is that the mismatch in the former can, in principle, be ‘‘repaired’’ by nick
translation even in MMR‐deficient extracts, whereas the latter cannot.
Production of Bacteriophage M13K07. M13K07 is a helper phage.
When host bacteria harbor both phagemid and M13KO7, the gene II
product of the phage interacts with the f1 intergenic region present in the
phagemid and initiates rolling circle replication to generate copies of one
strand of the phagemid DNA (ssDNA). The permissive Escherichia coli
strains must possess pili to accept the phage. One such suitable strain is
XL1 blue, which contains a tetracycline selectable F’ factor. (When work-
ing with phage, caution must be used not to contaminate the environment:
sterile tips should be employed, used tips and pipettes should be discarded
in 80% ethanol, and flasks and centrifuge bottles should first be washed out
with 10 N NaOH and then with 80% ethanol).
PRODUCTION OF RECEPTIVE (MALE) XL1 BLUE CELLS. XL1 blue cells
from a glycerol stock are streaked out on a 2 YT/Tet (5 g/ml) plate and
incubated overnight at 37. (To produce 1 liter 2 YT medium, 16 g
tryptone, 10 g yeast extract, and 5 g NaCl are dissolved in water and the
pH is adjusted to pH 7.0 prior to autoclaving. To produce 2 YT plates,
15 g agar are added to 1 liter 2 YT medium prior to autoclaving.) Five
single colonies are picked the next day and inoculated into 5 ml of 2 YT/
Tet medium (5 g/ml) each. They are allowed to grow at 37 overnight. (To
prepare a new glycerol stock, 10 l of the overnight culture is added to 5 ml
of 2 YT/Tet medium [5 g/ml] and incubated at 37 for 6 h. Six hundred
microliters is then mixed with 400 l of 50% glycerol and the stocks are
stored at 80.) As the F0 factor can be lost, the clones should be tested for
its presence as follows.
A thick line of each overnight culture is streaked on a 2 YT/Tet
(5 g/ml) plate in the morning using a sterile inoculation loop. One micro-
liter of M13K07 phage from a stock with a titer of at least 106 is spotted at
the beginning of each line (make also one control plate without phage).
After 6 h of incubation at 37, the lines are checked for plaque formation at
the site of phage release. Clear transparent spots (plaques) indicate that the
respective XL1 blue clone is receptive to phage infection. A few cells are
lifted with a sterilized Pasteur pipette (without touching the plaques),
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streaked out on a fresh 2YT/Tet (5 g/ml) plate, and incubated overnight
at 37.
PRODUCTION OF M13K07 PHAGE. Five milliliters of 2 YT/Tet medium
(5g/ml) are inoculatedwith a singlemaleXL1blue colony and incubated at
37 for 6–8 h. Five 4 ml aliquots of liquid top agar (autoclaved, melted,
aliquoted in snap‐cap tubes, and kept a 44) are prepared. Two hundred
microliters of the bacterial culture are added to 100 l of five different
dilutions of M13K07 (or phosphate‐buffered saline [PBS] as a blank; rea-
sonable dilutions of a 1.7 1013 pfu/ml stock: 109–1012 ¼ 1.7  104–101
pfu/ml ¼ 17,000–17 plaques) and incubated for 10 min at 37. Bacteria
(blank) and bacteria/phage mixtures are added to the top agar, mixed
briefly, and then poured evenly onto prewarmed 2YT/Tet (5g/ml) plates.
The plates are allowed to dry at room temperature for 20 min and then
incubated overnight at 37. After 12–15 h of incubation, the plates should
show a confluent opaque bacterial layer with plaques (number should be
consistent with the corresponding phage dilutions). One liter of 2 YT/Tet
(5 g/ml)/Kan (30 g/ml) medium in a 5‐liter conical flask is inoculated with
one single plaque from the bacterial layer by aspirating a plug containing the
selected plaque with a sterile Pasteur pipette and flushing it into the culture
medium. The phage culture is incubated overnight at 37 with shaking.
The next day, it is centrifuged at 2700g for 30 min at 4. The pellet is
discarded, and the supernatant containing the phage is transferred to new
tubes and centrifuged at 10,800g for 30 min at 4. The pellet is discarded
and the supernatant is incubated at 70 for 30 min and then left at room
temperature for 10 min. The phage solution is centrifuged at 10,800g for
10 min at 4 and the supernatant is transferred to a 2‐liter conical flask, to
which one‐fourth of the volume of 20% PEG/2.5M NaCl is added, and the
phage particles are precipitated overnight at 4 without shaking.
The next day, the PEG‐precipitated phage particles are centrifuged at
10,800g for 30 min at 4. The supernatant is discarded and all traces of it are
removed from the neck of the flask with a paper towel. The pellet contain-
ing the phages is resuspended in a minimal volume (6–8 ml) PBS, pH 7.4,
with shaking for 1 h at room temperature. The suspension is then trans-
ferred to Eppendorf tubes and centrifuged at 20,800g for 10 min at 4 in a
tabletop centrifuge. The supernatant containing the purified phages is then
aliquoted (the pellet consisting of residual bacterial cells is discarded) and
the aliquots are stored at 4.
DETERMINATION OF PHAGE TITER. Five milliliters 2 YT/Tet (5 g/ml)
medium are inoculated with a single colony of the tested male strain and
allowed to grow at 37. Six hours later, seven dry 2 YT/Tet (5 g/ml)
plates and 7  4 ml liquid sterile top agar aliquots in a 44 water bath are
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prepared. Assuming that the new phage stock concentration is 1013 pfu/ml,
serial dilutions in PBS, pH 7.4, are made and 100 l of phage dilutions
107–1012 (or PBS as a blank) are added to 200 l of the bacterial culture,
mixed briefly, incubated for 10 min at 37, mixed with 4 ml top agar, and
plated onto prewarmed 2 YT/Tet (5 g/ml) plates. The plates are incu-
bated at 37 for at least 15 h. The plaques on the plates with the higher
dilutions are counted, the average value is calculated, and the pfu/ml are
calculated (e.g., 50 plaques on the plate with the 1010 dilution corresponds
to 500 pfu/ml and thus the stock has a titer of 5  1012 pfu/ml).
Production of Single‐Stranded DNA. When using plasmids derived
from pGemZf(þ), the sequence of the ssDNA corresponds to the lower
strand shown in the Promega catalog.
Day 1. XL1 blue are transformed with 20 pg of the desired plasmid
(e.g., pGem_IDLinker40 to produce the DT substrate).
Day 2. One hundred millilters of 2YT/Amp (100 g/ml)/Tet (5 g/ml)
medium is inoculated with a single transformed colony and incubated
overnight at 37 with shaking at 200–250 rpm.
Day 3. The OD600 of a 1/10 dilution of the overnight culture is
measured. Then, 2 1 liter of 2 YT/Amp (100 g/ml)/Tet (5 g/ml)
medium in 5‐liter conical flasks is inoculated with the overnight culture
such that the OD600 at time 0 is 0.07. The cultures are grown at 37
 with
shaking at 220 rpm, and the OD600 is checked every 20 min until OD600
reaches 0.2–0.3 (after about 80 min). Then, a superinfection with the helper
phage M13K07 is made at a multiplicity of infection (MOI) of 20. Assum-
ing that OD600 ¼ 1 corresponds to 5  108 cells/ml (¼ 1.25  1011/liter),
2.5  1012 phage particles (250 l from a 1013 phage stock) have to be
added per liter. The bacteria are kept for 10 min at 37 without shaking and
are then shaken at 220 rpm for 90 min at 37. After 90 min, 30 g/ml
kanamycin are added to select for M13K07‐infected cells. The bacteria are
allowed to grow for a further 3 h. The cultures are cooled on ice for 30 min,
and the suspension is transferred to centrifuge bottles and centrifuged at
5000g for 30 min at 4. The supernatant is transferred to fresh centrifuge
bottles, heated to 70 for 30 min, equilibrated at room temperature for
15 min, and centrifuged at 10,000g for 15 min. This step kills and removes
remaining bacteria in the suspension. The supernatant is transferred to a
5‐liter conical flask and 1/4 volume ( 500ml) of 20% (w/v) PEG8’000/2.5M
NaCl is added. The phage particles are precipitated overnight at 4.
Day 4. The phage suspension is transferred into centrifuge bottles and
centrifuged at 10,000g for 30 min at 4. The supernatant is discarded and
the remaining liquid is removed with paper towels. The precipitated phage
particles form a whitish film on the wall of the centrifuge bottles, which is
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hardly visible. These are resuspended in a minimum volume of PBS, pH 7.4
(about 15 ml for 2 liter starting culture), with moderate shaking for 1–2 h at
room temperature. The resulting suspension is very dense and brownish
and is centrifuged at 24,000g for 15 min at 4. The supernatant containing
the phage particles is transferred to fresh centrifuge bottles, and the pellet
of residual bacterial cells is discarded. The phage suspension is now opaque
yellow.
If XL1 blue cells were used, the phage suspension is usually contami-
nated with chromosomal DNA. To test for this, 2 l of the phage suspen-
sion is loaded onto a 1% agarose gel. To remove the contamination, MgCl2
(15 mM final concentration) and 120 U DNase I are added, and the
suspension is incubated at 37 for 2 h. The phage capsid proteins will
protect the single‐stranded phage DNA from the DNase I. Completeness
of the reaction is checked by loading 2 l of the phage suspension before
the addition of DNase I and after 2 h of incubation. When the contaminat-
ing DNA has been removed, EDTA, pH 8, is added (60 mM final concen-
tration) to chelate Mg2þ and to block the activity of DNase I. The enzyme
is inactivated by heating the solution to 80 for 20 min. The phage particles
are resistant to such treatment. When the phage solution has cooled down
to 50 or less, proteinase K is added to a final concentration of 100 g/ml
and the solution is incubated at 37 overnight to digest the capsid proteins
and release the ssDNA. In the course of this process, the solution should
become clear.
Day 5. A 1/10 volume of 5% hexadecyltrimethylammonium bromide
(CTAB)/0.5 M NaCl (to prepare a 100‐ml stock solution, 2.92 g NaCl are
dissolved in 80 ml water, 5 g CTAB are added slowly with stirring, and the
solution is then heated to 65; water is added to a final volume of 100 ml) is
added to the proteinase K digestion from day 4, kept for 10 min at room
temperature, and centrifuged at 10,000g for 20 min at room temperature.
The pellet is dissolved in 5 ml 1.2M NaCl, 12.5 ml of cold absolute ethanol
is added, and the solution is kept at 20 for at least 1 h. It is then
centrifuged at 23,000g for 30 min at 4, and the pellet of ssDNA is rinsed
with 5 ml 70% ethanol and centrifuged again for 10 min. This second pellet
are significantly smaller and whiter than that from the CTAB/NaCl precip-
itation. It is air dried and dissolved in about 4 ml 10 mM Tris–HCl, pH 8.0,
0.1 mM EDTA. The DNA concentration is determined by measuring the
OD260 (the multiplier for ssDNA is 40). The yield is typically about 0.5 mg
ssDNA/2 liters of starting culture.
Annealing and Purification of 30 and 50 Substrates. For construction of
the 30 substrate, 200 g of pGem_IDLinker39 (for 30 heteroduplex) and
200 g of pGem_IDLinker40 (for 30 homoduplex) are digested with SapI.
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The resulting 30 heteroduplex will contain a nick 291 bp 30 from the
deletion site; the 30 homoduplex will contain the nick at the same site.
For construction of the 50 substrate, 200 g of pGem_IDLinker39 (for
50 heteroduplex) and 200 g of pGem_IDLinker40 (for 50 homoduplex)
are digested with BanII. The resulting 50 heteroduplex will contain a nick
369 bp 50 from the deletion site; the 50 homoduplex will contain the nick at
the same site. Completeness of the digests is checked on a 1% agarose gel
and, when complete, the DNA is precipitated and then dissolved in 500 l
10 mM Tris–HCl, pH 8.
Annealing is performed in 3 ml of a buffer containing 10 mM NaCl,
1 mM EDTA, 50 mM Tris–HCl, pH 7.6, 200 g linearized plasmid DNA,
and 100 g ssDNA (mole ratio dsDNA:ssDNA ¼ 1:1). Subsequent steps
are performed exactly the same as for the production of the (þ/) sub-
strate. The circular, nicked DNA is purified further by electrophoresis on
0.8% agarose gels to remove the contaminating ssDNA, which interferes
with the MMR assays and with the restriction digest by NdeI.
Construction of G/T and G/C Mismatch Repair Substrates
Experimental Strategy
The vector used is a derivative of the pGEM‐13Zf(þ) vector (Promega).
The original vector contained six PleI restriction sites (isoschizomer of
N.BstNBI), which were removed by QuickChange site‐directed mutagene-
sis (Stratagene) and appropriate primers. Furthermore, the linker sequence
50‐GGCCGCGATCTGATCAGATCCAGACG TCTGTCAACGTTGG-
GA‐30 was cloned between its NotI andHindIII restriction sites. Using site‐
directed mutagenesis, a single recognition site for the nickase N.BstNBI
(New England Biolabs) was inserted, which is situated either 352 bp 30
from the mismatch if the complementary (top) strand is nicked or 337 bp
50 from it when the viral (bottom) strand is nicked (Fig. 3).
FIG. 3. Schematic representation of the production of mismatch repair substrates by the
primer extension method.
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To construct the hetero‐ and homoduplex substrates, the following
PAGE‐purified primers were used (Microsynth GmbH, Switzerland) in
primer extension reactions:
 for G/T: 50‐CCAGACGTCTGTCGACGTTGGGAAGCTTGAG‐30
 for G/C: 50‐CCAGACGTCTGTCAACGTTGGGAAGCTTGAG‐30
In this method, oligonucleotides can be used that carry modified bases,
e.g., 6‐methylguanine, 8‐oxoguanine, thymine dimers, and cisplatin ad-
ducts. However, it is highly advisable to check the quality of oligonucleotides
containing these modifications by mass spectrometry. For example, 6MeG
is incorporated into oligonucleotides as a 6‐O‐methyl‐2‐N‐isobutyryl‐20‐
deoxyriboside. The isobutyryl protecting group does not come off by
ammonia treatment (standard deprotection procedure for synthetic oligonu-
cleotides) and has to be removed with (1,8‐diazabicyclo [5.4.0] undec. ‐7‐enc
(DBU) (a strong base) in anhydrousmethanol over the course of several days
in the dark. This procedure is often incomplete and the partially protected
primers reduce primer extension yields and interfere with the MMR assay.
Phosphorylation of Primers
The primers are phosphorylated in a 100‐l reaction volume containing
4 nmol of the corresponding primer, 1 polynucleotide kinase (PNK)
buffer, 5 mM DTT, 1 mM ATP, 100 g/ml bovine serum albumin (BSA),
and 10 U T4 DNA PNK. The reaction is incubated for 1 h at 37, followed
by 10 min at 70 to inactivate the enzyme. One hundred microliters of 2M
LiClO4 and 800 l acetone are added, and the mixture is placed on ice for
30 min and then centrifuged at 20,800g for 20 min at room temperature in a
tabletop centrifuge. The pellet is washed with 1 ml 80% acetone and
centrifuged at 20,800g for 10 min at room temperature. It is dried and
dissolved in 100 l 10 mM Tris–HCl, pH 8.0, 0.1 mM EDTA.
Primer Extension
Sixty micrograms of the ssDNA (57 pmol) is annealed with a 2.1‐fold
molar excess (120 pmol) of the appropriate primer in a total volume of
240 l containing 1 T4 DNA polymerase reaction buffer. The solution
is heated for 6 min at 85 in a heat block and then allowed to slowly cool
down to room temperature. The extension is done in a 600‐l reaction
volume in 1 T4 DNA polymerase reaction buffer containing 100 g/ml
BSA, 1 mMATP, 1 mM dNTPs, 2400 U T4 DNA ligase, and 54 U T4 DNA
polymerase. The reaction is incubated for 1 h at 37, followed by incubation
at 70 for 20 min to inactivate the enzymes. The efficiency of the reaction is
checked on a 1% agarose gel (Fig. 4, lane 3).
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Cesium Chloride Gradient Purification
Twelve grams of CsCl are dissolved in 10.5 ml TE buffer, pH 8.0, and
240 l ethidium bromide solution (10 mg/ml) are added. The DNA is nicked
in the presence of high ethidium bromide concentrations and light and thus
the ethidium bromide‐ and DNA‐containing solutions should be kept in the
dark. The primer extension reaction is transferred into a 6‐ml ultracentri-
fuge tube (Sorvall S/L, Sleeve Conical), and the tube is filled to the top with
the CsCl/ethidium bromide solution; bubbles are removed and the tube is
sealed. The counterweight is prepared in the same way; the weight differ-
ence has to be 5 mg. The CsCl gradient centrifugation is then performed
with a Sorvall Stepsaver 65V13 rotor at 60,000 rpm for 16–18 h at 4 (with
slow deceleration below 20,000 rpm). The centrifuge tube, fastened in a
clamp in the darkroom, is pierced at the top with a 25‐gauge needle to
allow air to enter. An ultraviolet (UV) lamp is switched on and the bright
orange band that appears about midway of the tube is sucked out with a
18‐gauge needle and a 1‐ml syringe by puncturing the tube slightly below
the substrate band. The needle is removed and the DNA is ejected into a
2‐ml Eppendorf tube containing 700 l water‐saturated n‐butanol. The
solution is mixed by inverting the tube gently, and the upper phase is then
removed and the lower phase containing the DNA is transferred to the
next Eppendorf tube. This is repeated until the DNA‐containing phase is
completely colorless (about six times). The DNA is dialyzed for 1 and 3
h against 1 liter of 10 mM Tris–HCl, pH 8.0, 0.1 mM EDTA. Afterward, the
DNA is precipitated in 0.3 M NaOAc, pH 5.5, and 2 volumes of ice‐cold
ethanol, left at 20 for at least 1 h, and centrifuged. After drying, the
FIG. 4. Production of hetero‐ and homoduplex MMR substrates by the primer extension
method. Aliquots of the various steps in the production of these substrates were separated on
a 1% agarose gel containing 0.5 g/ml ethidium bromide and visualized on a UV
transilluminator. M, 1‐kb DNA ladder; lane 1, 110 ng ssDNA; lane 2, Miniprep DNA; lane 3,
1 l primer extension G/T; lane 4, 0.5 l primer extension G/T after cesium chloride gradient;
lane 5, nicked Miniprep DNA; lane 6, nicked G/T substrate. The mobilities of open circular
(oc), covalently closed circular (ccc), and single‐stranded (ss) DNA molecules are shown on
the right.
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pellet is redissolved in 90 l 10 mM Tris–HCl, pH 8.5. The purified
substrate is examined on a 1% agarose gel (Fig. 4, lane 4).
Nicking of the Substrate
The purified substrate is nicked with the nicking enzyme N.BstNBI
(New England Biolabs) at position 352 in the top (30) or 337 in the bottom
(50) strand. The nicking reaction is performed in an 80‐l volume contain-
ing 45 l purified substrate, 0.1 mg/ml BSA, 1 N.BstNBI buffer, and 50 U
N.BstNBI and incubation is carried out overnight at 16. One microliter is
loaded on a 1% agarose gel to check for completeness of the reaction. If
complete, the DNA is purified employing the MinElute reaction cleanup
kit (Qiagen). The DNA is eluted in 20 l 10 mM Tris–HCl, pH 8.5, and the
volume is adjusted to 80 l with the same buffer. The concentration and
quality of the final substrate are determined with analytical agarose gels
(Fig. 4, lane 6) and/or a Nanodrop.
Preparation of Nuclear Extracts
Nuclei are isolated as described (Iaccarino et al., 1998) and are resus-
pended in 500 l cold extraction buffer/1.5 ml packed nuclei (extraction
buffer: 25 mMHEPES/KOH, pH 7.5, 10% sucrose, 1 mM phenylmethylsul-
fonyl fluoride [PMSF], 0.5 mM DTT, 1 g/ml leupeptine, 1 tablette/5 ml of
protease inhibitor cocktail ‘‘Complete Mini’’ [Roche]). The volume of re-
suspended nuclei is measured, and 0.031 volume of cold 5 M NaCl (final
concentration of NaCl is 0.155M) is slowly (1 drop/min) added with gentle
stirring in the cold room. Themixture is then rotated for 1 h at 4 to allow the
proteins to leave the nucleus.After this, nuclei are pelleted by centrifugation
at 14,500g for 20 min at 2 in a tabletop centrifuge. The supernatant is
transferred to a dialysis bag and dialyzed for 2 1 h against 2 liters cold
dialysis buffer (25 mM Hepes/KOH, pH 7.5, 50 mM KCl, 0.1 mM EDTA,
10% sucrose, 1 mM PMSF, 2 mM DTT, 1 g/ml leupeptine). The extract is
clarified by centrifugation at 20,000g for 15min at 2 in a tabletop centrifuge.
The supernatant is aliquoted, snap frozen in liquid nitrogen, and stored at
80. The concentration of the proteins is determined with a Bradford
assay, and the salt concentration is determined using a conductivity meter.
In Vitro Mismatch Repair Assays
Mismatch Repair Assays with G/T and G/C Substrates
Restriction enzymes and positions of the restriction sites used in the
interpretation of MMR efficiency are shown in Fig. 5. The G/T substrate is
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refractory to cleavage with AclI and SalI. If the G/T mismatch is repaired
to A/T, anAclI recognition sequence is restored (AclI cuts the plasmid now
three times instead of twice). When the G/T is repaired to G/C, a unique
SalI recognition site is restored.
In vitro mismatch repair assays are carried out in 20‐l volumes con-
taining 20 mM Tris–HCl, pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM
glutathione, 50 g/ml BSA, 0.1 mM each dNTP, 1.5 mM ATP, 5 ng/l
substrate (total 100 ng ﬃ 48 fmol), and 3.75 g/l nuclear extract (total
75 g). Generally, a 10 MMR buffer containing 200 mM Tris–HCl, pH
7.6, 400 mM KCl, 50 mM MgCl2, 10 mM glutathione, 500 g/ml BSA, and
1 mM each dNTP (if the assay is to be performed with [‐32P]dATP, dATP
has to be omitted) is prepared, and 20‐l aliquots are made and stored at
20. These aliquots are only thawed once and kept for less than a month.
FIG. 5. Schematic representation of the G/T and G/C substrates. The relevant restriction
sites and their nucleotide positions are shown.
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In the final reaction, the concentration of KCl is adjusted to 110 mM
with 1 M KCl. We observed that the reaction works well even if only
1.7 pmol [‐32P]dATP together with dGTP, dTTP, and dCTP are included
in the reaction. It should thus be noted that, despite the dialysis, the
nuclear extracts still contain a residual pool of dNTPs, which permits
DNA synthesis.
For the radioactive MMR assay, 10 MMR buffer (‐dATP), 1 M KCl,
DNA substrate, 15 mM ATP, 1.7 pmol [‐32P]dATP 10 Ci, and the
nuclear extract are mixed to reach the aforementioned concentrations.
For the cold MMR assay, 10 MMR buffer containing all four dNTPs is
used and the [‐32P]dATP is omitted. The MMR reaction is incubated for
45 min at 37 and is then stopped by adding 30 l freshly prepared stop
solution (1.12% SDS, 41.67 mM EDTA, 83.33 g/ml proteinase K) and
incubated again for 30 min at 37. The DNA is purified employing the
MinElute reaction cleanup kit (Qiagen). The eluted DNA is digested with
the appropriate restriction enzymes in a 50‐l volume for 3 h at 37.
The RNA in the samples is removed by adding 2.5 g RNase A (taking
care to eliminate any contaminating DNase activity of the RNase A pre-
parations before use) and incubation for 15 min at 37. Then, 0.2% SDS
and 3.6 g proteinase K are added and the mixture is incubated for 15 min
at 37. The DNA is precipitated with 0.3 M NaOAc, pH 5.5, and 2.5
volumes cold 100% ethanol. The pellet is dissolved in 10.5 l 10 mM
Tris–HCl, pH 8.5, and 6 bromphenol blue loading buffer (15%[w/v]
Ficoll 400, 0.25% [w/v] bromphenol blue) is added to a final concentration
of 1.5‐fold. The DNA is loaded onto a 1% agarose gel and run for 45 min
at 90 V. The DNA can be visualized in a UV transilluminator (Fig. 6, left);
in case of radiolabeled assays, the gel is vacuum dried at 80 for 75–90 min
and autoradiographed using a PhosphoScreen (Molecular Dynamics)
(Fig. 6, right).
Mismatch Repair Assay with Insertion/Deletion Substrates
In vitro MMR assays are carried out basically as described earlier
except for monitoring with the restriction enzymes. The efficiency of repair
of the (þ/) substrates is checked by subjecting the DNA to a restriction
digest with BsaI (New England Biolabs), which linearizes the DNA sub-
strates, and with the sensor enzymes AvrII and BglII (both New England
Biolabs), which cut only when deletion (in the case of AvrII) or insertion
(in the case of BglII) occurs. The two fragments (1833 and 1361 bp)
indicative of repair are visualized on 0.8% agarose gels.
The efficiency of repair of 30 and 50 substrates is visualized by subjecting
the DNA to restriction digest with the linearizing enzyme BsaI and the
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single sensor enzyme BglII. As the 30 and 50 substrates contain the extra-
helical DT on the continuous strand, insertion occurs almost exclusively.
DNA Affinity Purification
DNA‐coated beads are washed twice with buffer W110 (20 mM Tris–
HCl, pH 7.6, 110 mM KCl, 5 mM MgCl2) and once with equilibration
buffer (1 MMR buffer adjusted to 110 mM KCl) while the MPC is
standing on ice. The conditions to allow binding of the proteins to DNA
are 1 MMR buffer, total of 110 mM KCl, 1.5 mM ATP, and 360 g of
nuclear extract per microgram of DNA. First, the components without the
nuclear extract are added to the beads and incubated for 5 min at the
FIG. 6. Repair of the G/T substrate in vitro. The substrate containing a G/T mispair in the
AclI/SalI site of the phagemid substrate was incubated with MMR‐proficient or ‐deficient
nuclear extracts in the presence of [‐32P]dATP and digested with the appropriate restriction
enzymes to test for efficiency of the repair reaction and incorporation of radioactivity into the
different fragments. After the MMR assay, the restriction fragments were separated on a 1%
agarose gel containing 0.5 g/ml ethidium bromide and visualized on a UV transilluminator
(left). The dried gel was subsequently exposed to a PhosphoScreen (right).
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desired temperature. The nuclear extract is then added and incubated with
the DNA for the desired time at the desired temperature. After this, the
tubes are put into the cold MPC and the beads are allowed to attach. The
supernatant is withdrawn and the beads are washed twice with equilibra-
tion buffer and once with buffer W110, buffer W200 (20 mM Tris–HCl, pH
7.6, 200 mM KCl, 5 mM MgCl2), and DNase buffer (20 mM Tris–HCl,
pH 7.6, 110 mMKCl, 10 mMMgCl2). Proteins are eluted by cleavage of the
FIG. 7. Scheme of the DNA affinity purification of the ‘‘mismatch repairosome.’’
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DNA with DNase I by adding 0.9 U DNase I (Roche) in 15 l DNase
buffer per microgram of DNA and incubation at 37. The DNase I solution
is usually added in two portions with incubation at 37 for 10 min after each
addition. The eluate is then put into the MPC once more, as some beads
are usually cotransferred. The supernatant of this step constitutes the
eluate, which is either subjected directly to PAGE or precipitated with
20% TCA (Fig. 7).
Conclusions
The eukaryotic MMR is a complex interplay of numerous polypeptides.
Given that MMR malfunction is linked to human cancers, both inherited
and sporadic (Jiricny and Marra, 2003; Truninger et al., 2005), detailed
understanding of the molecular transactions that take place during the
recognition and metabolism of the various types of MMR substrates may
help identify new genetic loci that predispose to malignancy. Moreover,
identification of new interaction partners of the individual MMR factors
may lead to the discovery of new metabolic pathways that involve these
versatile polypeptides. Thus, in addition to mismatch correction, MMR
proteins and their homologs are involved in genetic recombination, both
meiotic and mitotic (Harfe and Jinks‐Robertson, 2000; Lipkin et al., 2002;
Snowden et al., 2004), and in somatic hypermutation and class switch
recombination of immunoglobulin loci (Neuberger et al., 2005). The role
of MMR proteins in DNA damage signaling is another process that is
highly relevant to human health, as MMR malfunction can result in sub-
stantial resistance to cancer chemotherapy (Stojic et al., 2004). The meth-
ods described in this chapter permit the study of the interactions of the
MMR system with DNA modifications such as those generated in genomic
DNA by chemotherapeutics.
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[19] Analysis of DNA Mismatch Repair in Cellular
Response to DNA Damage
By LIYA GU and GUO‐MIN LI
Abstract
Significant advances have been made in identifying and characterizing
the roles of DNA mismatch repair (MMR) proteins in cellular response to
DNA damage. Insights into this process have been obtained by performing
interactions of mismatch recognition proteins (e.g., MutS) with DNA
adduct‐containing duplexes and by analyzing cellular responses (including
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Abstract
The human mismatch repair (MMR) proteins hMLH1 and
hPMS2 function in MMR as a heterodimer. Cells lacking either
protein have a strong mutator phenotype and display micro-
satellite instability, yet mutations in the hMLH1 gene account
for f50% of hereditary nonpolyposis colon cancer families,
whereas hPMS2 mutations are substantially less frequent and
less penetrant. Similarly, in the mouse model,Mlh1/ animals
are highly cancer prone and present with gastrointestinal
tumors at an early age, whereas Pms2/ mice succumb to
cancer much later in life and do not present with gastro-
intestinal tumors. This evidence suggested that MLH1 might
functionally interact with another MutL homologue, which
compensates, at least in part, for a deficiency in PMS2. Sterility
of Mlh1/, Pms2/ , and Mlh3/ mice implicated the Mlh1/
Pms2 and Mlh1/Mlh3 heterodimers in meiotic recombination.
We now show that the hMLH1/hMLH3 heterodimer, hMutL;,
can also assist in the repair of base-base mismatches and single
extrahelical nucleotides in vitro . Analysis of hMLH3 expression
in colon cancer cell lines indicated that the protein levels
vary substantially and independently of hMLH1. If hMLH3
participates in MMR in vivo , its partial redundancy with
hPMS2, coupled with the fluctuating expression levels of
hMLH3, may help explain the low penetrance of hPMS2
mutations in hereditary nonpolyposis colon cancer families.
(Cancer Res 2005; 65(23): 10759-66)
Introduction
Mismatch repair (MMR) proteins are a highly conserved group of
polypeptides that play key roles in the correction of mispairs
arising during DNA replication. They also prevent recombination
between nonidentical sequences and participate in the signaling of
certain types of DNA damage. The importance of MMR proteins in
the maintenance of genomic integrity is underscored by the finding
that germ line mutations in MMR genes predispose to hereditary
nonpolyposis colon cancer, a common familial cancer predisposi-
tion syndrome (reviewed in refs. 1, 2). The principal MMR players
in human cells are homologues of the bacterial MutS and MutL
proteins. hMutSa, a heterodimer of the MutS homologues hMSH2
and hMSH6, binds base-base mismatches and small insertion/
deletion loops, whereas hMutSh (a heterodimer of hMSH2 and
hMSH3) binds only insertion/deletion loops. This in vitro evidence
could be corroborated by analysis of the phenotypes of MMR-
deficient cells: Those lacking hMSH2 are fully MMR deficient and
display a mutator phenotype and microsatellite instability that is
consistent with the loss of repair of both base-base mismatches
and insertion/deletion loops. Cells lacking hMSH6 retain a strong
mutator phenotype but their microsatellite instability is limited to
mononucleotide repeats due to the functional redundancy with
hMutSh in insertion/deletion loop repair. This situation is mirrored
in hereditary nonpolyposis colon cancer families, where the
penetrance of hMSH2 mutations is substantially higher than that
of alterations in the hMSH6 locus (reviewed in ref. 2).
Whereas it is generally accepted that hMutSa and hMutSh are
the mismatch recognition factors that initiate MMR (reviewed in
ref. 3), the function of the MutL homologues remains speculative.
The human genome contains numerous genes that have significant
sequence homology to mutL and to yeast MutL homologue and
postmeiotic segregation genes; however, to date, only hMutLa,
a heterodimer of hMLH1 and hPMS2, could be shown to be
involved in MMR. Correspondingly, hMLH1- or hPMS2-deficient
cells have a strong mutator phenotype and high microsatellite
instability (reviewed in ref. 1). In in vitro studies, hMutLa could
be shown to associate with hMutSa on a mismatch-containing
substrate (4) and was suggested to act as a ‘‘molecular matchmaker’’
between these protein complexes and the downstream effectors of
repair (reviewed in ref. 3). hMutLh, a heterodimer of hMLH1 and
hPMS1, has been biochemically characterized but could not be
shown to participate in MMR in vitro (5). This finding was
substantiated by in vivo evidence: Mice carrying a disruption in
the Pms1 gene display neither microsatellite instability nor cancer
predisposition (6). hMLH3 was identified through its interaction
with hMLH1 on Far Western blots (7); however, this heterodimer,
hMutLg, has not been biochemically characterized and its role
in mammalian MMR has not been established. MLH3 was first
identified in Saccharomyces cerevisiae and its gene product,
scMlh3p, was shown to bind scMlh1p (8, 9) and to be involved in
meiotic recombination (reviewed in refs. 10, 11). As mlh3 mutants
display amutator phenotype similar to that ofmsh3-deficient strains
(8, 12), it was suggested that the two polypeptides are involved in the
repair of a subset of insertion/deletion loops. hMLH3 seems to be
involved in meiotic recombination (13, 14) and the same is true for
the murine Mlh3 (14). As both Mlh1- and Mlh3-deficient mice are
sterile (reviewed in refs. 10, 11), it was suggested that the two
polypeptides function together. However, unlike Mlh1/ animals
(6), Mlh3/ mice did not succumb to cancer in the first 9 months
of life (15). The roles of the various MMR factors and the pheno-
types of mice with defects in MMR genes are listed in Table 1.
The involvement of MutL homologue malfunctions in human
cancer is not as clear cut as in the case of the MutS homologues.
Mutations in hMLH1 predominate in hereditary nonpolyposis
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colon cancer, accounting for nearly 50% of all known germ line
MMR gene mutations (2). Surprisingly, no germ line mutations
have been found in hPMS1 or hPMS2 , which was unexpected, given
the key role of the latter protein in MMR. Recent immunohisto-
chemical analysis of 1,048 unselected colon tumors revealed the
lack of hPMS2 in f1.5%, a proportion similar to that of MSH2-
deficient cancers (16). Genetic analysis identified germ line
mutations in hPMS2 in a number of these patients and it is likely
that the remainder will also be linked to genetic alterations once
the problems associated with sequencing of the hPMS2 locus are
overcome (there are f20 hPMS2 pseudogenes on chromosome 7,
which interfere with DNA sequencing). However, these patients do
not belong to typical hereditary nonpolyposis colon cancer families
and the penetrance of these mutations seems to be very low. One
possible explanation for this finding is that the defect in hPMS2 is
partially compensated for by another MutL homologue, such as
hMLH3. Germ line hMLH3 missense and frameshift mutations
have been described in familial colorectal cancer cases but the
implication of these alterations in carcinogenesis is ambiguous. In
some cases, the mutation in hMLH3 was identified in families
carrying a second MMR gene mutation, whereas no mutations in
the other MMR genes could be identified in other cases (17–19). A
similar discrepancy applies also to the microsatellite instability
status of the tumors (17, 20). The role of hMLH3 in MMR and of
hMLH3 mutations in cancer thus remains open to question. In an
attempt to provide answers to these questions, we examined the
role of hMLH3 in MMR in vitro .
Materials and Methods
cDNA Vectors
pFastBac1-His6-hMLH3. The cDNA of hMLH3 (Swiss-Prot entry
Q9UHC1) was used as template for a PCR reaction where (His)6 tag
was added at the NH2 terminus of hMLH3 using the primers hMLH3fo1
(5V-CGCGGATCCACCATGTCGTACTACCATCACCATCACCATCACG-
ATTACGATATCCCAACGACCGAAAACCTGTATTTTCAGGGCATCAAGTG-
CTTGTCAGTTGAAG-3V) and hMLH3re1 (5V-ATTTGCCTACTGGTGG-
GACC-3V). The fragment was then cleaved with BamH1 and PflM1 and
cloned between the corresponding sites in pFastBac1 (Invitrogen, San
Diego, CA).
pTXB1-hMLH3 (amino acids 961-1,453). The COOH-terminal part
of hMLH3 cDNA coding for amino acids 961 to 1,453 was amplified by
PCR from pFastBac1-His6-hMLH3 using the primers fMLH3-Ct (5V-GG-
GAATTCCATATGGAGAACTGTGTGATATCAGAAACTC-3V) and rMLH3-Ct
(5V-AAGGCCGCTCTTCCGCACATTGGTGGCTCACAGGGAGGCATG-3V). The
PCR product was subcloned between the NdeI/SapI sites of pTXB1 (New
England Biolabs, Beverly, MA).
Expression of hMutL;
The Bac-to-Bac baculovirus expression system (Life Technologies,
Gaithersburg, MD) was used according to the instructions of the manu-
facturer. Spodoptera frugiperda Sf9 cells (2  108; Life Technologies) were
infected with either a single recombinant baculovirus or with a combina-
tion of two viruses at a multiplicity of infection of 10. Cells were harvested
72 hours after infection and total extracts were prepared as described (21).
Partial purification of hMutLg from Sf9 extracts was done using Ni-NTA
agarose (Qiagen, Hilden, Germany), and the QIAexpressionist system was
used according to the instructions of the manufacturer using 5 mL of 50%
Ni-NTA slurry per 100 mg of protein extract.
hMutLg was expressed also in bacteria using a bicistronic vector
pET11b-His6-hMLH3/MLH1 (cloning information on request) in the BL21
strain of Escherichia coli . After induction of expression at 37jC for 4 hours
with 0.4 mmol/L isopropyl-h-D-thiogalactopyranoside, the heterodimer was
expressed but was insoluble. Nevertheless, the protein could be used to
quantify the relative abundance of hMLH3 in HeLa cells.
hMLH3 Antibody Production and Purification
The COOH-terminal polypeptide of hMLH3 (amino acids 961-1,453) was
expressed using the Impact-CN-System (New England Biolabs) in BL21
E. coli transformed with pTXB1-hMLH3 (amino acids 961-1,453). The
peptide was purified using fast protein liquid chromatography on a MiniQ
4.6/50 PE column (Amersham Pharmacia, Uppsala, Sweden) and used to
immunize rabbits at Eurogentec (Seraing, Belgium). The rabbit polyclonal
antibody was then affinity-purified using the COOH-terminal polypeptide
immobilized on a nitrocellulose membrane. In brief, 100 Ag of the purified
polypeptide were blotted onto a nitrocellulose membrane by standard elec-
trophoretic transfer, visualized by Ponceau S staining, and the correspond-
ing band was cut out. The membrane was blocked with 5% nonfat dry milk
in TBST [20 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, and 0.1% Tween
20] for 60 minutes, incubated with 700 AL of the polyclonal antibody for
4 hours at 4jC, and washed thrice with TBST for 15 minutes. The mem-
brane was then cut into small pieces (1  0.5 cm) and the antibody was
eluted from the membrane by incubation for 20 minutes at room tem-
perature in 0.1 mol/L glycine (pH 2.5). The supernatant was collected and
the pH was neutralized by an equal volume of 1 mol/L Tris-HCl (pH 8.0).
The purified antibody was stored at 20jC in 50% glycerol.
It was used to perform all the experiments described in this study except
for the immunoprecipitation of hMLH3 from human cell extracts.
Human Cell Lines and Preparation of Cell Extracts
All the colon cancer cell lines, HEK293, and HeLa cell lines used in this
study were obtained from the cell line repository of Cancer Network Zurich.
The hPMS2-deficient cell lines HeLa clone 12 (22) and Hec-1A (23) were kindly
provided by Dr. Margherita Bignami (ISS, Rome, Italy). The cell line HEK293T
was derived from HEK293 by immortalization with adenovirus 5 DNA and
transfection with SV40 large Tantigen (24). The hMLH1 gene in this cell line is
epigenetically silenced by promoter hypermethylation (25). The 293T La cell
line was developed in our laboratory (26). In these cells, the hMLH1 c-DNA
was stably integrated under the control of the tetracycline response promoter
Table 1. Overview of mammalian MutS and MutL homologues and their roles in MMR
Heterodimer Components MMR role Phenotype of knockout mice
hMutSa hMSH2 Repair of base-base mismatches and small loops Lymphomas, gastrointestinal, skin, and other tumors
hMSH6 Lymphomas, gastrointestinal, and other tumors
hMutSh hMSH2 Repair of loops Lymphomas, gastrointestinal, skin, and other tumors
hMSH3 Gastrointestinal tumors
hMutLa hMLH1 Repair of all MMR substrates Lymphomas, gastrointestinal, skin and other tumors; sterility
hPMS2 Lymphomas, sarcomas; male sterility
hMutLh hMLH1 ? Lymphomas, gastrointestinal, skin, and other tumors
hPMS1 No phenotype
hMutLg hMLH1 ? Lymphomas, gastrointestinal, skin, and other tumors
hMLH3 Sterility
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using the Tet-Off system (Clontech, Palo Alto, CA). In the absence of
doxycycline, these cells express hMLH1 and are MMR proficient. All the cell
lines were cultured at 37jC in a 5% CO2–humidified atmosphere and
maintained in the appropriate media. Whole cell extracts from these cell lines
were prepared as described (26) without modifications. The origin and MMR
status of the cell lines used in this study is listed in Table 2.
Western Blot Analysis
Western blots were done as previously described (26) using the following
primary antibodies: our rabbit polyclonal anti-hMLH3 (1:400), anti-hMLH1 and
anti-hPMS2 from BD PharMingen (San Diego, CA) (1:4,000 and 1:1,000, respec-
tively), and anti-h-tubulin (1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA).
Coimmunoprecipitation Analysis of hMLH1 and hMLH3
HeLa whole cell extract (1 mg) was incubated in a total volume of 500 AL in
NP40 Lysis Buffer [50 mmol/LTris-HCl (pH 8.0), 125 mmol/L NaCl, 1% NP40, 2
mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 1 complete pro-
tease inhibitory cocktail (RocheMolecular Biochemicals, Basel, Switzerland)]
for 3 hours at 4jC with the anti-hMLH1 (6 Ag; BD PharMingen) or anti-
hMLH3 (10 Ag; Santa Cruz Biotechnology) antibodies. The immunoprecipi-
tates were captured by incubation for 30 minutes at 4jC with 50 AL of 50%
slurry of Protein A/G PLUS agarose (Santa Cruz Biotechnology). The agarose
beads were then washed thrice with cold NP40 Lysis Buffer and the proteins
were eluted with SDS sample buffer and subjected to Western blot analysis.
Control experiments were done either in the absence of antibody or in the
presence of 25 units of Benzonase (Merck, Whitehouse Station, NJ).
Analysis of the hMLH3 Promoter and Treatment of Cells
with 5-Aza-2V-deoxycytidine
The hMLH3 5Vflanking region was analyzed for CpG content with the
CpG plot software of the European Bioinformatics Institute (http://
www.ebi.ac.uk/emboss/cpgplot/) and its methylation status was evaluated
with methylation-specific PCR as described previously (16). Primer
sequences for the unmethylated reactions were 5V-GTTGTGTGTAGTTTTT-
GGAGTTG-3V(sense) and 5V-CTCCCAACACCTAAAACTAACA-3V(antisense),
which amplified a 229 bp product. The methylation-specific primers were
5V-CGCGTAGTTTTCGGAGTC-3V (sense) and 5V CTAAAACTAACGAAACG-
CACG 3V(antisense), which amplified a 205 bp product. The PCR conditions
are available on request.
To reactivate the expression of hMLH1 and hMLH3 , 2,5  105 HEK293T
cells were seeded on a 78 cm2 dish on day 0 and treated with 3 Ag/mL of
5-aza-2V-deoxycytidine (Fluka, Buchs, Switzerland) on days 2 and 5. The
medium was changed 24 hours after each addition of the drug and the cells
were harvested on day 8.
Microarray Experiments
Microarray experiments were done as described previously (27). Gray
columns in the graphs represent mRNA levels based on raw signals detected
in the corresponding cell lines with the Affymetrix HG-U133A microarray.
Mismatch Repair Assays
The assays were done as described previously (28, 29).
Results
Expression of hMutL; in Sf9 cells and production of anti-
hMLH3 antibody. To produce the recombinant hMLH3 and
hMutLg factors, S. frugiperda Sf9 cells were infected with
baculoviruses carrying cDNAs encoding hMLH1 and/or hMLH3 .
Infection of Sf9 cells with the hMLH3 virus alone yielded the
protein in an amount that was hardly detectable by Western blott-
ing. The amount of expressed protein was significantly increased
when the cells were coinfected with both hMLH1 and hMLH3 vec-
tors (Fig. 1A), suggesting that the presence of hMLH1 is necessary
for the stabilization of hMLH3 in Sf9 cells. This is reminiscent of
hMSH6 and hPMS2, both of which require their heterodimeric
partners (hMSH2 and hMLH1, respectively) for stability. However,
the amount of the recombinant heterodimer obtained was too low
Table 2. Characteristics of the human cell lines used in this study
Cell lines Origin MMR status* MMR protein defect
c
Genetic complementation
293 Embryonic kidney epithelium +
293T Embryonic kidney epithelium  hMLH1, hPMS2, hMLH3
293T La+ Embryonic kidney epithelium + hMLH3 hMLH1 cDNA
CaCo2 Colon carcinoma +
CO115 Colon carcinoma  hMLH1, hPMS2
Colo741 Colon carcinoma +
CX-1 Colon carcinoma +
GP5D Colon carcinoma  hMSH2, hMSH6, hMSH3, hMLH3
HCT116 Colon carcinoma  hMLH1, hPMS2, hMSH3
HCT116+Ch.3 Colon carcinoma + hMSH3 Chromosome 3
HT29 Colon carcinoma +
Hec1A Endometrial adenocarcinoma  hPMS2, hMSH6
Hec1A+Ch.7 Endometrial adenocarcinoma  hMSH6 Chromosome 7
HeLa Cervical carcinoma +
HeLa clone 12 Cervical carcinoma  hPMS2
LS411 Colon carcinoma  hMLH1, hPMS2
SW48 Colon carcinoma  hMLH1, hPMS2
SW480 Colon carcinoma +
SW837 Colon carcinoma +
*+, MMR proficient; , MMR deficient (these cell lines are unable to repair both base-base mismatches and insertion/deletion loops, with the exception
of Hec1A+Ch.7, which is able to repair insertion/deletion loops).
cThe primary alteration of MMR protein expression is reported in bold. Lack of hMLH1 or hMSH2 lead to proteolytic degradation of hPMS2, or hMSH6
and hMSH3, respectively. The hMSH3 gene in HCT116 cells is mutated as a consequence of the MMR defect. The hMLH3 alterations are those described
in this study; other alterations have been reported elsewhere (see text).
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to permit extensive purification. The reasons underlying the low
levels of expression are unknown at this time, but it is possible that
high amounts of the full-length protein may be toxic (7).
Commercially available antibodies could detect the recombinant
hMLH3 protein on Western blots but failed to detect the
endogenous protein in all the human cell lines used in this study
(data not shown). Therefore, we raised our own polyclonal rabbit
antiserum, directed against the COOH terminus of hMLH3, which
contains the hMLH1-interacting domain. The affinity-purified
antibody (Fig. 1B) detected a band of the expected size (f160
kDa) in Sf9 lysates infected with the hMLH1 and hMLH3 vectors,
whereas no signal was visible when we probed lysates of uninfected
cells (Fig. 1C). The purified antibody was then tested using extracts
of various human colon cancer cell lines. The antibody highlighted
a double band migrating at the expected size of hMLH3 (Fig. 1D,
bottom). As the faster migrating band was also observed in Western
blots done with the preimmune serum (data not shown), and as the
abundance of the slower-migrating band correlated with hMLH3
mRNA expression levels in the same cell lines (Fig. 1D, top), we
concluded that the latter is the specific band. As shown in Fig. 1D ,
the levels of hMLH3 fluctuate significantly in the tested cells lines
and seem to be independent of the amount of hMLH1 and hPMS2
expressed in the same cells.
Relative abundance of hMLH3 in human cells and its
interaction with hMLH1. Given that hMLH3, hPMS2, and hPMS1
interact with the same region of hMLH1 (30), we wanted to ask
whether the relative abundance of the three different heterodimers
can be correlated with the phenotype of the cells. Therefore, we did
semiquantitative Western blots where we compared the intensity
of bands due to endogeneous hMLH3 and hPMS2 proteins in
HeLa cells with that of bands due to known amounts of the
corresponding recombinant proteins (Fig. 2A). These experiments
revealed that hMLH3 is f60 times less abundant than hPMS2.
Considering that hPMS1 is f10 times less abundant than hPMS2
in human cells (5), hMLH3 exists in the cells at levels significantly
Figure 1. Expression of hMutLg in Sf9 cells, anti-hMLH3 antibody specificity,
and endogenous levels of hMLH3 in colon cancer cell lines. A, expression of
hMLH3 in Sf9 cells infected either with a baculovirus vector expressing hMLH3
or with a mixture of hMLH1- and hMLH3-expressing viruses. This Western blot
shows that hMLH3 is stabilized in this system by hMLH1. B, Coomassie blue
staining of rabbit polyclonal anti-hMLH3 serum before (Serum ) and after
(Anti-hMLH3 ) affinity purification. C, Western blot analysis of whole cell extracts
of Sf 9 cells uninfected (TE Ctrl , 2 Ag) or coinfected with the hMLH1/hMLH3
baculoviruses (TE MutLc , 2 Ag). The recombinant polypeptide (amino acids
961-1,453) used for the generation of the antibody was loaded in the third lane
(1 ng). Anti-hMLH3, affinity-purified serum used at 1:400 dilution; Pre-serum,
preimmune serum used at the same dilution. D, microarray analysis of mRNA
expression levels (top ) and Western blot analysis of protein levels (bottom ) of
hMLH3 in a series of colon cancer cell lines (50 Ag of whole cell extract per lane);
n.s., nonspecific band detected by the anti-hMLH3 antibody in human cell
extracts.
Figure 2. Relative abundance of hMLH3 and its interaction with hMLH1
in vivo. A, the recombinant hMLH3 and hPMS2 proteins were loaded onto a
denaturing polyacrylamide gel in the indicated amounts and visualized by
Western blotting with the respective antibodies. The relative abundance of the
two polypeptides was calculated by comparing the intensity of the hMLH3 and
hPMS2 bands with those of the endogenous proteins present in 50 Ag of HeLa
whole cell extract. The blot is representative of two independent experiments,
and the intensities of the bands were calculated by densitometry.
B, coimmunoprecipitation of hMLH3 and hMLH1 in HeLa cells. One milligram of
whole cell extract was incubated with or without 6 Ag of anti-hMLH1 antibody
(top ) or 10 Ag of anti-hMLH3 antibody (bottom ). DNase, reaction done in the
presence of 25 units of Benzonase. Ponceau staining for IgG is also shown to
show equal loading. Ctrl, 50 Ag of HeLa whole cell extract.
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lower than those of the other two hMLH1-interacting partners
hPMS2 and hPMS1. In spite of this difference, hMLH3 was found to
physically interact with hMLH1 in Far Western experiments (7)
and in mammalian two hybrid assays (30). We could confirm
this interaction using immunoprecipitation experiments in which
the anti-hMLH1 antibody could immunoprecipitate both hMLH3
and hPMS2 from human cell lysates (Fig. 2B, top) and the anti-
hMLH3 antibody precipitated the endogenous hMLH1 (Fig. 2B,
bottom). No proteins were detected in control experiments where
the precipitating antibody was omitted. The interaction between
hMLH3 and hMLH1 was not mediated by bound DNA because
treatment with DNase before incubation with the antibodies failed
to abolish the interaction between the two proteins (Fig. 2B, top).
hMLH1 is not required for the stability of hMLH3 in human
cells. hPMS2 and hPMS1 are stabilized by the presence of hMLH1
(1, 31). Considering this characteristic of these two MutL
homologues, together with the finding that hMLH1 was required
for the stabilization of hMLH3 in baculovirus-infected Sf9 cells
(Fig. 1A), we expected to observe substantially decreased levels of
endogenous hMLH3 in human cell lines lacking hMLH1. Surpris-
ingly, we could detect hMLH3 in hMLH1-deficient HCT116 cells,
and the restoration of hMLH1 expression by chromosome 3
transfer resulted in no appreciable increase in hMLH3 level (Fig. 3A,
bottom left). This shows that the presence of hMLH1 is not required
for hMLH3 stability in human cells. The relative amounts of intra-
cellular hMLH3 were also unaffected by hPMS2 levels, as shown by
comparison of hMLH3 band intensity in Western blots of extracts
of the hPMS2-deficient Hec-1A cells with those of a Hec-1A clone in
which the expression of hPMS2 was restored by chromosome 7
transfer (Fig. 3A, bottom right). hMLH3 protein levels failed to
correlate with hMLH1 and hPMS2 expression also in other colon
cancer cell lines, such as SW480 or Caco2, that express both
hMLH1 and hPMS2, or LS411, CO115, or SW48 that lack hMutLa
(Fig. 3B).
Having established that the level of hMLH3 in cells is not
dependent on hMLH1 but that it correlates well with hMLH3
mRNA levels (Fig. 3B), we wondered whether the fluctuation of
hMLH3 expression in the tested cell lines could be linked with
cytosine methylation, which is known to silence several key genes
in colon cancer (32). The human embryonic kidney cell line 293T is
deficient in both hMLH1 and hMLH3 (Fig. 3C) and it could be
shown that the CpG islands that constitute the promoters of
hMLH1 (25) and other genes (33) are silenced by hypermethylation
in these cells. As the hMLH3 promoter also contains a CpG island,
we reasoned that the lack of hMLH3 expression in this cell line
might also be linked to the transcriptional inactivation of its
promoter. This prediction was substantiated in two independent
experiments. First, treatment of 293T cells with the demethylating
agent 5-aza-2V-deoxycytidine partially restored the expression of
both hMLH1 and hMLH3 (Fig. 3C). In the second experiment, we
treated genomic DNA of 293T and the parental 293 cells (which
express both hMLH1 and hMLH3; Fig. 3C) with sodium bisulfite,
which deaminates cytosines to uracils, but leaves 5-methycytosines
unchanged. Methylation-specific PCR showed that the promoter of
the hMLH3 gene in 293T cells was indeed methylated (data not
shown). As expected, expression of high amounts of hMLH1 in the
293T-derived 293T La+ cells resulted in the stabilization of hPMS2
(26) but did not affect hMLH3 levels (Fig. 3C). The promoter of the
hMLH3 gene can thus be silenced by cytosine methylation, but this
is most likely not the only mechanism that results in the lack of
expression of the protein, as 5-aza-2V-deoxycytidine treatment
failed to induce the expression of hMLH3 in GP5D cells (Fig. 3D).
Figure 3. Expression of hMLH3 in vivo is
independent of hMLH1 and hPMS2 and can
be controlled by cytosine methylation.
A, microarray analysis of hMLH3 mRNA
(top ) and protein (bottom ) expression
in hMLH1-deficient HCT116 and
hPMS2-deficient Hec-1A cells. Correction of
the MMR defect by transfer of chromosome
3 or 7, which carry wild-type copies of the
hMLH1 and hPMS2 genes, respectively, had
no effect on hMLH3 expression. B, hMLH3
expression is independent of hMLH1/hPMS2
expression in a panel of MMR-proficient and
MMR-deficient cell lines. Legend as in (A).
C, the hMLH3 promoter in 293T cells in
silenced by methylation. Expression of
hMLH1 in 293T-La cells does not alter
hMLH3 levels but demethylation of the
promoter by 5-aza-2V-deoxycytidine
(5-Aza-dC ) treatment results in the
reappearance of hMLH3, together with
hMLH1, the promoter of which is also
methylated in these cells. D, down-regulation
of the hMLH3 gene in GP5D cells is not
mediated by cytosine methylation. The
promoter was shown by methylation-specific
PCR to be unmethylated and 5-Aza-dC did
not reactivate hMLH3 expression in these
cells. In the Western blot experiment, 50 Ag
of total extract were used per lane.
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Role of hMutL; in in vitro mismatch repair. The observation
that extracts from 293T-La+ cells are MMR proficient (26)
despite their lack of hMLH3 suggested that hMutLg does not
play a major role in MMR in vitro . However, the possibility
that it acts as a backup to hMutLa in the absence of hPMS2
could not be excluded. Therefore, we tested extracts of the
human cell line HeLa clone 12, which expresses hMLH1, hPMS1,
and hMLH3 but lacks hPMS2. As shown in Fig. 4A , these extracts
were deficient in the repair of heteroduplex substrates containing
either a G/T mismatch or an insertion/deletion loop of one or
two nucleotides, but their repair proficiency on all tested
substrates could be restored by the addition of recombinant
hMutLa. Before concluding that hMutLg does not participate in
MMR, we considered the possibility that the expression level of
endogenous hMLH3 in the tested human cell lines might be too
low to be detectably active in our in vitro assay. Therefore, we
decided to test whether in vitro MMR activity may be detected in
the presence of higher amounts of the heterodimer. These
experiments were done with the hMutL a, h, and g deficient
extracts of 293T cells supplemented with whole cell extracts from
Sf9 cells expressing comparable amounts of hMutLa or hMutLg
(Fig. 4B, inset). As shown previously, extracts of Sf9 cells
overexpressing hMutLa could complement the MMR defect in
the 293T extracts very efficiently, whereas extracts of uninfected
Sf9 cells failed to do so (Fig. 4B ; ref. 26). Interestingly, when
extracts of Sf9 cells expressing hMutLg were used, we observed
an increase in repair activity of f20%. Similar results were
obtained when the hMutLg was enriched by Ni-agarose
chromatography, showing that the observed MMR activity was
specific to hMutLg. We detected similar repair activities on
substrates containing a G/T mismatch or a 1-base loop with a
nick located either 5V or 3V from the mismatch, but no activity
was observed on a substrate containing insertion/deletion loops
of two or four nucleotides (Fig. 4B ; data not shown). These
experiments show that although physiologic levels of hMutLg are
insufficient to mediate mismatch correction in our in vitro MMR
assays, the factor can participate, albeit with low efficiency, in
the correction of base-base mispairs and one-nucleotide inser-
tion/deletion loops.
Discussion
Like its S. cerevisiae homologue (8), the mammalian MLH3 gene
(7) could be shown to be involved in meiotic recombination
(13–15). However, whereas the S. cerevisiae (8) and Schizosaccharo-
myces pombe (12) proteins play a small but distinct role in the
repair of a subset of insertion/deletion loops, no similar evidence
existed for mammalian MLH3. In this present study, we set out to
search for this evidence.
We first wanted to study the expression of hMLH3 and confirm
the existence of hMutLg in vivo . Using a newly generated antibody,
we showed that hMLH3 is much less abundant than the other two
known hMLH1 interactors, hPMS2 and hPMS1. Despite this, we
could confirm the physical interaction between hMLH3 and
hMLH1 in HeLa cells by immunoprecipitation experiments.
Surprisingly, although hMLH1 was required for hMLH3 stability
in Sf9 cells (Fig. 1A), no such requirement was apparent in human
cells where no degradation of hMLH3 occurred in the absence of
hMLH1 (Fig. 3A and B). We also failed to observe any significant
competition between hMLH3 and hPMS2 for hMLH1, showing that
in human cells hMLH3 might be stabilized by interaction with
another, as yet unidentified, protein. This finding is supported by
evidence from meiosis in mice, where Mlh3 was seen to bind to
pachytene chromosomes before Mlh1 and, after Mlh1 recruitment
to these sites, foci containing Mlh3 alone persisted (11, 15). It was,
therefore, suggested that Mlh3 could either exist alone or interact
with a different partner (11). Immunoprecipitation experiments
revealed a direct interaction of scMlh3p with Sgs1 helicase in
meiotic S. cerevisiae cells (34) and hMLH3 was shown to bind
hMSH4 in meiotic human cells (14); however, the identification of
the putative hMLH3 partners that might help stabilize it in mitotic
cells must await the results of future experiments.
The ultimate objective of this work was to elucidate the role of
hMLH3 in human MMR. We first tested extracts of human HeLa
clone 12 cells, which lack hPMS2 (22) and thus contain only
hMutLh and hMutLg. As the former heterodimer is devoid of MMR
activity in our in vitro MMR assay (31), any observed repair activity
could be ascribed to hMutLg. The extracts were MMR deficient on
all tested substrates (Fig. 4A), which suggested that the hMutLg
heterodimer does not participate in MMR. However, as hMLH3 is
generally much less abundant in human cells than hPMS2, we
Figure 4. In vitro MMR assays. A, the MMR defect of cytoplasmic extracts
of the hPMS2-deficient cell line HeLa clone 12 can be corrected by the addition of
0.2 Ag purified hMutLa. The repair efficiencies were determined on heteroduplex
substrates containing a G/T mismatch, or +1 (D1) or +2 (D2) insertion/deletion
loops. B, cytoplasmic extracts of 293T cells, which lack hMLH1, hMLH3, and
hPMS2 were supplemented with 2 Ag of whole cell extract from Sf9 cells
coinfected with hMLH1/hPMS2 (Sf9-La ), hMLH1/hMLH3 (Sf9-Lc), or the latter
partially purified on Ni-agarose (Sf9-Lc-Ni ). MMR efficiency was tested on
heteroduplex substrates containing a G/T mismatch, or +1 (D1) or +2 (D2)
insertion/deletion loops. The amounts of hMutLa and hMutLg complexes used
for complementation were comparable (inset ). Whole cell extracts from
uninfected Sf 9 cells (Sf9 ) or Sf9 extract that underwent Ni-agarose (Sf9-Ni )
chromatography were used as negative controls. Columns, result of at least
three independent experiments; bars, SE. Cytoplasmic extract of the
MMR-proficient HeLa cells was used as the positive control.
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wanted to exclude the possibility that the lack of repair activity is
linked to insufficient amounts of hMutLg. Therefore, we tested the
MMR activity of extracts of 293T cells, which are deficient in all
three MutL homologues, supplemented either with recombinant
hMutLa or hMutLg (Fig. 4B). The former factor complemented the
MMR defect in the 293T extracts on all tested substrates. When
comparable amounts of hMutLg were used, we observed a small
but significant (f20%) repair with both G/T and +1 insertion/
deletion loop substrates. This repair activity was not due to an
intrinsic repair activity of the Sf9 extracts per se, as extracts from
uninfected Sf9 cells were repair deficient in the complementation
experiments. As there are no available functional assays to test the
activity of hMutLg, a possibility exists that this heterodimer was
isolated in a partially inactive form. However, we consider this
possibility unlikely because all the procedures used were identical
to those used for the preparation of the Sf9 extract expressing
hMutLa, which was fully active. Moreover, immunoprecipitation
experiments done with Sf9 extracts expressing hMutLg showed
that hMLH3 was able to bind hMLH1 (data not shown). The
sensitivity of the in vitro MMR assay remains, however, rather low
so that the contribution of hMutLg to the repair process in vivo
might be higher. Interestingly, the repair activity of hMutLg was
limited to G/T mismatch and 1-base loops, as we failed to observe
any repair activity using +2- and +4-base-loop substrates. The latter
result indicates that hMutLg seems to be involved in the repair of
substrates recognized by hMutSa rather than insertion/deletion
loops of more than one extrahelical nucleotide recognized by
hMutSh. This is in contrast to the data obtained in S. cerevisiae
where the role of scMlh3p seems to be in the repair of a subset of
insertion/deletion loops together with scMutSb . The role of hMLH3
in mammals thus might differ from that in lower eukaryotes.
Our findings, suggesting that hMutLg may play a backup role
in human MMR, are supported by evidence from the mouse
model. As noted above, Mlh3 null mice were not cancer prone in
the first 9 months of life and showed no gross defects in MMR
(15). However, a long-term study of these animals, coupled with a
highly sensitive analysis of their genomic DNA, provides evidence
for the involvement of Mlh3 defects in both MMR and
tumorigenesis. Mlh3/ mice have a shorter life span than the
wild-type controls and more than half of the animals develop
cancers, including gastrointestinal tumors after the 9-month time
span. Importantly, Mlh3 deficiency increased the levels of
mutations in long mononucleotide repeats, although to a lesser
extent than in Pms2/ mice (35). Taken together, our results and
the mouse model data suggest that the hMutLg heterodimer
functions in the repair of base-base mismatches and small
insertion/deletion loops.
Considering the possible involvement of hMLH3 in human
MMR, the identification of hMLH3 silencing through promoter
hypermethylation is of particular interest. We showed that the
hMLH3 promoter is methylated in 293T cells and that the protein
is consequently not expressed. In this particular cell line, the
methylation could be caused by the presence of the SV40 large T
antigen. However, using methylation-specific PCR, we could
detect partially methylated hMLH3 promoters in the colon
cancer cell line LS411 and in the ovarian cancer cell line
A2780/CP70, and fully methylated in the leukemia cell line Jurkat
(data not shown), which shows that hMLH3 silencing via
promoter hypermethylation can also be unrelated to the presence
of SV40 large T antigen.
Although recombinant hMutLg possessed detectable repair
activity in our in vitro MMR assays, hPMS2-deficient cells expressing
hMLH3 display a strong mutator phenotype (refs. 16, 23; this study).
This suggests that hMLH3, most likely in the form of hMutLg,
does not play a major role in MMR in vivo . However, the detection
of sequence variants of hMLH3 in the germ line of families
predisposed to colorectal cancer (17, 20), coupled with our detection
of epigenetic silencing of hMLH3 in human cell lines, suggests
that this gene may play a role in human cancer, possibly in
combination with other risk factors. If hMutLg does indeed play a
backup role for hMutLa in vivo , the fluctuating abundance of
hMLH3, such as that observed in the tested cell lines (Figs. 1 and 3),
might help explain the variable penetrance of hPMS2 mutations
in hereditary nonpolyposis colon cancer families (16).
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7. Conclusions 
 
The mismatch repair system (MMR) is an important determinant in the 
response to chemotherapeutic agents by mediating the cytotoxic effects of the 
applied drugs. 
O6-methylguanine (mG), the most cytotoxic lesion induced by SN1-type 
methylating agents, is recognized both in mG/T and mG/C mispairs by the 
human MMR factor MutSα. In bandshift experiments, mG/T and mG/C were 
recognized with equally low efficiency, comparable to a homoduplex control 
oligonucleotide ([1]; our unpublished results). The strongly reduced repair of 
mG-containing substrates in our in vitro MMR assays mirrored this weak 
recognition. It has been reported that mismatch recognition by MMR depends 
on the sequence context and other groups observed similar binding properties 
of hMutSα to mG/T and G/T mispairs ([2]; Paul Modrich, personal 
communication). Although we tested two unrelated sequences in the bandshift 
experiments, no appreciable differences in the recognition by hMutSα could 
be observed. Since bandshift experiments are not standardized and therefore 
performed in a remarkable diversity, this discrepancy may originate from 
different assay conditions. Another explanation could be that, by mischance, 
both our sequences are not optimal substrates for an efficient recognition by 
MMR factors. Probably, this very weak recognition made it impossible to 
detect a putative minor fraction of molecules undergoing futile repair opposite 
mG. This could simply argue for the absence of a futile repair scenario and 
could be taken as proof of an alternative model. However, given that Paul 
Modrich’s group provided evidence for the former hypothesis in vitro by using 
substrates differing in sequence from ours [3], we believe that the observed 
discrepancy between the two sets of data is due to different efficiencies of the 
initial recognition of the lesion. This could also account for the fact that no 
single-stranded regions were visualized opposite mG in our system. 
Furthermore, no concluding statement about which nucleotide is inserted 
across the lesion could be made. The in vitro system used in this study turned 
out to exert a variety of unpredictable and complex activities on our 
substrates, making the study of single events extremely difficult. In addition, 
substrate preparations varied in our hands and showed slightly different 
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behavior in the MMR assays. The reconstituted systems, on the other hand, 
run the risk of showing experimental artefacts due to the enormous restriction 
to a small subset of proteins. Since MMR has been shown to work in Xenopus 
egg extracts as well [4, 5], one could consider the possibility of switching to 
the frog system. But although Xenopus eggs are extremely rich in enzymatic 
activities and provide an interesting system to examine the mechanism of 
mismatch correction at a crucial stage of life in vertebrates, the extracts 
harbor several disadvantages. 1) The overall repair efficiency is significantly 
lower than that observed in human nuclear extracts. A G/T mismatch, for 
example, is repaired up to 60% in our in vitro system compared to 3-12% 
repair in Xenopus extracts. Furthermore, repair of mG-containing substrates 
has never been studied and there is no published information about 
recognition of this lesion by the Xenopus MMR system; 2) Different 
distributions of the various mismatch recognition efficiencies in Xenopus 
extracts and monkey kidney cells raise the question of relevance to the 
human system [5, 6]; 3) DNA strand breaks act as signals for the induction 
and direction of MMR rather than being start or end points for excision and re-
synthesis [4], thus differing from the human system [7]. In addition, and 
probably as a consequence, the repair of mismatches is not strictly biased to 
the nicked strand as observed in human MMR [4, 7]; 4) The oocyte is 
provided with a very specialized complement of proteins and cellular 
components, and it is possible that mismatch repair concentrates 
predominantly on the correction of DNA replication errors during this stage of 
development.   
5-fluorouracil (5-FU), an antimetabolite widely used in the treatment of 
colorectal cancer, inhibits thymidylate synthase (TS) and can be incorporated 
into both RNA and DNA. Although the cytotoxicity is probably due to 
pleiotropic effects of the drug, DNA incorporation has been suggested to play 
a major role [8, 9]. We could show that 5-FU/G mismatches are very efficiently 
processed by both MMR and BER. In the absence of MMR, TDG and UNG, 5-
FU/G repair was completely abolished in our in vitro system, implying that 
MBD4 and SMUG1 do not contribute significantly to this repair event. Indeed, 
SMUG1 turned out to be inactive under standard MMR conditions. Although 
the enzyme was active in the supplied reaction buffer, it did not show any 
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activity in the MMR buffer. Since the latter mimics a physiological 
environment, this finding was very surprising and it would be of interest to find 
working conditions in order to study all the glycosylases at once. In the 
absence of both TDG and UNG, MMR processed 5-FU/G mismatches equally 
well as G/T mispairs. 5-FU/A mismatches, although not recognized in 
bandshift experiments, were nevertheless processed to a minor extent by the 
MMR system, as could be shown by visualization of radiolabeled repair DNA 
synthesis. Interestingly, TDG and UNG reduced the observed MMR 
processing, indicating a direct competition between the two repair pathways. 
We do not know how and if TDG and UNG really cooperate in vivo.  Bandshift 
experiments with the two glycosylases revealed an interaction between TDG 
and 5-FU/G- but not 5-FU/A-containing oligonucleotides (data not shown). 
This is consistent with the idea that 5-FU/A mismatches are recognized and 
repaired by other glycosylases than TDG, namely UNG or SMUG1 [9, 10]. 
Our results imply a possible link between the presence or absence of 
glycosylases, in particular TDG, and the efficiency of 5-FU-based 
chemotherapies.  
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